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Abstract
Genome wide association studies (GWAS) have proved to be a successful method
in cataloguing loci influencing thousands of complex human disease phenotypes.
However, elucidating the causal mechanisms underlying such associations has
proved challenging due to the regulatory nature of the majority of signals.
In Chapters 2 and 3, I hypothesised that promoter-capture Hi-C (PCHi-C)
data might have utility in physically linking disease-associated regulatory variants
to their target genes, in a tissue-specific manner. To examine the genome-wide
enrichment of GWAS summary statistics within PCHi-C chromatin contact maps
I developed a novel statistical method, ‘blockshifter’. I applied blockshifter to a
compendium of GWAS summary statistics for 31 traits and PCHi-C data across
17 primary blood tissues, and found convincing evidence for the enrichment of
immune-mediated disease (IMD) GWAS signals in lymphocyte specific chromatin
interactions, providing support for the hypothesis. Taking a more gene-centric
approach I developed ‘COGS’, a novel method for integrating GWAS and PCHi-C
to prioritise specific causal variants, genes and cellular contexts for functional
follow up. With a focus on IMD, I prioritised tissue-context specific interactions in
CD4+ T cells linking putative causal variants for type 1 diabetes, to the promoter
of IL2RA. The effect of these variants on IL2RA expression was subsequently
validated by allele specific expression, by a collaborator, supporting the approach.
In Chapter 4, I hypothesised that summary statistics from multiple, well
powered GWAS of related diseases might be exploited to provide insight into rarer
related diseases or disease subtypes. To investigate this I developed a PCA based
framework to generate a lower dimensional basis, summarising input GWAS traits.
I constructed such a basis from ten IMD GWAS studies, excluding variants in
the HLA region, and projected on summary GWAS data from multiple sources
in order to characterise individual principal components (PCs). By projecting on
both summary and individual level genotype data for juvenile idiopathic disease
subtypes, I was able to show that a single PC was able to discriminate enthesitis-
related and systemic forms of the disease from other subtypes.
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Chapter 1
Introduction
1.1 Foreword
The main aims of this thesis are threefold:
Aim One: Investigate whether the promoter interacting regions (PIRs) identified
by promoter-capture Hi-C (PCHi-C) are enriched for GWAS signals in a
cell-context specific manner.
Aim Two: Develop methods to integrate GWAS signals with PCHi-C data in
order to prioritise putatively causal SNPs, genes and tissue contexts for
functional followup.
Aim Three: Develop a framework for constructing a summary of the genetic rela-
tionships between multiple immune-mediated diseases (IMD) and evaluating
how they might be useful in characterising rarer or clinically heterogeneous
IMDs.
The work presented in this thesis is, like a majority of contemporary research,
of a cross-disciplinary nature encompassing the fields of genetics, genomics and
statistics. Given this scope, I have organised the material such that each subsequent
chapter contains a more specific introduction to the relevant concepts, studies
and literature that it is concerned with. In contrast, this introductory material
is of a more general nature covering key concepts and technologies that form
a foundation for subsequent chapters. In Section 1.2, to provide background to
aims one and two, I describe how eukaryotic genomes are organised, the main
empirical methods for measuring facets of this organisation (including PCHi-C),
and how such genomic organisation is of relevance to human disease. Section 1.3
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introduces key population genetic concepts and statistical frameworks that I rely
on throughout this thesis to achieve my aims. In the final section (Section 1.4), I
provide a general introduction to IMDs with an emphasis, relating to aim three,
on their shared and distinct genetic architectures. I finish by briefly touching on
how the integration of genetic and functional data might afford a more, robust,
molecular taxonomy of IMDs.
1.2 The role of genome organisation in health and
disease
In 1958 ’On protein synthesis’ was published setting out Sir Francis Crick’s
’Central Dogma’ on how information stored in DNA could give rise to the complex
biochemistry essential for life (Crick, 1958). In it, he stated a flow of information
from DNA, which through transcription to intermediate RNA species, is ultimately,
translated to proteins, in order to elicit cellular function.
Five years later Monod and Jaques were the first to characterise this process
in prokaryotes using the polycistronic lac operon in Escherichia coli (Jacob and
Monod, 1961). Empirically, they demonstrated the presence of ‘regulatory’ genes
and sequence elements, whose function was to control the activity of a set of target
genes. These regulatory genes, which we now call ‘transcription factors’, were
shown to function by interacting with the cognate DNA sequence elements to
regulate the expression of a short lived intermediate that they called ‘messenger’
RNA (mRNA).
1.2.1 The canonical eukaryotic protein coding gene
At the sequence level, the canonical eukaryotic protein-coding gene, which I refer
to subsequently as a ‘gene’, consists of multiple elements that are required for
functional transcription.
The Promoter Found directly upstream of the transcriptional start site (TSS),
the promoter initiates binding of RNA Polymerase II (Pol II), the enzyme
responsible for transcribing DNA to mRNA. Generally such promoter se-
quences consist of two elements; a region immediately upstream of the TSS
known as the ‘core promoter’ and a region upstream to this, known as the
‘proximal element’ or ‘regulatory promoter’ (Kanhere and Bansal, 2005).
The former provides sequence cues for the binding of the Poll II complex,
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with the latter thought to provide a more subtle, context-specific modulation
of expression rate through the binding of cofactors such as transcription
factors. As a result promoters are highly heterogeneous between genes
reflecting different abilities to drive transcription in different tissue contexts.
The Enhancer In Eukaryotes the activity of the promoter in controlling tran-
scription is augmented by actions of short (between 100-500 bp) sequences,
known as enhancers. Enhancers function by the binding of specific tran-
scription factors that once recruited interact with co-factors and Pol II to
potentiate transcription of a target or set of target genes. In higher organisms,
enhancers, unlike promoters are often found at some distance (up to 1Mb)
either upstream or downstream from their target gene. This effect over
distance means that they are often found in the intronic regions of non-target
genes or even ‘skip’ multiple intervening genes to exert their function.
To understand such action at a distance it is useful to summarise current
knowledge about the organisation of DNA within a eukaryotic cell.
1.2.2 Chromatin structure
In humans, a majority of cells contain a complete copy of an individuals genetic
material. At a large scale this can be observed as classical karyotype consisting of
22 pairs of autosomal chromosomes and one pair of sex determining allosomes.
This large body of genetic material must be efficiently packed into the cell nucleus,
a specialised sub-cellular organelle. At the lowest level, DNA polymers associate
with specialised proteins called histones that spool the DNA into approximately
146 bp supercoils known as nucleosomes (Figure 1.1a) to form euchromatin (Fig-
ure 1.1b) (Higgs et al., 2007). In turn euchromatin can be further compacted to
form the higher order structure of heterochromatin (Figure 1.1c and d). Gener-
ally euchromatin is an indicator for more active chromosomal regions whereas
heterochromatin identifies those that are more quiescent. Indeed, The formation
of euchromatin and heterochromatin is highly regulated (Lawrence et al., 2016)
through multiple mechanisms.
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Fig. 1.1 A model for the formation of chromatin in Eukayotes. a) Specialised
proteins called core histones (blue) form ≈ 146 bp DNA coils called nucleosomes.
b) Nucleosomes form at regular intervals along the DNA double helix in the
so called ‘beads on a string’ configuration. This configuration is permissive to
gene transcription and is modulated by chemical modification of histone tails. c)
Mediated by the non core histone, H1, this ‘bead on a string’ configuration, known
as euchromatin, is further packed into fibres known as chromatin. d) These densely
packed 30nm chromatin fibres, known as heterochromatin are generally less
permissive to gene transcription. Image adapted from an original image by Richard
Wheeler under CC BY-SA 3.0 license [https://commons.wikimedia.org/wiki/File:
Chromatin_Structures.png].
1.2.3 Regulation of chromatin state
DNA-Methylation
At the DNA level, the addition of methyl groups to individual cytosine (C) bases
is widespread. In mammals this methylation occurs at specific di-nucleotides
known as CpG’s (5’-C-phosphate-G-3’). This methylation is context specifc, for
example, the methylation of gene promoter regions is associated with attenuation
of gene transcription, where as methylation of gene bodies has a reciprocal re-
lationship (Jones, 2012). It is thought that DNA-methylation indirectly affects
chromatin structure by recruiting, methyl-CpG-binding domain proteins (MBDs)
which with co-factors promote chromatin remodelling (Du et al., 2015) .
Covalent histone modification
At the unit of the nucleosome, constituent histone proteins have polypeptide
‘tails’ (Figure 1.1b) that through the action of specific enzymes may be covalently
modified. For example, Histone 3 (H3) has a specific lyseine at position 27
(K27) that when acetylated (ac) correlates with more active chromatin (H3K27ac).
Many such histone modifications have been described, correlating with different
chromatin activation levels which are reviewed in (Lawrence et al., 2016).
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Key to the study of histone modifications has been the development of ChIP-
seq, which has made it possible to catalogue the location of specific modifications
on a genome-wide scale across multiple tissues and organisms. ChIP-seq is an
umbrella term for the process of using antibodies raised to specific DNA binding
proteins (Landt et al., 2012). These antibodies are extremely specific and there-
fore can be used to precipitate histones with particular covalent modifications in
complex with the DNA to which they associate. This DNA can then be sequenced
and mapped back to the genome, allowing the elucidation of the physical location
of the modified nucleosome. The ChIP-seq method can be applied to any DNA
interacting protein for which a specific antibody can be raised, and has been used
successfully to interrogate and characterise the binding of many transcription
factors (The ENCODE Project Consortium, 2012).
The mechanisms by which such modifications are able to affect chromatin
state are varied, for example, H4K16ac is thought to loosen intra-nucleosome
binding, thus favouring the formation of euchromatin and transcription factor
accessibility (Shogren-Knaak et al., 2006).
Fig. 1.2 A catalogue of covalent histone modifications in eukaryotes. The central
sphere indicates a nucleosome complexed with DNA (black). Histone tails are
blown up for clarity with specific residues and their possible modifications num-
bered. Image adapted from an original from Lawrence et al. (2016), ©Elsevier
Ltd. reproduced under license.
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DNA accessibility
The accessibility of chromatin and its constituent DNA is also a useful marker of
activity. One such assay, DNase hypersensitivity (DHS) assay with sequencing
(DNase-Seq), involves digesting chromatin with the DNA cleaving enzyme DNase
I (Song and Crawford, 2010). Regions of open chromatin are more accessible
to the enzyme, and are therefore more likely to be a cleaved. These cleavage
products, can be isolated and sequenced and their physical locations, known
as DHS regions, found by mapping to a reference genome. The DHS assay is
technically challenging and more recently has been replaced with the assay for
transposase-accessible chromatin using sequencing (ATAC-Seq) which requires
less biological input material (Buenrostro et al., 2015).
Chromatin segmentation
Due to the number of modifications that individual nucleosomes can undergo the
number of possible combinations is large (Figure1.2), requiring the combined
analysis of heterogeneous sources of data derived from CHiP-Seq, ATAC-Seq and
RNA-Seq experiments. This precipitated the development of software to integrate
datasets performed on the same cell type to identify patterns of modifications,
transcription factor binding, accessibility and transcription that correlate with
chromatin activity (Ernst and Kellis, 2012; Hoffman et al., 2012). This has allowed
the annotation of tissue specific ‘chromatin segments’, regions of chromatin with
similar properties (e.g. combinations of histone modifications) (Ernst and Kellis,
2015) and their subsequent characterisation into more conceptual constituent
elements such as enhancers.
1.2.4 Chromatin organisation in three dimensions
However, this linear cataloguing of the non-coding portion of the genome described
in the previous section, misses additional complexity, in that chromatin fibres
associate to form higher order three dimensional structures. Whilst some of
these associations are structural, allowing the very long fibres of chromatin to
be efficiently packed within a cell, many have specific functions associated with
replication and the regulation of gene expression. The recent development of
high-throughput methods, known as chromatin conformation assays, for assessing
this three dimensional structure has begun to reveal the underlying complexity of
this structure and how it effects cellular function.
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Chromatin conformation assays
Building on the Nuclear Ligation assay (Cullen et al., 1993) Dekker et al. (2002)
described a molecular technique, chromosome conformation capture (3C) for
interrogating intact nuclei for the presence of specific interactions (Figure 1.3).
Subsequently this was extended through, chromosome conformation capture-on-
chip (4C), to examine all interactions with a specific locus (Simonis et al., 2006).
Further development gave rise to carbon copy chromosome conformation capture
(5C), that allowed the interrogation of all interactions within a specific locus of
up to 1Mb in size (Dostie et al., 2006). These techniques for investigating higher
order chromatin structure dovetailed with the emergence of massively parallel
sequencing techniques leading to the development of Hi-C.
Fig. 1.3 Methods for interrogating chromatin conformation. Image adapted from
an original from Davies et al. (2017), ©Springer Nature reproduced under license.
Hi-C
Hi-C involves cross-linking genomic DNA with formaldehyde resulting in covalent
links between spatially adjacent chromatin segments. This chromatin is then
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digested with a restriction enzyme and sticky ends are filled in with biotin labelled
nucleotides. Ligation is then performed under dilute conditions, thus favouring
intra-molecular ligation events. The DNA is then purified and then sonically
sheared and fragments are then enriched for biotinylated junctions, which then
undergo paired end sequencing (Lieberman-Aiden et al., 2009) (Figure 1.3).
Hi-C resolution is limited by two main factors. Firstly, the protocol involves a
restriction enzyme digest, usually HindIII, and interactions are called based on the
resultant fragments generated, in practice if HindIII is used this limits resolution to
approximately 4Kb. Secondly, the complexity of the sequence libraries generated
means that to increase the effective resolution by a factor n requires an n2 fold
increase sequencing reads which is prohibitive for general implementation (Jäger
et al., 2015).
ChIA-PET and Capture-C
In a parallel, an alternative experimental method, chromatin interaction analysis
by paired-end tag sequencing (ChIA-PET) was being developed, that harnessed
immunoprecipitation techniques to enrich for interactions based on the presence
of specific DNA binding proteins (Fullwood et al., 2009). The main limitation
of ChIA-PET is that the ChIP step results in a relatively modest enrichment for
targeted chromatin interactions. Consequently the number of sequence reads
available for mapping genuine contacts is attenuated resulting in reduction in
the sensitivity to uncover interactions (Davies et al., 2017). More recently the
development of hi-ChIP (Mumbach et al., 2016) has overcome some of these
limitations, resulting in meaningful reductions in the amount of biological input
material required. However, both ChIA-PET and hi-ChIP still rely on specific
antibody binding to target proteins, which themselves are subject to bias in their
efficacy (Davies et al., 2017).
In contrast to the immunoprecipitative methods mentioned previously, other
chromatin methods use sequence based DNA capture techniques to enrich for
contacts containing specific sequences of interest. Capture-C (Hughes et al., 2014)
combines 3C techniques with sequence specific capture allowing a detailed picture
of chromatin contacts at 100’s of individual ‘viewports’ to be assembled (Davies
et al., 2016). Whilst capture-C overcomes the main limitations of other techniques
(e.g. high biological material input requirements and reliance on protein specific
iummunoprecipitation) it is limited to the one-to-many contact nature of 3C and
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subsequent multiplexing considerations limit the number of viewports that can be
assayed to the hundreds.
Capture Hi-C
These limitations have lead to the parallel development of Capture Hi-C (CHi-
C) (Dryden et al., 2014). This method combines in situ ligation adaptations to
conventional Hi-C methodology using a sequence capture library design to target
specific regions of the genome. The promoter capture Hi-C (PCHi-C) methodology
used extensively in this thesis, for example, targets the 5’ and 3’ of restriction
fragments that overlap gene promoters genome-wide (Mifsud et al., 2015). This
results in the subsequent enrichment of distal sequences that come into contact
with the promoter regions targeted by the capture design.
It should be stressed that whilst some of the techniques described above have
been subsumed by subsequent developments, there is no ‘best’ technique. At the
genome-wide scale Hi-C can give a relatively non-biased overview of 3D genome
topology useful for the understanding of how higher level chromatin organisation
operates genome-wide. In contrast capture-C can be used to characterise specific
interactions identified through orthologous empirical methods (e.g. ChIP-Seq or
ATAC-Seq) in detail. As such PCHi-C occupies the middle ground operating as
a bridge between genome-wide Hi-C and locus specific capture-C, important for
transducing information between the two scales of chromatin organisation.
Chromatin looping
An important locus for deriving tissue specific mechanisms of enhancer action
over a distance has been the murine locus control region (LCR) responsible for
the expression of the β −globin gene cluster. The LCR itself contains multiple
tissue context specific enhancers, the most distal of which is located 70kb from
the β −globin gene locus. Tolhuis et al. (2002) were able to show, using 3C, that
the tissue specific expression of the α and β −globin genes were modulated by
the physical interaction of specific LCR enhancers to the promoters of these genes,
looping out the intervening εγ and βh1 genes.
Topologically associated domains (TADs)
At a more global level Dixon et al. (2012) used Hi-C to describe the phenomenon
of topologically associated domains(TADs). These domains are areas of chromatin
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that interact with increased frequency when compared with those outside of the
TAD, and their boundaries are enriched for the DNA binding proteins CTCF and
cohesin. Chromatin looping events identified through Hi-C were found to also
preferentially occur within rather than between TADs (Dixon et al., 2012; Rao
et al., 2014; Sexton et al., 2012), an observation that was subsequently validated
using capture-C (Hughes et al., 2014). Whilst such TAD architecture seems to be
independent of tissue context (Dixon et al., 2012) its ablation, through the removal
CTCF binding domains can have significant localised effects on the regulation
of gene expression (Zuin et al., 2014). Recent work in mice has demonstrated
that novel tissue-specific TAD borders can occur at promoters of developmentally
regulated genes. These borders can be separated by the differential enrichment
of DNA-specific binding proteins such as cohesin and histone modifications such
as H3K4me3 and H3K27ac (Bonev et al., 2017). The question remains as to
whether the correlation between such epigenetic marks and the regulation of
chromatin organisation is causative. Whilst this is an active area of research,
recent work has shown provisional support for H3K4me1 having a causal role
in the stabilisation of long range chromatin looping events through the active
recruitment of cohesin (Yan et al., 2018).
1.2.5 Chromatin organisation and disease
In the previous section I discussed the role and main mechanisms underlying
the choreography between the 3D genome and gene expression. An outstanding
question is to what extent alterations at the sequence level can attenuate or ablate
chromatin contacts and thereby alter tissue specific transcriptional programmes to
cause disease?
In rare monogenic disease
An early example of how ectopic long range chromatin looping could be modulated
through the actions of a single nucleotide polymorphism (SNP) was observed
through the genetic mapping of preaxial polydactyly (PPD). Using the sasquatch
(Ssq) mouse model for PPD, Lettice et al. (2003) characterised a prominent limb
enhancer (ZRS) modulating Shh gene expression over 1Mb away responsible
for the PPD phenotype. Using segregation analysis in multiple human families
exhibiting the PPD phenotype they were able to show that all affected individuals
were homozygous for SNPs overlapping the human-syntenic region of ZRS. In
this highly penetrant monogenic setting, where homozygosity for a specific and
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rare non-coding allele segregates with disease status, there are few additional
examples. Indeed, whilst sequencing studies have identified a large volume of
protein coding SNPs responsible for mongenic disease (Lek et al., 2016), a recent
study investigating the effect of rare variation on neurodevelopmental disorders
estimated that between 1-3% of cases might be caused by de novo non-coding
variation (Short et al., 2018).
In common polygenic disease
This situation is somewhat reversed in the context of common polygenic disease,
where a majority of associated variants, identified through genome-wide asso-
ciation studies (GWAS) have been found to occur outside of the regions of the
genome coding for proteins (1000 Genomes Project Consortium et al., 2015). This
has been problematic because GWAS have not typically led to the identification of
disease causing genes. This observation (which I expand upon in Section 1.4.4),
alongside results emerging from model organisms such as yeast (Bloom et al.,
2013), opened up the possibility that knowledge about 3D genome organisation
and its interplay with gene regulation might have utility in the interpretation of
causal mechanisms underlying complex traits. One such early study used 3C
evidence to show that a Type 1 diabetes (T1D) association signal on chromosome
16, located within the intron of the gene CLEC16A, might instead regulate a more
distal gene DEXI for which little biology was known (Davison et al., 2012). This
study highlighted that the physical location of an association might be an imperfect
method of prioritising genes for functional characterisation and that chromatin
conformation capture might provide a valuable orthogonal method.
This was brought in to sharp contrast by Smemo et al. (2014), who inves-
tigated an obesity associated locus within the intron of the FTO gene on chro-
mosome 16 (Frayling et al., 2007). Previous efforts to characterise the region,
including mouse knockout studies, had provided support for causality of the FTO
gene (Church et al., 2009). Using 4C Smemo et al. (2014) showed evidence for
the interaction in mouse brain tissue of a region, syntenic for the human associ-
ated region, with the promoter of Irx3 rather than Fto precipitating considerable
controversy. This controversy was resolved by Claussnitzer et al. (2015) who
used multiple sources of genomic evidence (including Hi-C) to elucidate a role
for the human causal variant in abrogating ARID5B transcription binding. This in
turn affected regulation of IRX3 and IRX5 expression through chromatin looping
causing a downregulation of thermogenesis.
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1.3 Statistical methods for genomic analysis
In the previous section I introduced the concept that common variants, through
chromatin looping events, can modulate complex disease risk via the dysregulation
of distal gene expression. Next I expand on the statistical techniques and chal-
lenges relevant to robustly identifying common causal variants in complex disease.
My focus on methods for testing association rather than linkage is mostly technical
as the high genetic heterogenity combined with low effect sizes underlying a ma-
jority complex disease genetic architectures considerably disadvantages the power
of linkage compared to association based approaches (Risch and Merikangas,
1996).
1.3.1 Relevant population genetics concepts
Prior to discussing such statistical methods, it is worth touching on population
genetics concepts that have particular relevance to the methods of statistical
association I subsequently describe. In this section I introduce allele frequencies,
how over many generations these vary and give rise to structure in genetic data.
Finally I touch upon ‘heritability’ a concept that can be used to measure the relative
contributions of environment and genetics to the variability of a phenotype within
a population.
Allele frequency and Hardy-Weinberg equilibrium
In 1908, separate publications from Wilheim Weinberg and G. H. Hardy set out
a mathematical framework for modelling allele frequencies within a population
that would arise over many generations of random mating. Consider a SNP for a
diploid organism consisting of a alleles A0 and A1. In a large population of size N
the frequencies of A0 and A1 can be estimated as p =
C(A0)
2N and q =
C(A1)
2N , C(A0)
and C(A1) are the observed allele counts of A0 and A1 accordingly. In a large
population p and q can be viewed as the probability of obtaining A0 or A1 from
random sampling, and given that there are only two possible alleles p+ q = 1.
An assumption of this model is that whilst each individual contains two alleles
(as they are diploid), these are independently sampled from the population and
so may be considered separately. A natural extension of this model is to consider
the probability of obtaining a specific set of alleles or genotype when sampling an
individual from the population. Given the previous observation of the probability
of sampling a single allele (i.e. p+q = 1) it follows that (p+q)2 = 12. Here p2
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and q2 correspond to the frequencies of the homozygous genotypes, A0A0 and
A1A1 respectively and frequency of the heterozygous genotype, that exists in two
configurations A0A1 and A1A0 is 2
√
p2q2. This Hardy-Weinberg principle of
equilibrium (HWE) relies on the assumption of stable allele frequencies within a
population, and thus makes a number of implicit assumptions that relate to this,
that include random mating, no population migration and that the target alleles are
not under selection.
Linkage Disequilibrium
Due to the mechanism of meiosis, the process of recombination randomly shuffling
genetic material between parental gametes, alleles at neighbouring SNPs become
less correlated. On an individual level this results in a set of SNPs (normally
spatially proximal) at different loci being non-randomly associated, these alleles
are said to be in linkage disequilibrium (LD). To characterise LD pairwise between
two SNPs various metrics have been defined (Devlin and Risch, 1995). By far
the most commonly applied is the correlation coefficient r. Let PA and PB be
the estimated minor allele frequency at SNPs A and B respectively where PAB is
frequency of the minor alleles at A and B co-occurring on the same chromosome
then
r =
PAB−PAPB√
PA(1−PA)PB(1−PB)
. (1.1)
Here PAB is equivalent to the haplotype1 frequency of minor alleles at A and B. In
general the square of the correlation coefficient is used in order to remove the sign
introduced, as this arbitrarily dependent on the way in which alleles are labelled.
Heritability
Total heritability, H2, is the proportion of the phenotypic variance, σ2P that can be
attributed to genetic differences, σ2G, among individuals (Equation 1.2).
H2 =
σ2G
σ2P
. (1.2)
This definition is flexible, for example, we might imagine σ2G combining with
an environmental factor, E, with a phenotypic variance σ2E such that σ2P = σ2G +
σ2E . However, this flexibility makes H2 hard to estimate without making strong
1A group of alleles from the same chromosome
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assumptions. Instead we might think of σ2G as the sum of variances across a
range of additive (A), dominant (D) and interaction (I) effects, such that σ2G =
σ2A +σ
2
D +σ2I . This leads to the definition of narrow-sense heritability, which is
the proportion of phenotypic variance explained by additive genetic effects
h2 =
σ2A
σ2P
. (1.3)
We can define a further quantity, h2g, called SNP heritability, as the proportion
of variation in the trait that can be explained by additive effects of commonly-
occurring SNPs whose genotype we can measure2. In practice h2g ≤ h2 ≤ H2
reflecting the increasing flexibility of their underlying definitions.
1.3.2 Genome Wide Association Studies
GWAS, employ, in a hypothesis-free manner, the methods described in the sub-
sequent sections, to a phenotyped population for which the majority of common
variation (MAF>5%) has been measured with the aim of uncovering whether
such variation is associated with the target phenotype. These associations, once
discovered, can implicate novel biological mechanisms underpinning the measured
phenotype, for example autophagy in Crohn’s disease (Zhang et al., 2008), and
more recently are being used to stratify individual disease risk (Wray et al., 2019),
a pre-requisite of ‘personalised’ medicine (Jameson and Longo, 2015). Whilst
early studies examined the theoretical underpinnings of such approaches under a
variety of scenarios (Wang et al., 2005), robust technologies to measure such a
large amount of genotypes across a suitably powered cohort were in their infancy.
The first reported GWAS, concerning age-related macular degeneration (Klein
et al., 2005), assayed 160,000 SNPs across 96 cases and 50 controls, finding an
association with the CFH gene, implicating a role for the complement system of
innate immunity in disease pathogenesis. A watershed moment occurred in 2007
on the publication of the Wellcome Trust Case Control Consortium paper (Well-
come Trust Case Control Consortium, 2007). This married the technological
breakthrough in the large scale measurement of SNP genotypes, begun with the in-
ternational HapMap project (International HapMap Consortium et al., 2007), with
a collaborative approach to data sharing and analysis enabling the first large scale
GWAS, that included 2,000 cases for each of seven diseases and 3,000 controls,
2indeed this is also known by the pseudonym ‘chip’ heritability in reference to the underlying
genotyping platforms employed
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typed over 500,000 SNPs. Over the intervening years, iterative improvements to
SNP genotyping platforms, statistical imputation methods and the aggregation of
ever larger sample cohorts across a plethora of traits and diseases, has resulted
in an exponential growth in the catalogue of human variation associated with
human disease (Figure 1.4). For example a recent study of educational attainment
assessed 1.1 million individuals across 9 million SNPs (Lee et al., 2018).
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Fig. 1.4 Growth of Genome-Wide Association studies. a) Growth in the cumulative
number of GWAS studies. For orientation Klein et al. (2005) and Wellcome Trust
Case Control Consortium (2007) studies are shown. b) The cumulative growth of
recombination blocks associated with one or more traits as a function of genome
coverage over the same period. The red dotted line shows where half of the
genome has been associated with one or more traits. Data downloaded from
GWAS catalogue (25/01/2018).
1.3.3 Hypothesis testing
Hypothesis testing underlies many statistical inference approaches to GWAS. Key
to the approach is defining a null hypothesis, H0, that contradicts a theory about a
particular phenomenon for which data has been collected. For example, consider
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a random variable X with an observed value x, if the distribution of X under H0 is
known, H0 : X ∼ fX , then it is possible to associate a probability of observing a
value sampled from fX by
Pr(X = x | H0). (1.4)
More generally we might take repeated samples from fX , selecting a statistic,
known as a ‘test’ statistic, in order to provide a summary of those repeated
samples. In most contexts this test statistic is devised such that it has a known
distribution under H0. Under the Neyman-Pearson approach, we partition this
known H0 distribution, into values of the test statistic which are unlikely to be
observed if repeated samples of x are truly drawn from this distribution. This
partition is called the critical region, and its probability is defined as α . If the
sample test statistic, falls within this critical region, then H0 is rejected and the
alternative, H1 is accepted. The value of α , is also known as the Type 1 error
rate as it equates to the probability of erroneously rejecting H0 when it should
have been accepted. The Neyman-Pearson approach also defines β , the Type II
error rate, which, in contrast, reflects the probability of erroneously accepting H0,
with it’s value relating to both sample size and the nature of H1. This approach
to hypothesis testing is applied in a frequentist setting, where we assume that a
parameter or test statistic of X has a true value, and that this is can be estimated by
appropriate sampling from fx. This is in contrast to a Bayesian philosophy, that
assumes that the parameters are themselves random variables and as such have
their own distributions. Thus, in the Bayesian setting, we instead estimate the
posterior probability of H0,
Pr(H0 | X = x) = Pr(X = x | H0) Pr(H0)Pr(X = x) , (1.5)
which summarises how strongly H0 is supported by the observed value, x. A
key concept here is the requirement for selecting a prior probability for the null
hypothesis, Pr(H0) before observing x. This reflects our belief that H0 is not fixed
but is itself a random variable and as such has an associated probability of being
true. In the field of genetics, frequentist approaches are used more widely, in
contrast to Bayesian approaches, which are used for pragmatic reasons, such as
for settings when sample size is small, there is a need to include prior information
or where we wish to compare non-nested hypothesis (Section 1.3.5).
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1.3.4 Frequentist approaches to genetic association testing
Generally, associations arise where we observe that one set of observations or
events is statistically dependent on another. Most statistical tests for association
utilise this dependence and examine the likelihood under the null hypothesis,
H0 that the two events are truly independent. It is important to note that such
association tests in isolation cannot imply causality, a subject of debate outside the
scope of this thesis. Tests of genetic association apply this principal of dependence
to the field of genetics, by examining whether a quantitative or binary outcome is
dependent on exposure to one or more underlying genetic variants.
In order to illustrate different approaches let us imagine a simplified fictitious
study, where we measure the presence, A1 or absence A0 of a particular allele of a
genetic variant, A in a set of N1 individuals with disease, D+, and N0 without D−.
A natural method of summarising our findings is a 2×2 contingency table (Pearson
and Blakeman, 1906) where each element reflects the frequency of two events.
A1 A0
D− a b
D+ c d
Table 1.1 A contingency of an association study where we wish to examine the
statistical dependence of disease outcome (D−/D+) on genetic variant exposure
(A0/A1)
Odds ratios
The main metric of effect size in binary contingency tables, the focus of our
fictitious example, is the odds ratio (θ ). To compute this we first compute the
conditional probability of having the disease contingent on not having the variant
(Pr(D+|A0)). We can express the odds of having the disease contingent on not
having the variant as Pr(D
+|A0)
1−Pr(D+|A0) , similarly the odds of having the disease con-
tingent on having the variant is Pr(D
+|A1)
1−Pr(D+|A1) . The odds ratio for disease associated
with variant A1 is thus:
θ =
Pr(D+|A1)
1−Pr(D+|A1)
Pr(D+|A0)
1−Pr(D+|A0)
, (1.6)
which using the labels from Table 1.1 simplifies to cbad .
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This estimate of effect size does not tell us whether this effect is significant,
such that it is meaningfully different from the value we would expect if D and
A were independent (i.e. θ = 1). In order for this we need to elucidate, given
our study size, the uncertainty attached to our estimate of the odds ratio (θˆ ). The
distribution of θˆ is skewed towards values greater than one because low values are
constrained by zero whereas large values are not. This can be overcome by using
the natural logarithm of θˆ such that βˆ = log(θˆ). We can compute an approximation
of the standard error of βˆ as σβˆ =
√
1
a +
1
b +
1
c +
1
d , where a,b,c and d are the
counts from the joint distributions of our contingency table (Table 1.1). Under the
assumption that sample size is large, the estimate of our odds ratio, θˆ , follows a
normal distribution, allowing us to obtain a standardised Z score (Z = βˆσβˆ
). This
test statistic can then be used as the basis of a hypothesis test where under the null
βˆ = 0, which is rejected if the Z-score intersects with the critical region defined
by α .
Testing for association in biallelic single nucleotide polymorphisms
The previous section dealt with inference based on odds ratios in the case of two
categorical variables. In general, most organisms are ploidy indicating that they
have more than one set of chromosomes. Humans have a ploidy of two which
means that for a given a binary allele where A1 and A0 indicate the allele is present
or absent respectively, an individual is sampled from four possible configurations
(Table 1.2). By updating our contingency table so the joint distributions reflect
allele counts rather than individuals we can compute odds ratio’s accordingly.
Configuration Name Value
A0A0 Homozygous A0 0
A1A0 Heterozygous 1
A0A1 Heterozygous 1
A1A1 Homozygous A1 2
Table 1.2 Value indicates the number of alleles present in a configuration
Linear Regression
In the previous section I discussed methods for estimating effect sizes and their
significance given two sets of categorical variables. Here I introduce the linear
model for testing for genetic association where the outcome variable is quantitative,
rather than binary.
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Let g be a vector of genotypes for a set of n individuals for a given bial-
lelic SNP such that g = (g1,g2, . . . ,gn−1,gn),gi ∈ {0,1,2} (Table 1.2). Let y =
(y1,y2, . . . ,yn−1,yn). Generally we wish to understand whether yi = f (gi)+ ε ,
where f (gi) is a linear function that can be parameterised by a slope, β and an
intercept, β0 such that yi = β0 +βgi + ε , where ε ∼ N(0,σ2ε ) is an error term that
allows for residual variability (i.e. that the value of yi may be a function of other,
unmeasured factors). We seek to optimise the selection of both β0 and β such that
any differences in the vector of predicted outcome variables, yˆ, from applying the
linear function of g, are minimised with respect to the observed vector of outcomes,
y. We can estimate the difference between y and yˆ as y− yˆ, which results in a
vector of residual values, r = (r1,r2, . . . ,rn−1,rn) which can be summarised in the
residual sum of squares quantity RSS =∑ni (r2i ) =∑
n
i (yi− (βˆ0 + βˆgi))2. There are
multiple analytical procedures to solve for estimates of βˆ0 and βˆi that minimise
RSS, however the ordinary least squares (OLS) method provides a closed form
such that:
(
βˆ0, βˆ1
)T
=
(
XT X
)−1 XT y, (1.7)
where X =

1 g1
...
...
1 gn
.
Such an approach can be extended to the genotypes of multiple SNPs and
outcomes by replacing g with a genotype matrix G, where rows and columns
match samples and SNPs respectively and the elements of G belong to {0,1,2}
(Table 1.2).
Logistic Regression
Linear regression can be successfully used for inference when the outcome is
quantitative, but it is less suitable when the outcome is binary such that y ∈ {0,1}.
Fitting a linear model is unsuitable as the model space allows for parameters that
might result in predictions such that y< 0 or y> 1. An alternative approach is to
employ a logistic function on g where:
f (gi) =
1
1+ exp−(β0+βgi)
, (1.8)
in this case the vector of outcomes, y, is projected onto the odds scale such that
y = f (g)1− f (g) . In its simplest case a logistic model will generate exp(β1) that are
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equal to the odds ratio computed using simpler methods previously described. Its
main utility is in its ability to incorporate other covariates and nuisance parameters
by the addition of terms to the linear predictor.
1.3.5 Bayesian approaches to genetic association testing
Canonical frequentist approaches described in Section 1.3.4 have an important
limitation in that their currency, the p-value is unable to capture how confident
we are that a SNP is truly associated with a trait (Stephens and Balding, 2009).
Conversely a Bayesian posterior provides a strength of evidence for a given
hypothesis albeit with additional assumptions and computational burdens. Such
posterior probabilities naturally allow the comparison of different hypothesis and
lead to a Bayesian interpretation of hypothesis testing, central to this are the
concept of Bayes factors.
Bayes Factors
In 1935 Harold Jeffreys described how Bayes theorem could be used to compare
competing hypotheses (Jeffreys, 1973). As an illustrative example, consider two
hypothesis H0 and H1, representing the null and alternative respectively. Given
the observation of some data, D, we compute posterior probabilities Pr(H0|D) and
Pr(H1|D). We are interested in the relative support for H1 compared to H0 which
can be expressed as a quantity known as the Bayes Factor.
BF =
Pr(H1|D)
Pr(H0|D) . (1.9)
If we define the prior odds as Pr(H1)Pr(H0) , then
Pr(H1|D)
Pr(H0|D) , the posterior odds (PO) can
be expressed by
PO = BF×prior odds,
as set out by Kass and Raftery (1995).
In the context of a case/control setting, let θ be the odds ratio for a given
SNP under additive assumptions, and let β = log(θ), we may assume that β = 0
and β ∼ N(0,W ) for some specified W under H0 and H1 respectively. Thus we
construct the Bayes factor as:
BF =
Pr(D|β ∼ N(0,W ))
Pr(D|β = 0) . (1.10)
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Here, W can be estimated from one of the frequentist approaches previously
mentioned.
Wakefields asymptotic Bayes Factors
In three papers (Wakefield, 2007, 2008, 2009) Wakefield introduced an asymptotic
Bayes Factor (aBF), for use in association studies, with a simple closed form,
requiring as input only the maximum likelihood estimate of βˆ and its variance
V . Such an approach was not only computationally tractable but circumvented
the considerable difficulties in obtaining genotype level information, as it could
be computed from summary level statistics (e.g. p-values or odds ratios and
their standard errors). The aBF relies on a normal prior N(0,W ) on β . For a
dichotomous trait a value of W = 0.2 has been suggested (Giambartolomei et al.,
2014) as this approximates to a Pr(θ > 1.4|θ < 1.4−1) of 5 %. This prior when
combined with the assumption that maximum likelihood estimate of βˆ is sampled
from a normal distribution N(β ,V ) yields:
aBF =
√
V +W
V
× exp
(
− z
2W
2(V +W )
)
(1.11)
where z2 is the Wald statistic βˆ
2
V .
Fine mapping using asymptotic Bayes Factors
The Wellcome Trust Case Control Consortium et al. (2012) show that under the
scenario of a single causal variant within a given genomic region containg k SNPs,
then the Bayes factor for that region to be causal is the mean of the individual
Bayes Factors for all the SNPs in the region,
BFreg =
1
k
k
∑
i=1
BFi, (1.12)
where BFi is the Bayes factor associated with the ith SNP being causal, which can
be approximated by aBFi introduced in the previous section. Furthermore they
define the single causal variant posterior probability for ith SNP, which substituting
for aBF becomes
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sCVPPi ≈ aBFikaBFreg
≈ aBFi
∑kj=1 aBF j
. (1.13)
However such a relationship does not consider the case where there are no causal
variants within the region. To do this we must alter the definition of BFreg, to
include a term for the Bayes factor associated with a model containing no causal
variants or Pr(D|H1)Pr(D|H0) = 1 such that
sCVPPi ≈ aBFiπ(
π∑kj=1 aBF j
)
+π0
, (1.14)
where π and π0 are the prior probabilities for a SNP to be causal or not causal
respectively. Under the assumption that π is small with respect to k then we
approximate π0 = 1− kπ ≈ 1 leading to
sCVPPi ≈ aBFiπ(
π∑kj=1 aBF j
)
+1
. (1.15)
Therefore under the strong assumptions, that a given physical region contains
a single causal variant, we can define single causal variant posterior probabilities
(sCVPP) for each a SNP. By ordering and taking the cumulative sum of these pos-
terior probabilities we can compute credible sets of SNPs that incorporate a given
amount of posterior probability (e.g. 95%). In some cases given well powered
studies and dense genotyping or imputation this can lead to the identification of
single variants upon which the overwhelming majority of the posterior probability
is focused, which are then amenable to empirical follow up (Huang et al., 2017).
1.3.6 Approaches to high dimensional data
In previous sections I have focused on inference, however statistical approaches are
also concerned with describing and summarising the structure of high dimensional
data such as arises from GWAS. Such high dimensional data occurs where the
number of observations or predictors, p is much larger than the sample size n,
resulting in the so called curse of dimensionality; as p increases so does the volume
of the space from which our n are sampled, resulting in increased sparsity. If p far
exceeds n, as is usual in genomics, then this sparsity is such that robust inference is
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challenging. Statistical approaches in this area concern themselves with three main
approaches, feature selection, shrinkage (transformation) and extraction (Hastie
et al., 2009).
Feature Selection: These are approaches that seek to uncover a subset of the
predictors or features that are of relevance to the outcome variable(s). Ex-
amples include forward stepwise selection, where predictors are recursively
added to a model, and retained only if they improve model performance.
Feature Shrinkage: Shrinkage approaches are concerned with fitting a model
with all predictors whilst constraining coefficient estimates. An example of
such an approach is ridge regression, which modifies conventional regression
approaches (Section 1.3.4), that minimise residual sum of squares, to include
a shrinkage parameter, that penalises larger coefficients. Although such
an approach improves model performance, its interpretation compared to
feature selection methods is challenging as the coefficients of predictors are
still non-zero. This has lead to the development of alternative approaches
such as the lasso that perform shrinkage, allowing for zero coefficient
estimates.
Feature Extraction: This final class of approaches seeks to transform the predic-
tors available in high dimensional datasets in order to derive a much smaller
number of features that provide useful summaries of any structure that may
be apparent within the data. In most cases, derived features consist of linear
combinations of the the original features, therefore reducing the number
of dimensions that need to be considered. One of the main approaches is
principal component analysis (PCA), which I discuss further in the next
section.
1.3.7 Principal component analysis (PCA)
Consider A a matrix of n observations across p variables where p>> n. In such
a situation, it is desirable to obtain a representation that summarises A using a
reduced number of variables. PCA is one method that achieves this by concen-
trating the variance across all p into independent principal components using
eigen-decomposition of the covariance matrix, C = AT A. Eigen-decomposition is
the process of factorising a square diagonisable matrix, such as C into an orthogo-
nal set of p eigenvectors, v, and p eigenvalues, λ , such that Cv = λv. Thus, C or
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indeed A when applied to an eigenvector only shrinks or elongates the eigenvector
by the magnitude of the corresponding eigenvalue. These eigenvectors are linear
combinations of the original variables that are ordered by the amount of variance
they capture, the magnitude of which is captured by the corresponding eigenvalue.
This allows dimension reduction as we can select a subset of the p eigenvectors,
that capture a majority of the variance in A to take forward for analysis.
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Fig. 1.5 Example of the principal component transformation of a simulated ma-
trix of random variables X and Y (n = 100). a) Y is a linear function of X
(generative function shown as a grey dashed line) with added Gaussian noise,
εx,εy ∼ N(0,0.3). The centre of the points, (x¯, y¯), is marked in red. Points 99 and
18 are hilighted for illustrative purposes as these are the extreme deviates for X and
Y respectively b) Transformation shown as dashed lines to the first principal axis,
shown as a solid black line. The distance between the centroid and the projection
is the principal component score which is maximal for point 99. c) Transformation
to the second principal axis, here the score for point 18 is maximal. d) Biplot
showing the principal component scores for both principal axes (blue/red points
from b and c).
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Figure 1.5a illustrates this point, showing the simple case of a two-dimensional
projection of a set of points onto two possible principal component axes. Here,
matrix v, becomes the axes, for a new coordinate system or basis. To transform A
onto this new basis we compute Av, illustrated as dashed lines connecting original
points to the principal axes (bold lines) in Figure 1.5b (1st principal axis) and
Figure 1.5c (2nd principal axis).
For this simple case, we observe that there are two such principal axes or
components (as there are two variables), that have two notable relations to each
other. Firstly both axis share the same origin (x¯,y¯), which leads to an alternative
viewpoint of PCA as an optimisation problem that seeks to find the set of k
dimensions (where k ≤ p) that minimise the euclidean distance between a set
of points. The centroid can be thought of as the zeroth principal axis serving as
the origin linking all k dimensions. This constraint enforces the second notable
relation, that any k is orthogonal to any other k, such there is no shared variance
between any k. As the total variance, the trace of C, is constrained this means
that each subsequent k captures less variance than the previous. Indeed ∑λ =
tr(C), where λ are elements of the vector of eigenvalues obtained from eigen-
decomposition of C and it is this relation that allows us to compute the ratio
of variance explained by each principal axis. The distance of the projection
(blue/red points) on the principal axis (bold) from the centroid are the principal
component ‘scores’ for each sample. We can plot these scores in a ‘biplot’ (Figure
1.5d) to obtain a graphical summary of the sample, here PC1 and PC2 capture
approximately 60% and 40% of the total variance respectively.
In this case the PCA is for illustrative purposes only as n> p it has no benefit
over a simple scatter plot. Careful thought needs to be given to how input variables
are scaled, for example if one variable is measured in metres and another in
kilometres then it will appear that the former has a higher variance. As PCA
optimises variance between variables this will unintentionally cause the variable
measured in metres to have a much greater effect on the basis generated. One
method to overcome this is to standardise the variables by mean-centring and
dividing through by the variance, thus performing PCA on the correlation rather
than variance-covariance matrix (i.e. C).
Whilst eigen-decomposition of the variance-covariance matrix, C is one
method of performing PCA, in practice it is computed through the singular value
decomposition of A as detailed in Appendix C.1. This approach has multiple
benefits in that it does not require the computationally intensive calculation of the
variance-covariance matrix, and the loss in precision this can involve.
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1.4 Towards causal mechanisms in immune-mediated
disease
In the first section I described various high-throughput genomic methods that have
been developed to interrogate the context-specific mechanisms by which genes
can be regulated with a focus on chromatin organisation. I introduced GWAS and
related statistical approaches that have been used to identify regions of the genome
harbouring risk SNPs for common complex disease. Here, I expand (Section 1.2.5)
on the evidence that integrating GWAS data, both across related traits, and with
other sources of high-throughput data is essential to understanding the molecular
mechanisms that ultimately modulate complex disease risk. I propose that such
knowledge is useful as it could be used to augment or replace disease classifications
traditionally based on clinical phenotypes, with more mechanistic ones recognising
the blurred lines that often separate related diseases. For the purposes of this
thesis I concentrate on a smaller subset of related phenotypes, incorporating
autoinflammatory and autoimmune diseases that I unify under the umbrella term
immune-mediated disease (IMD).
1.4.1 Epidemiology of immune-mediated disease
A key property of the adaptive immune system is the ability to recognise pathogens
from self-antigens. Dysregulation of this process results in damage to healthy
tissues, autoimmunity and auto-inflammation. Currently, over 80 diseases have
been found to have an underlying immune-mediated pathogenesis, with approxi-
mately half presenting as rare diseases, defined as affecting 5 people or fewer in
10,000 (Hayter and Cook, 2012). The collective health burden of more common
IMDs such as type 1 diabetes (T1D), rheumatoid arthritis (RA), inflammatory
bowel disease (IBD) and multiple sclerosis (MS) is high with approximately 7 - 9%
of the European population affected (Cooper et al., 2009). Although environment
is a contributing factor in disease susceptibility, the genetic heritability, defined
as the proportion of phenotypic variance (Section 1.3.1) attributable to genetic
variability, is also important, ranging from 0.39 in primary biliary cirrhosis (PBC)
to 0.9 in ankylosing spondylitis (AS) (Gutierrez-Arcelus et al., 2016).
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1.4.2 Genetics of of immune-mediated disease
It was in the early 1970’s that a role for the human leukocyte antigen (HLA)
region was first suggested in ankylosing spondilitis (AS) (Brewerton et al., 1973),
and to this day the HLA-B27, class I association with this disease remains the
strongest HLA effect of all IMDs. Subsequent work identified a role for the class II
HLA-DQβ in modulating risk for T1D (Todd et al., 1987), and in the intervening
years associations across a majority of IMDs have been mapped to this region.
Such relationships provide significant insight into putative disease processes given
that IMDs can be roughly dichotomised as having a predominantly class I or class
II disease association (Parkes et al., 2013). Class I HLA associated diseases, which
include psoriasis and AS, seldom share associated alleles and are predominantly
seronegative, that is they are not associated with specific auto-antibodies. In
contrast those characterised by associations in the class II HLA region, which
include T1D and systemic lupus erythematosus (SLE), often share risk alleles
but associate with specific auto-antibodies (e.g. anti-neutrophilic cytoplasmic
autoantibody for SLE) and are thus predominantly seropositive. Furthermore, such
seropositive disease are often found to have associations proximal to genes that
are the targets of their autoantibodies, for example INS in T1D (Bell et al., 1984)
and insulin auto-antibodies. In the intervening years with the advent of GWAS,
hundreds of regions of the genome have now been associated with one or more
IMDs, and detailed analysis supports a central role for both the adaptive and innate
immune system in IMD susceptibility, supported by a more limited number of
disease-specific loci. Such a wealth of new data has lead to a more systematic
analyses of whether associations are shared or distinct between distinct IMDs.
1.4.3 Immune-mediated diseases have both shared and distinct
genetic architectures
Evidence for co-morbidity between autoimmune and auto-inflammatory diseases
has long been observed. For example, between 4 and 9% of individuals with
T1D are also affected by coeliac disease (CEL) (Somers et al., 2006) compared
to a general population incidence of 0.8% (Choung et al., 2017). In the era of
GWAS it has been possible to examine both genome-wide and locus specific
evidence for genetic overlap between immune-mediated diseases. An early study
examining whether a genetic overlap could be responsible for the co-morbidity
between T1D and CEL found evidence for overlap at 7 out of 28 regions showing
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association in either disease (Smyth et al., 2008). Interestingly, two of these
overlapping loci, located at 2q12 and 6q25, demonstrated opposing effects between
the two diseases. Following up on this, Cotsapas et al. (2011) found evidence for
pervasive sharing across seven immune-mediated diseases. These early studies
were limited by sample size and the genotyping platforms on which they were
constructed, which were conceived to cover, by exploiting linkage disequilibrium
in European populations, as much common variation as possible. Without denser
genotyping maps it was therefore difficult to elucidate trait-specific fine scale
genetic architecture, and thus whether the overlap observed was due to the sharing
of causal variants or different variants in genomic proximity.
With this in mind a consortium of 11 immune disease mediated traits, pooled
both established and emerging associated regions, mining the developing 1000
Genomes resource (1000 Genomes Project Consortium et al., 2015), to obtain all
available variants observed with a minor allele frequency above 1% in European
populations local to known IMD associations. This compendium of approximately
186 densely genotyped regions, assaying approximately 200,000 SNPs, formed
the backbone for a new bespoke genotyping platform, the ImmunoChip, which
could be used to fine map existing associations (Cortes and Brown, 2011) at an
unprecedented resolution.
This dense mapping, showed that although there was extensive sharing between
IMD risk loci as had been suggested by GWAS, the picture was more complex than
initially suggested (Parkes et al., 2013). Whilst associated ImmunoChip regions
were shared between diseases, a number exhibited opposing effects, conferring
risk in one disease but protection in another. Focusing on T1D, Onengut-Gumuscu
et al. (2015) collected summary statistics for an additional 15 IMDs that had
been analysed using the ImmunoChip platform into the ImmunoBase resource3.
Using an enrichment method that controlled for LD, they were able to robustly
demonstrate, within T1D-associated ImmunoChip regions, an enrichment pattern
that discriminated between antibody positive and negative diseases as previously
suggested (Parkes et al., 2013). Fortune et al. (2015) adapted a pre-existing
statistical colocalisation method, coloc (Giambartolomei et al., 2014), to show
robust evidence for the sharing of causal variants at over a third of the associated
regions analysed. However the picture of phenotypic and genetic sharing between
diseases is complex, for example Fortune et al. (2015), highlighted three regions,
associated with T1D but not with other autoimmune diseases, that instead showed
3https://www.immunobase.org
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overlap with type 2 diabetes. This observation has subsequently been extended to
five T1D/T2D regions where evidence suggests a shared causal variant (although
in one region opposing effects) by a more recent study (Aylward et al., 2018).
Even within IMD, shared genetic architecture is complex, for example psoriatic
arthritis and RA show relatively little genetic overlap even though treatment with
anti-TNF therapy is effective in both indications (Eyre et al., 2017). Understanding
such results biologically is hampered as whilst GWAS are effective at identifying
associated variants, elucidating the mechanism by which they act has proved far
more challenging.
1.4.4 Integrating functional genomics with GWAS
Having found convincing associations and assessed their overlap between diseases
for IMD densely mapped regions, it was clear that a majority of associated variants
existed outside of the regions of the genome coding for proteins, a theme common
to complex disease (1000 Genomes Project Consortium et al., 2015; Maurano
et al., 2012).
In a landmark paper Farh et al. (2015), developed PICS, an attempt to use
lead variants retrieved from the GWAS catalogue (MacArthur et al., 2017), in
combination with the 1000 genomes reference panel, to fine map association
signals in the absence of dense genotyping information. They integrated these
results with empirically derived markers for active regulatory chromosome regions
across 33 cell types from the Epigenome Roadmap project (Roadmap Epigenomics
Consortium et al., 2015). This showed that candidate causal variants were en-
riched in a trait and cell type specific manner within such regulatory regions. For
example, putative causal variants for IMDs were enriched in lymphoid specific
regulatory regions, a result that was subsequently confirmed in a study of T1D
using credible sets of SNPs (Section 1.3.5) derived from ImmunoChip dense
genotype data (Onengut-Gumuscu et al., 2015).
Although this integrative approach could be used to prioritise target cell types
and regulatory regions, this was offset against a growing understanding of the
complexity underlying cell type specific gene regulation. Importantly this reg-
ulatory complexity challenged the established doctrine of the prioritisation of
causal candidate genes through the ad hoc combination of being physically located
with an associated region and having relevant biology (for specific examples see
Section 1.2.5).
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One systematic approach to link causal variants to their target genes is to
elucidate the genetic architecture underlying gene expression, through expression
quantitative trait locus (eQTL) studies. Guo et al. (2015) used a statistical method,
coloc (Giambartolomei et al., 2014), to look for colocalisation between eQTLs
identified from a study of three primary immune cell types with GWAS summary
results for 10 immune-mediated traits tissues. Interestingly, they found only
limited overlap, describing convincing statistical colocalisation in only six genes.
A more recent study employing a Mendelian randomisation approach to connect
eQTL and GWAS studies also found limited evidence for colocalisation between
eQTLs (Zhu et al., 2016) within immune-mediated traits (Huang et al., 2017).
Such a lack of colocalisation within IMD, is most likely explained by the fact that
eQTL studies are expensive and technically demanding to carry out, limiting not
only sample size and thus power, but also the breadth of tissue contexts that can
be assayed. More recent studies are beginning to highlight the role of underlying
tissue contexts underlying IMD causal variant mechanisms (Alasoo et al., 2018;
Soskic et al., 2019).
The overarching conclusion of the integrative studies highlighted is that with-
out an understanding of the tissue context within which causal variants, identified
through association studies, act, elucidation of underlying causal mechanisms is
challenging.
1.4.5 Towards a mechanistic taxonomy of immune-mediated
disease
Whilst, the systematic translation of GWAS results to causal mechanisms has
proved challenging, the distinct and shared genetic architectures between different
IMDs present an opportunity to organise diseases based on shared molecular
phenotypes. Indeed, medicine is to some extent, through the application of
diagnostic labels, a systematic categorisation of disease-causing phenotypes. In
the past this clustering of individuals sharing clinical features, and pathologies
has provided both insight into disease aetiology as well as the development of
evidence based treatment options (McCarthy, 2017). As a consequence many
diseases are currently classified by their presentation, which in the case of IMDs,
is often a proxy for target destruction (e.g. T1D and insulin producing pancreatic
β -cells). However in previous sections I have described how, at least at a the level
of genetic risk, a more complex picture has emerged, such as in T1D where a
central role for adaptive immune system dysregulation interfaces with biological
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pathways influencing β -cell function that are themselves shared with Type 2
diabetes. Such pervasive sharing between IMDs (Cotsapas et al., 2011; Fortune
et al., 2015; Gutierrez-Arcelus et al., 2016; Li et al., 2015; Parkes et al., 2013)
provides scientific support for a new taxonomy of IMDs such as that suggested over
a decade ago by McGonagle and McDermott (2006), that recognises that IMDs fall
on a spectrum that at its extremities separates auto-inflammatory and autoimmune
diseases. However the further development of such a taxonomy depends on
first gaining a greater understanding of the underlying causal mechanisms and
pathways at work. Such an effort is already well underway, with much progress
being in made in the fine-mapping of causal variants (Asimit et al., 2019; Huang
et al., 2017; Wallace et al., 2015; Wang et al., 2018), however as set out in the
previous section such information needs to be integrated with other sources of
genomic information, in order to suggest causal genes and tissues, critical for
uncovering disease mechanisms. Uncovering mechanism for individual causal
variants is only part of the story, as these then need to be integrated with existing
knowledge to identify biological pathways that might be shared across multiple
associated regions (Evangelou et al., 2014; Raychaudhuri et al., 2009; Rossin et al.,
2011; Võsa et al., 2018). This suggests that approaches at the causal variant scale,
as well as more holistic approaches that consider the full spectrum of IMD genetic
architectures, are likely to be syntergistic in attempts to develop a therapeutically
useful molecular taxonomy of disease aetiology.
1.5 Organisation of the thesis
In this thesis I develop novel methods and apply them to IMD genomic and
genetic datasets in order to better understand causal mechanisms and how at
the genome level these are shared and distinct between different diseases. In
chapters 2 and 3 I develop methods to integrate novel data on three dimensional
genome organisation with data from GWAS. These methods allow a data driven
prioritisation of putative causal genes and tissue contexts in which they operate. In
chapter 4 I develop a PCA dimension reduction technique to in order to summarise
the genetic relationships between ten IMDs using GWAS summary statistics
as input. Amongst other applications, I investigate whether such summaries
have utility in teasing apart the genetic architecture of a clinically heterogeneous
juvenile idiopathic arthritis (JIA) cohort, of modest sample size.
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1.6 Publications
During this thesis I have contributed to a number of publications which have
arisen either directly or indirectly from the work contained in this thesis. Where
applicable these are referenced in each relevant chapter, but I list them here for
completeness.
• Schofield, E. C., T. Carver, P. Achuthan, P. Freire-Pritchett, M. Spivakov,
J. A. Todd, and O. S. Burren (2016). CHiCP: a web-based tool for the
integrative and interactive visualization of promoter capture Hi-C datasets.
Bioinformatics 32(16), 2511–2513.
Initial concept, co-developed the software and wrote the paper.
• Javierre, B. M.*, O. S. Burren*, S. P. Wilder*, R. Kreuzhuber*, S. M. Hill*,
S. Sewitz,J. Cairns, S. W. Wingett, C. Várnai, M. J. Thiecke, F. Burden, S.
Farrow, A. J.Cutler, K. Rehnström, K. Downes, L. Grassi, M. Kostadima,
P. Freire-Pritchett,F. Wang, BLUEPRINT Consortium, H. G. Stunnenberg,
J. A. Todd, D. R. Zerbino, O. Stegle, W. H. Ouwehand, M. Frontini, C.
Wallace, M. Spivakov, and P. Fraser (2016). Lineage-Specific Genome
Architecture Links Enhancers and Non-coding Disease Variants to Target
Gene Promoters. Cell 167(5),1369–1384.e19.
Method development and analysis described in Chapters 2 and 3, contributed
to writing the paper.
• Burren, O. S.*, A. Rubio García*, B.-M. Javierre*, D. B. Rainbow*, J.
Cairns, N. J.Cooper, J. J. Lambourne, E. Schofield, X. Castro Dopico, R.
C. Ferreira, R. Coulson, F. Burden, S. P. Rowlston, K. Downes, S. W.
Wingett, M. Frontini, W. H.Ouwehand, P. Fraser, M. Spivakov, J. A. Todd,
L. S. Wicker, A. J. Cutler,and C. Wallace (2017). Chromosome contacts
in activated T cells identify autoimmune disease candidate genes. Genome
Biology 18(1), 165.
Method development and analysis described in Chapters 2 and 3, co-wrote
the paper.
• Inshaw, J. R. J., A. J. Cutler, O. S. Burren, M. I. Stefana, and J. A. Todd
(2018). Approaches and advances in the genetic causes of autoimmune
disease and their implications. Nature Immunology 19(7), 674–684.
Performed analysis using methods detailed in Chapter 2 to prioritise type 1
diabetes candidate genes.
• Eijsbouts, C. Q., O. S. Burren, P. J. Newcombe, and C. Wallace (2019,
January). Fine mapping chromatin contacts in capture Hi-C data. BMC
Genomics 20(1), 77.
This paper describes an alternative statistical method to CHiCAGO for
calling promoter interacting regions resulting in a posterior probability for
each interaction. I Investigated whether incorporation of these posterior
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probabilities with the method described in chapter 2 could improve candidate
gene prioritisation.
• Thaventhiran, J. E. D.*, H. L. Allen*, O. S. Burren*, J. H. R. Farmery, E.
Staples, Z. Zhang, W. Rae, D. Greene, I. Simeoni, J. Maimaris, C. Penkett,J.
Stephens, S. V. V. Deevi, A. Sanchis-Juan, N. S. Gleadall, M. J. Thomas,
R. B. Sargur, P. Gordins, H. E. Baxendale, M. Brown, P. Tuijnenburg, A.
Worth,S. Hanson, R. Linger, M. S. Buckland, P. J. Rayner-Matthews, K. C.
Gilmour, C. Samarghitean, S. L. Seneviratne, P. A. Lyons, D. M. Sansom,
A. G. Lynch, K. Megy, E. Ellinghaus, D. Ellinghaus, S. F. Jorgensen, T.
H. Karlsen, K. E.Stirrups, A. J. Cutler, D. S. Kumararatne, S. Savic, S. O.
Burns, T. W. Kuijpers, E. Turro, W. H. Ouwehand, A. J. Thrasher, and K. G.
C. Smith (2018). Whole Genome Sequencing of Primary Immunodeficiency
reveals a role for common and rare variants in coding and non-coding
sequences. bioRxiv (Under revision).
Performed analyses to elucidate novel causes of Primary Immunodeficiency
and co-wrote the paper.
* indicates equal contribution.

Chapter 2
Detecting tissue specific enrichment
of GWAS signals in PCHi-C data
2.1 Foreword
2.1.1 Chapter Summary
In this chapter I introduce a promoter capture Hi-C dataset (PCHi-C) covering 17
primary haematopoietic cell types (Javierre et al., 2016). I compile a compendium
of univariate GWAS summary statistics across 31 traits, proposing a simple LD
based method, Poor Man’s Imputation (PMI), in order to impute missing data.
To assess whether the tissue and trait specific enrichment of GWAS associations
reported in the literature (Farh et al., 2015; Onengut-Gumuscu et al., 2015) can be
replicated using context specific PCHi-C annotations I develop a novel statistical
method, blockshifter, that takes into account the correlation inherent in both GWAS
and PCHi-C datasets. Through simulation I assess blockshifter performance under
different assumptions and conditions. I conclude by presenting the results of the
application of blockshifter to the GWAS compendium.
2.1.2 Attributions
Parts of the work presented in this chapter are included in Javierre et al. (2016)
and Burren et al. (2017) and were carried out collaboratively with Fraser, Spi-
vakov, Ouwehand and Diabetes and Inflammation Laboratories as part of the
BLUEPRINT/IHEC project (Stunnenberg and Hirst, 2016). Specifically:-
• Dr. Mattia Frontini and Dr. Tony Cutler supplied sorted primary cells.
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• Dr. Biola Marie-Javierre, under the supervison of Prof. Peter Fraser carried
out all promoter-capture Hi-C experiments.
• Dr. Steven Wingett carried out initial sequence data processing using the
HiCUP pipeline (Wingett et al., 2015).
• Dr. Jonathan Cairns and Dr. Mikhail Spivakov supplied PCHi-C chromatin
contact maps called using the CHiCAGO pipeline (Cairns et al., 2016).
• Dr. Chris Wallace helped with the conceptualisation of PMI, blockshifter
and simulation design.
2.1.3 Motivation
In chapter 1 I described how variants associated with common disease, are enriched
in non-coding regions of the genome with putative tissue specific gene regulatory
function, in a disease relevant manner. One mechanism for the action of such
regulatory regions is through the formation of physical chromatin interactions with
their target gene promoters. However, the overall relevance of such a mechanism to
underlying disease processes is currently unknown. One line of evidence for such
a contribution is through the demonstration of the enrichment of disease associated
variants in a tissue specific manner, using PCHi-C data. Most published GWAS
functional enrichment methods focus on allowing for local correlation structure
caused by LD. However, PCHi-C datasets contain significant local structure that
must be taken into account. This motivated me to develop a novel statistical
method for examining GWAS enrichment in promoter interacting regions (PIRs)
that explicitly takes into account this structure, whilst also taking into account LD.
2.1.4 Software availability
PMI and blockshifter methods described in this chapter are available from https:
//github.com/ollyburren/CHIGP and blockshifter simulations are available from
https://github.com/ollyburren/blockshifter_simulations. Both are available under
GNU General Public License v3.0.
2.2 Background
Understanding the tissue context in which disease associated variants function can
provide important information for the design of follow up functional experiments.
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In Chaper 1, I touched on various analyses that integrate GWAS with tissue specific
genome annotations in order to prioritise relevant tissue contexts (Farh et al., 2015;
Maurano et al., 2012; Onengut-Gumuscu et al., 2015) which I expand upon here.
2.2.1 Gene set enrichment analysis inspired methods
Early software tools for analysing the enrichment of GWAS association signals in
specific functional annotations, built on methodologies such as gene set enrichment
analysis (GSEA) (Subramanian et al., 2005), developed to analyse high throughput
gene expression datasets. In the context of GWAS, a set of genes with some shared
functional annotation is selected, for example, those sharing a common Gene
Ontology (GO) term (Ashburner et al., 2000). Variants are then assigned to genes
on the basis of proximity, with the most significant association within a fixed
genomic window surrounding a gene being taken forward for analysis (Wang et al.,
2007). This yields two sets of association p-values; those mapping to genes in the
functional annotation to be assayed and the other mapping to a set of background
genes, that do not. In the example of Wang et al. (2007) the non-parametric
Kolmogorov-Smirnov test is then used to examine whether both sets of association
p-values are drawn from the same distribution, to infer enrichment. Recognising
the need to adjust for confounders such as gene size and LD, the procedure above
is repeated a number of times using a set of association statistics generated from
shuffling case/control assignment. This permutation step has drawbacks in that it
requires access to the underlying genotype data and is computationally intensive,
however it does allow the generation of a well specified null distribution of test
statistics which is critical in order to suitably adjust the observed test statistic.
In order to remove the requirement of individual genotyping data, Liu et al.
(2010), used the publicly available HapMap reference genotype data set (Inter-
national HapMap Consortium et al., 2007) to define local LD structure between
variants for approximately independent LD blocks. This LD across each block is
then used as the covariance matrix, Σ, for a multivariate normal (MVN) distribu-
tion, such that Z ∼MVN(0,Σ), which can be used to rapidly generate summary
association statistics under the null hypothesis of no association. Such an approach
allows the generation, genome-wide, of a background distribution of summary
association statistics, that take into account local correlation structure due to LD.
This obviates the need for study-specific individual genotyping data, requiring
only summary association statistics for the trait of interest, for which enrichment
is to be assessed.
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Early efforts to characterise enrichment in specific classes of genome annota-
tions, whilst finding plausible enrichment (Maurano et al., 2012), were challenging
to confidently interpret. This was mainly due to the reliance on parametric en-
richment methodologies that were less robust to local interdependencies within
classes of genomic annotations. For example, the base composition of a genomic
region may correlate with empirical techniques, underlying an annotation, such as
ChIP-seq (Benjamini and Speed, 2012). Such phenomena introduce complicated
localised correlation structures within an annotation, that lead to an inflation in
enrichment statistics generated if they are not explicitly accounted for.
Another limiting factor was that in order to increase trait coverage by us-
ing curated databases of robustly associated trait variants, such as the GWAS
catalogue (MacArthur et al., 2017), implicit thresholds were applied, as such
catalogues build on findings curated from the literature, rather than the full set of
GWAS summary statistics for a given trait. This thresholding not only precluded
the incorporation of potentially informative sub-genomewide results (Schork et al.,
2013), but also reduced resolution, and depending on the size distribution of anno-
tation classes being examined lead to challenges in non-biased variant assignment.
Another consideration of thresholding is ascertainment bias, or so called
winner’s curse (Xiao and Boehnke, 2009). Let β be the natural logarithm of
the population odds ratio at a given SNP, and βˆ its sample estimate, it follows
that E(βˆ ) = β , however when a threshold, α ′, is applied to βˆ we observe that
E(βˆ | |βˆ |> α ′) ̸= β , here α ′ is chosen such that α = 1−2Φ
(
|βˆ |
σβˆ
)
is the required
significance threshold ( whereΦ is the integral of the pdf of the normal distribution
and σβˆ is the standard error of βˆ ). This occurs in the context of an under powered
analysis where the effect size at the declared associated SNP will tend to be more
extreme by chance than its true value, conversely, truly associated SNPs, with
effect sizes less extreme by chance, will tend not to be declared associated.
Various methods for integrating GWAS with functional annotations that over-
come some of these inherent challenges have been suggested. These can roughly
be divided into three approaches, which I describe in detail in the following
sections.
2.2.2 Matched SNP sets methods
In a matching approach, SNPs in the functional annotation of interest are matched,
by various confounding characteristics (e.g. LD and allele frequency) to a control
set of SNPs, as exemplified by the GARFIELD software package (Iotchkova
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et al., 2019). GARFIELD takes as inputs all univariate p-values from a given
GWAS, these are then pruned, using LD information from a relevant reference
set of genotypes such that r2 is less than 0.1 between variants within 1Mb of a
trait-associated variant. Functional genomic annotations are assigned to SNPs
based on either direct overlap of SNPs in the pruned list or overlap with those in
strong LD (r2 > 0.8).
As previously discussed, due to factors including gene length, minor allele
frequency and residual LD after pruning, the significance of any enrichments calcu-
lated will be inflated. To overcome this an empirical distribution of the enrichment
under the null hypothesis, that there is no enrichment, must be computed. To do
this GARFIELD repeats the steps described in the previous paragraph on random
sets of variants that have been matched to the true set by key metrics including
number of LD partners, distance to the closest transcriptional start site (TSS) and
minor allele frequency (MAF). Thus, by computing many of these matched null
enrichment statistics an empirical p-value can be computed that is adjusted for
potential confounders.
2.2.3 Circularised permutation methods
Drawing on insight gained from the ENCODE project (ENCODE Project Consor-
tium et al., 2007), Bickel et al. (2010) rigorously described a ‘block subsampling
method’ which can robustly assess the dependence of one genomic annotation
with another. The utility of such an approach, albeit in a simpler form was demon-
strated in the analysis of tissue specific gene expression within human regions of
differing levels of Neanderthal ancestry (Sankararaman et al., 2014). Trynka et al.
(2015) were the first to show that such an approach, exemplified in the GoShifter
software, could be used to overcome not only the non-random distribution of
genomic annotations with respect to each other, but also the correlation between
GWAS signals caused by LD.
In brief the method employed by GoShifter (Trynka et al., 2015), is composed
of three steps; Firstly, (Figure 2.1(a)) for a given SNP indexing an association,
all variants above a certain LD threshold (r2 > 0.8) are retrieved using a relevant
reference genotype set (e.g. 1000 Genomes (1000 Genomes Project Consortium
et al., 2015)). Secondly the proportion of annotations which overlap one or more of
these variants is computed. Finally the region encompassing all variants identified
in initial step is circularised (Figure 2.1(b)). Random rotations of the circularised
region are then performed whilst keeping SNP position constant, preserving the
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Index SNP
AnnotationLD SNP
c) Rotationb) Circularisationa) SNP Selection
Fig. 2.1 GoShifter method overview; a) SNPs in high LD with a SNP indexing
the association signal of interest are selected. SNPs overlapping the functional
annotation of interest are counted in order to compute an enrichment statistic.
b) In order to generate a null distribution of enrichment statistics, the LD block
defined by variants in a is circularised, such that the ends are joined. c) This
circularised block is then rotated, whilst keeping the positions of SNPs constant,
again counting those SNPs that overlap the functional annotation of interest. Step
c is repeated many times in order to generate the required null distribution of
enrichment statistics.
structure of both annotation and variant data (Figure 2.1(c)). For each of these
random shifts, the proportion of features overlapping variants is recomputed,
which is used to generate a set of empirically derived null statistics. An empirical
p-value can then be computed as the proportion of null statistics exceeding the
observed overlap proportion.
2.2.4 Statistical modelling methods
The final approach, exemplified by fgwas (Pickrell, 2014) and PAINTOR (Kichaev
et al., 2014), requires the specification of a joint probability model of variant
association and annotation membership based on physical overlap. Whilst the
goal of this approach is enhanced fine mapping a bi-product is computation of
annotation specific priors or weights that can be interpreted as an enrichment
statistic.
Taking the fgwas approach as an example the likelihood is specified as follows:
L (y|θ) =
M/K
∏
k=1
(
Pok (1−Πk)+Πk
k
∑
i=1
πikP1ik
)
. (2.1)
Here K and M are parameters of the approach used to model LD, such that the
former represents the number of SNPs in a block and whilst the latter is the total
number of SNPs to be considered. P0k is therefore the probability of the observed
association statistics (Dk) across a block k under the assumption that there are
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no causal variants or P(Dk|H0). Conversely, P1ik is the probability of Dk under
the assumption of one causal variant, or P(Dk|H1). Finally, for the kth block, Πk
and πik are prior probabilities for the block or the ith SNP to be the causal SNP
respectively. Importantly, πik is modelled as:
πik =
exi
∑ j∈Sk e
x j
, (2.2)
where Sk is the set of SNPs in block k and
xi =
L
∑
l=1
λlIil, (2.3)
where l indexes annotations while L is the number of annotations and Iil is set
to 1 if the ith SNP overlaps annotation l and zero if not. The relevant parameter
for assessment of enrichment of GWAS association signals in an annotation l is
λl . fgwas optimises the likelihood (Equation 2.1), for a given dataset, and in so
doing ’learns’ values of λ across all input functional annotations, L. Care has
to be taken not to overfit the model to the data and fgwas employs a penalised
regression strategy in order to mitigate this. The likelihood function employed
by fgwas is hierarchical, and this additional flexibility allows the modelling of an
arbitrary number of annotations in an additive manner.
Limitations of existing approaches
Trynka et al. (2015) used simulation to compare GoShifter to the matched SNP
set approach and noted that the latter was not well calibrated to control for Type 1
error. They also detected a dependence between choice of matching parameters
and observed enrichment. Conversely the circularised permutation approach they
employ is based on few assumptions, it does however suffer from the fact that
it takes an implicit thresholding approach requiring an input of index variants.
As previously discussed (Section 2.2) this will result in missing associations that
might be driven by sub genome-wide signals and loss of resolution when applied
at the genome-wide scale.
Both statistical modelling and circularised permutation approaches can be used
to examine conditional enrichment between annotations, allowing insights to be
gained as to how correlation between two sets of distinct annotations (e.g gene TSS
and DNaseI hypersensitivity) might be driving enrichment. In theory, matched
SNP set approaches could be accommodated to allow for this functionality, in
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practice the increase in constraint in selecting matching background sets would
make accurate estimation of empirical p-values increasingly challenging.
Both statistical modelling and SNP matching approaches do not make specific
provision for localised structure within an annotation. As mentioned it is important
to control for intra-annotation dependencies within features of the same annotation
type in order to prevent inflation of enrichment test statistics. Indeed, this is a key
strength of circularised permutation techniques.
Another consideration is the complexity of the approach. The statistical mod-
elling approaches are the most computationally and operationally complex, espe-
cially when multiple annotations are considered. Both GoShifter and GARFIELD
are considerably less complex and as a result easier to employ, however this comes
at the cost of flexibility in the number of annotations that can be jointly considered.
It should be noted that the statistical modelling approaches generate enrichment
statistics that are calibrated to be employed as prior probabilities in downstream
fine mapping experiments, as such, enrichment is an intermediate rather than an
ultimate goal of such approaches.
2.3 PCHi-C maps: description and exploratory data
analyses
2.3.1 Tissue coverage
In this thesis I analyse PCHi-C contact maps for a total of 17 primary cell types of
the haematopoietic lineage and their empirical derivation as detailed in Javierre
et al. (2016). Briefly, each cell type was assessed over at least 3 biological
replicates (Table A.1). Promoter interacting HindIII fragments were called using
the CHiCAGO pipeline (Cairns et al., 2016).
2.3.2 Data format description
Contact maps in PeakMatrix format, consist of a baited or sequence captured
HindIII fragment, known as a ‘bait’ and a list of interacting HindIII fragments or
promoter interacting regions (PIR) within a particular cellular contexts (Figure 2.2).
Thus one row represents one interaction, between a bait and PIR. Additional
columns map CHiCAGO scores from each of the cell types examined. As the
number of bait pair interactions analysed by CHiCAGO is large, only those that
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Fig. 2.2 Illustration showing PCHi-C contact map of interactions for DUSP4. The
promoter capture HindIII fragment is labelled as ‘Bait’ and is highlighted in grey.
For ‘Tissue 1’ (black), a significant (CHiCAGO score > 5) interaction with a
downstream HindIII fragment or ‘Promoter Interacting Region’ (PIR) is shown
in blue. In contrast for ‘Tissue 2’ (red) CHiCAGO does not identify a significant
interaction. This information is encoded in one line of Peak Matrix format as
illustrated.
show evidence for at least one significant interaction (CHiCAGO score > 5) across
the 17 cell types are included.
2.3.3 CHiCAGO score distributions across cell types
I first wanted to understand at a global level, how CHiCAGO scores varied across
the different cell types. However, although CHiCAGO scores are quantitative
they are challenging to interpret due to their complicated bimodal distribution
(Figure 2.3a), with a majority of scores having a score of zero, a second peak
around 2 and an extremely large range (0-52). One method, employed in Javierre
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et al. (2016) to rescale data with large ranges, is the sinh−1 transform, which
reduces the variance and thus range in a non linear fashion. This is desirable
so that large CHiCAGO scores do not have undue influence on any inferences
made. In general, with this transformation applied the distribution across tissues
is very similar (Figure 2.3b), however neutrophils exhibit a different distribution,
with many more very low scoring fragments observed, potentially reflecting their
unusual segmented nuclear morphology (Javierre et al., 2016).
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Fig. 2.3 Distribution of CHiCAGO scores. a) Distribution of raw CHiCAGO
scores, across all cell types. There is an extreme right hand tail distribu-
tion, and for clarity scores above 50 are not shown. b) A ridge plot showing
arcsin(CHiCAGO score) distributions across Cell types. In both panels the red
dashed line represents CHiCAGO significance level.
2.3.4 CHiCAGO scores reflect lineage specificity
I used principal component analysis (PCA) on sinh−1 transformed CHiCAGO
scores to examine structure within the data. Overall approximately 50% of the
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variance was explained in the first two components. Using the PCA derived
loadings across all cell types and components I computed the Euclidean distance,
using this to perform ‘complete’ linkage agglomerative hierarchical clustering (See
Section 4.4.1). This analysis was able to broadly recapitulate the haematopoetic
lineage tree (Figure 2.4) providing support for the biological relevance of this
PCHiC dataset. In order to assess the influence of CHiCAGO score thresholding
on this result, I carried out a similar analysis setting all CHiCAGO scores less than
five to zero, obtaining identical clusters. This indicates that this lineage specific
signal is unaffected by employing the recommended thresholding approach and is
therefore appropriate for subsequent analyses.
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Fig. 2.4 Hierarchical clustering of PCHiC by CHiCAGO score profile that broadly
reconstitutes the Haematopoietic tree. Lymphoid; nB - naive B cells, tB - total B
cells, FetT - Fetal Thymus, aCD4 - activated CD4+ T cells, naCD4 - non-activated
CD4+ T cells, tCD4 - total CD4+ T cells, nCD8 - naive CD8+ T cells, nCD4
- naive CD4+ T cells, tCD8 - total CD8+ T cells. Myeloid; Mon - Monocytes,
Neu - Neutrophils, Mφ2 - M2 Macrophages, Mφ1 - M1 Macrophages, Mφ0 - M0
Macrophages, EndP - Endothelial Precursor cells, MK - Megakaryocytes, Ery -
Erythroblasts.
2.3.5 Characterisation of the localised structure within a PCHi-
C map
As discussed in the introductory material, for a given functional annotation (e.g.
DNase I hypersensitivity) there might be considerable localised structure. I expect
this to be a particular issue with PCHi-C datasets, as whilst PIRs might occupy
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seemingly disparate physical locations, they are all linked to one or more captured
promoter HindIII fragments. Due to this bait sharing, PIRs are likely to have
local structure as a result of both biological and technical phenomena. Local
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Fig. 2.5 Method for detecting local correlation structure in PCHi-C data. Squares
indicate individual PIRs, with pink to red indicating low to high CHiCAGO scores.
Duplicate PIRs are removed to obtain S′, which is duplicated and shifted to obtain
S′i. Spearman’s ρ is computed between S′ and S′i, with ρ ≫ 0 indicating the
presence of substantial local structure.
structure will manifest as a spatial correlation between fragment CHiCAGO
score and physical separation, which I examined using the following approach.
Let S = {s1,s2, . . . ,sm} be a column vector of CHiCAGO scores for m PIRs for a
particular cell type, ordered by PIR position (Figure 2.5). Where a PIR has multiple
scores (due to the interaction with multiple baits) I randomly sample one score
for that PIR in order to prevent duplication to obtain S′. I do this as the method
relies on offsetting and duplicate PIRs compromise such an approach. Taking S′
as a reference I shift PIRs by an offset i to obtain S′i = {s1+i,s2+i, . . . ,sm+i}. If
S′ is independent from S′i and if i > 0 we expect cor(S′,S′i) = 0. As shown in
Section 2.3.3, CHiCAGO scores do not follow a normal distribution, therefore I
use the non-parametric, Spearman’s correlation, taking the mean of the correlation
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coefficient ρ as a summary of the correlation structure across cell types. Focussing
on chromosome 1 I selected values of i, the fragment offset, that allowed the
interrogation of both local and distal correlation structures.
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Fig. 2.6 Extent of correlation between CHiCAGO scores and physical location for
PCHi-C maps
Across all cell types I observed large amounts correlation at smaller offsets,
demonstrating that local correlation structure presents specific challenges when
working with PCHi-C datasets (Figure 2.6). This effect decays and is nominal at
larger distances reflecting the nature of the underlying biological process being
assayed. At extreme offsets above 1000 I see a small negative correlation, that
can be explained as stochastic sampling variation in ρ as it approaches zero. This
finding of significant local dependence between PIRs underscores the importance
of employing an enrichment method specifically designed to mitigate against this
in order to generate well calibrated and believable enrichment statistics.
2.4 GWAS compendium: description and data pro-
cessing
In order to investigate a broad range of phenotypes I downloaded GWAS summary
statistics, covering 8 immune-mediated and 23 other traits, from online resources
(Table2.1). Genotyping error can create false associations, therefore I filtered all
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association statistics to include only robust associations by removing those SNPs
which were genome-wide significant (P < 5× 10−8) but for which no variants
within 500Kb and in LD (r2 > 0.6) with the lead SNP existed. Finally I removed
any SNP that was genome-wide significant but was not found in the 1000 Genomes
Phase III EUR genotype set.
There was a high degree of variation in the coverage of GWAS summary
statistics obtained, some studies contained information on approximately 5×105
SNPs whereas others were imputed to 1000 Genomes reference genotype set and
contained in excess of 7× 106 SNPs (Figure 2.7). This difference in coverage
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Fig. 2.7 Coverage, pre and post PMI over the Compendium of 31 GWAS traits.
Traits are grouped by broad categories, Immune-mediated (blue), Blood (red),
Metabolic (green) and Other (black). Grey shading indicates count of PMI imputed
SNPs, white counts where data was available from original dataset. The red line
is the mean of the total coverage over the entire dataset (≈ 6×106 SNPs). Trait
labels are expanded in Table 2.1.
will negatively impact the ability to annotate association signals to PIRs, which
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Trait Label Cases Controls
Multiple sclerosis MS 9,772 17,376
Celiac disease CEL 4,533 10,750
Type 1 diabetes T1D 8,000 8,000
Crohn’s disease CRO 6,333 15,056
Primary billiary birrhosis PBC 2,764 10,475
Ulcerative colitis UC 6,687 19,718
Systemic lupus erythrematosus SLE 4,036 6,959
Rheumatoid arthritis RA 14,361 43,923
Type 2 diabetes T2D 12,171 56,860
Haemoglobin HB 4,627
Mean corp. haemoglobin MCH 4,627
Packed cell volume PCV 4,627
Mean corp. haemoglobin conc. MCHC 4,627
Red blood cell count RBC 4,627
Mean corpuscular volume MCV 4,627
Platelet count PLT 48,666
Platelet volume PV 18,600
Body mass index BMI 322,200
Low density lipoprotein LDL 95,454
Tryglycerides TG 96,598
High density lipoprotein HDL 99,900
Total cholesterol TC 100,184
Insulin sensitivity INS 51,750
Insulin sensitivity BMI adj. INS BMI 51,750
Glucose sensitivity GLUCOSE 58,074
Glucose sensitivity BMI adj. GLUCOSE BMI 58,074
Height HEIGHT 253,288
Diastolic blood pressure BP DIA 69,395
Systolic blood pressure BP SYS 69,395
Lumbar spine bone mineral density LSBMD 32,961
Femoral neck bone mineral density FNBMD 32,961
Table 2.1 Compendium of 31 GWAS studies analysed. References for each study
included are available in Table A.2.
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in turn will complicate between study comparisons. Imputation can be used
to compute approximate association statistics for missing variants, however, it
generally requires access to underlying genotype data, which in this case was
unavailable for most traits. Methods exist for imputing summary statistics in the
absence of genotyping data such as GCTA (Yang et al., 2011) and IMPG (Pasaniuc
et al., 2014). These rely on access to either signed Z scores, odds ratios or β
coefficients and their standard errors, in order to estimate direction of effect, which
were not available for all studies in the compendium. This motivated me to develop
an alternative method to allow the processing of a wide range of traits for which
SNP coverage is heterogeneous and only univariate p-values are available.
2.4.1 Defining approximately LD independent blocks
As previously discussed (Section 1.3.1), LD is pervasive in the genome, and thus
a single causal variant at a given genetic locus will result in the statistical, but
non-causal, association of multiple variants. In order to assess the evidence for
variant causality that is comparable across multiple traits it is useful to derive
an a priori heuristic approach to grouping putative causal variants sharing an
association signal. In order to generate approximately independent LD blocks, I
used recombination frequency data derived from the CEU sample set of the Inter-
national HapMap Consortium (International HapMap Consortium et al., 2007) as
all GWAS in the compendium were derived from samples of European ancestry.
To generate blocks, for each chromosome, I ordered variants for which recombi-
nation frequency data was available according to GRCh37 human genome build.
I next computed the cumulative sum of recombination frequencies across the
ordered variants, for each chromosome, using 1cM boundaries to define groups of
variants in linkage disequilibrium. Using these ordered blocks of variants I derived
adjacent physical intervals. To do this I selected the variant from the previous
block with the largest physical location to define a start, defining the end as the
position of the variant in the current block with the maximal physical coordinate.
Such a scheme creates adjacent but potentially overlapping physical regions, and
to avoid this I added 1 base-pair the start coordinate of each block.
2.4.2 Poor man’s imputation pipeline
The poor man’s imputation pipeline (PMI) I developed, approximates the p-values
for missing SNP summary statistics for a given study using a suitable reference
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genotype set. Firstly the genome is split into approximately LD independent LD
regions (Section 2.4.1) enabling downstream LD computations to be tractable. For
each region I retrieve from a relevant reference genotype set (e.g. 1000 genomes)
all SNPs that have MAF > 1% and use these to compute pairwise LD in the
1000 Genomes European population cohort (EUR). The pipeline pairs each SNP
with missing p-values to the study SNP with maximum pairwise r2, r2max, if that
r2max > 0.6, and imputes the missing p-value as that at the paired SNP. SNPs with
missing data or without a pair above threshold are discarded, as are SNPs that are
included in the study but do not map to the reference genotype set.
2.4.3 Evaluation of PMI performance
Before using PMI in further analyses I wanted to assess the its performance
compared to classical imputation, where full genotypes are available. Firstly, I
selected all chromosome 1 SNPs from Okada et al. (2014), as a representative
sample. This study constitutes a well powered and fully EUR imputed data set.
To create a simulated non-imputed data set I pruned these results to contain only
SNPs for which p-values were reported in Stahl et al. (2010). I ran PMI on this
pruned data set and using bedtools (Quinlan, 2014), aligned the PMI generated
p-values with those from Okada et al. (2014). This resulted in a comparison
between 235,412 PMI imputed SNPs (Figure2.8).
Generally, there was good agreement between PMI imputed p-values and
those derived from classical imputation as reported in Okada et al. (2014) (ρ =
0.94). However, I note that there is considerably more noise in the more modestly
associated SNPs for which PMI tends to inflate evidence for association. An
explanation for this is that the assignment of p-values based on the PMI method
does not take into account the degree of LD. For example a pair of SNPs where
r2 > 0.99 will be highly correlated and therefore it is reasonable to expect similar
p-values. Conversely, if two SNPs are in more modest LD (e.g. r2 = 0.6) we
might expect a decay in association between the two. Such an effect is modelled
by classical imputation approaches (used in (Okada et al., 2014)) but not PMI
and thus might explain some of the modest inflation in PMI summary statistics
detected.
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Fig. 2.8 Comparison of p-values imputed by PMI versus those reported in Okada
et al. (2014) for Chromosome 1, each hexagonal point represents a bin of SNPs
with dark blue and light blue representing low and high counts respectively.
2.4.4 Generation of single causal variant posterior probabili-
ties
As discussed in Chapter 1, univariate GWAS p-values are unable to capture how
confident we are that a SNP is truly associated with a trait. The asymptotic Bayes
factor described in Wakefield (2009) is an attractive alternative as it integrates
information about study design and MAF into one metric albeit with the addition
of some strong assumptions (Section 1.3.5). The main assumption is that, for a
given locus, there exists up to one causal variant. This leads to the question of the
best way, genome-wide, to segment the genome, so as to minimise violation of this
assumption. One option is to select the set of segments for which LD for a given
population is minimised between adjacent segments. Liu et al. (2010) utilised
HapMap recombination data in the setting of GWAS pathway analysis to achieve
this and in follow up work I had found this to be a suitable segmentation (Burren
et al., 2014). Therefore for these reasons and for consistency I used the same LD
segmentation employed in the PMI pipeline (≈ 1cM). Another reason for using
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this framework is that because the single causal variant posterior probabilities
(sCVPP) are derived from a joint model of signals across a given region, LD is
naturally taken into account. This mitigates some of the negative effects of PMI,
naturally attenuating imputed signals with many LD partners. This occurs because
the sum of sCVPP across an LD block is equal to the posterior probability for
the region to contain a causal variant (Wellcome Trust Case Control Consortium
et al., 2012), which cannot exceed 1. Due to this joint modelling, large signals for
variants with many LD partners, exacerbated by PMI, will be equitably shared
thus reducing their overall individual impact, naturally reflecting the difficulty of
assigning causality to variants within blocks of extended LD.
2.4.5 Prior selection
The computation of aBF requires the selection of two priors. The first is πi which
is expectation of the ith SNP to be causal. I used πi = 10−4 ∀ i, that is we expect
1 in 10,000 SNPs across the genome to be causal (Giambartolomei et al., 2014).
The second prior relates to the value of
√
W , the standard deviation of a normal
prior for effect size θ such that θ ∼ N(0,W ), which depends on study design
considerations. For case/control studies I employ a value of 0.2, this is equivalent
to a 95% belief that the true relative risk is in the range of 0.66− 1.5 at any
causal variant (Huang et al., 2017). For quantitative trait settings I use 0.15, this is
because under the assumption that the outcome variable is normalised such that
it’s variance is 1, this is equivalent to a variance in trait explained of approximately
0.01 for a SNP with a MAF of 30%. The justification for these priors in discussed
further in the supplementary text of Giambartolomei et al. (2014) and Huang et al.
(2017).
2.4.6 HLA region
I excluded the HLA region (GRCh37:chr6:25-35Mb) from all downstream analysis
due to its extended LD and known strong and complex association with autoim-
mune disease. Both of these properties would overwhelm subsequent analysis
making it difficult to assess whether enrichment was solely driven by the HLA.
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2.5 blockshifter development
I sought to develop a method for efficient integration of GWAS data with PCHi-C
maps in order to assess enrichment of GWAS associations for each trait across
different tissues. Due to the reliance of PCHi-C on HindIII restriction fragments
and the high degree of localised structure in the data, publicly available enrichment
tools (as discussed Section 2.2) were unsuitable. Furthermore I wanted to develop
a non-thresholded approach based on the causal variant posterior probabilities
computed for the reasons outlined in Section 2.4.4.
Considerations
Any tool developed would first and foremost need to be able to account for
substantial local correlation structure (Section 2.3.5) that is present in both GWAS
and PCHi-C datasets (Figure 2.6). In order to be easily interpretable, any method
should compare the enrichment of a set of PCHi-C contacts between two sets of
tissues (a test and control set) in a competitive manner. Finally the implementation
should allow for the fast computation of enrichment statistics without the need for
high performance computing infrastructure.
For global tissue enrichment purposes we are concerned with PIRs and ignore
their promoter specific bait linkages i.e. a PIR which interacts with any bait is
considered to potentially relate to enhancer presence. This results in considerable
duplication as the same PIR can interact with multiple baits. I removed these
using the R duplicate command prior to subsequent analysis in order to speed
up performance.
2.5.1 The blockshifter method
I developed a hybrid circularised permutation method (Section 2.2.3) called block-
shifter, implemented in R, that satisfied the requirements above. This method
is competitive in nature and therefore requires user defined sets of test and con-
trol tissues for comparison, in addition to pre-computed GWAS study sCVPPi
(Section 2.4.4).
blockshifter uses a statistic, δ , the difference in the mean sCVPP between
variants overlapping a set of test and controls PIRs,
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δ =
(
1
n1
∑
i:i∈PIRtest
sCVPPi
)
−
(
1
n2
∑
i:i∈PIRctrl
sCVPPi
)
=
(
1
n3
∑
i:i∈PIRtest\PIRctrl
sCVPPi
)
−
(
1
n4
∑
i:i∈PIRctrl\PIRtest
sCVPPi
)
, (2.4)
where i indexes variants and n1 . . .n4 are the number of variants overlapping
a given set. Equation 2.4, shows that PIRs that are found in both test or control
sets are uninformative and therefore can be discarded and sufficient statistics to
calculate δ in each PIR are ∑i:i∈PIR and | i : i ∈ PIR | which can be efficiently
pre-calculated for a trait and stored.
Whilst the distribution of δ under the null could be estimated empirically,
central limit theorem specifies that the normalised sum of a large set independent
random variables is approximately normal, even if the random variables themselves
are not normally distributed. Such an approach is attractive as estimating the
normal distribution under the null, N(δnull,σ2δnull) requires fewer permutations as
only, E(δnull) and σ2δnull parameters require empirical estimation. Local correlation
between GWAS signals and between PIRs means that the variance of δnull will
be inflated if it naively calculated, as the sum of independent items. It therefore
must be estimated through a permutation procedure that preserves local correlation
structure
To increase the efficiency of this permutation, runs of one or more PIRs,
separated by up to n HindIII fragments are combined into ‘blocks’. These blocks
are then assigned into two groups based on test and control set PIR composition.
Homogeneous blocks, exclusively containing either test or control PIRs form an
‘unmixed’ group. Conversely, those with an heterogeneous composition of both
test and control PIRs make up a ‘mixed’ group. Unmixed groups are permuted
in a standard fashion by reassigning either test or control labels randomly, taking
into account the number of blocks in the observed sets.
The mixed blocks to be permuted require more care and here a modified
circularised permutation technique (Bickel et al., 2010; Trynka et al., 2015) is
employed. Each mixed block is circularised and the test or control labels of the
underlying PIRs rotated (figure 2.9). I store the mean posterior probabilities across
each possible permuted block. The number of choices at each block is small,
but there are many blocks from which sampling can take place. blockshifter then
randomly samples from each of these precomputed block permutations n times
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so that the proportion of underlying PIRs labels is the same as the observed set
and uses this to compute the set of δnull . Finally this distribution of δnull is used to
compute an empirical Z-score:
Z =
δ −δnull√
V∗ (2.5)
Where V ∗ is an empirical estimate of the variance of δnull .
HindIII
sCVPP
Observed
Block-
shifted
Fig. 2.9 Circularised permutation strategy for two ‘mixed’ blocks employed by
blockshifter. GWAS summary statistics are converted to sCVPP (red SNPs have
high sCVPPs). Mixed blocks are runs of adjacent HindIII PIRs found in either
‘test’ (purple) or ‘control’ (blue) tissue sets that are separated by n or more HindIII
fragments for which no PIR in either set exists, in this case n = 2. sCVPP can
be assigned to test or control labels based on PIR overlap and the sum for each
set can be stored. The difference in the weighted mean of the sum of posterior
probabilities between test and control sets can be used to compute enrichment.
However, to control for inflation due to correlation structure between SNPs and
between interactions I rotate the labels of HindIII fragments within the mixed
blocks to generate a set of test and control posterior probabilities under the null.
Such a strategy is not required for unmixed blocks with a single label. By sampling
from these null test statistics across the set of mixed and unmixed blocks (weighted
so that I select similar numbers of test and control PIRs to the observed data set) I
can rapidly generate an empirical null distribution, genome wide. This can be used
to adjust the test statistic to account for inflation due to underlying correlation
2.6 Power and type 1 error rates for blockshifter
Before employing any new method it is important to fully characterise its behaviour
under simulated conditions. In the case of blockshifter I wanted to examine type
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1 error rate and it’s relationship to a gap parameter indicating the number of
missing PIRs allowed within a ‘block’, which in turn defines the total number of
blocks. Intuitively selecting too small a gap size will result in a large number of
smaller blocks with a tendency to be of the unmixed block type and the resultant
permutation may be insufficient to estimate the variance of δnull. Conversely too
large a gap size will result in fewer larger blocks with a tendency to be mixed,
where larger scale PIR structure might begin to obscure more local correlation.
As described blockshifter, permutes PIR labels whilst maintaining the location
of GWAS summary statistics. Any simulation would require a reference test and
control PIR dataset that remains constant between simulations. I therefore selected
a test (Activated or Non-activated CD4+ T cells) and control (megakaryocyte
or erythroblast) set of PIRs with CHiCAGO score > 5, as a reference set for
blockshifter input.
In contrast I wanted to simulate GWAS summary statistics such that I could
control the level of enrichment and use these to understand the performance of
blockshifter under different scenarios.
2.6.1 Simulation of GWAS
In order to simplify computation I limited the simulation to utilise data for chro-
mosome 1, under the reasonable assumption that this would be representative
of genome-wide results. Firstly, I split chromosome 1 into approximately inde-
pendent LD blocks as described in Section 2.4.2. I used the EUR genotypes to
compute a correlation matrix, Σ for variants with a minor allele frequency > 1%,
using the snpStats R package(Clayton and Leung, 2007). GWAS Z scores can
be simulated from a multivariate normal distribution with mean µ and correlation
matrix Σ (Burren et al., 2014; Liu et al., 2010). Each LD block may contain no
causal variants (GWASnull ∼MVN(0,Σ)) or one (GWASalt ∼MVN(µ ,Σ), where
µ ̸= 0).
2.6.2 Enrichment scenarios
For GWASalt , I picked a single causal variant, i, and calculated the expected
non-centrality parameter (NCP) for a 1 degree of freedom χ2 test of association at
this variant and it’s neighbours. This framework is natural because, under a single
causal variant assumption, the χ2 at any variant, j, can be expressed as the χ2 at
the causal variant multiplied by the squared correlation, Σi j, between variants i
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and j (Chapman et al., 2003). In each case, I set the NCP at the causal variant to
80 to ensure that each causal variant was genome-wide significant (P< 5×10−8).
µ , the expected Z score is defined as the square root of this constructed χ2 vector.
To assess type 1 error rate and power I constructed three artificial scenarios as
follows:-
Null enrichment scenario: This scenario, is used to confirm control of type
1 error rate, and causal variants are assigned to PIRs without regard for
whether they were identified in test or control tissues.
Moderate enrichment scenario: In order to examine power, the ability of block-
shifter to reject the null hypothesis in the presence of simulated enrichment,
causal variants were preferentially located in test PIRs with a 50% probabil-
ity.
Strong enrichment scenario: This scenario mimics the preceding scenario with
causal variants being located in test PIRs with a 100% probability.
For all scenarios, I randomly chose 50 GWASalt blocks leaving the remaining
219 GWASnull . Enrichment is determined by the preferential location of simulated
causal variants within test PIRs. In all scenarios, each causal variant has a 50%
chance of lying within a PIR, to mirror a real GWAS in which we expect only a
proportion of causal variants to be regulatory in any given cell type. Note that a
PIR from the test set may also be in the control set, thus, as with a real GWAS,
not all causal variants will be informative for this test of enrichment.
In order to understand the effect of PMI, for each scenario, I further considered
variable levels of genotyping density, corresponding to ‘full’ genotyping (every-
thing in 1,000 Genomes), HapMap imputation (the subset of SNPs also in Stahl
et al. (2010) dataset) or genotyping array (the subset of SNPs on the Illumina
550 k array). Where genotyping density is less than full, I used PMI to fill in Z
scores for missing SNPs. I ran blockshifter, with 1,000 null permutations, for each
scenario and PMI-genotype density condition for 4,000 simulated GWAS, with a
blockshifter block gap size parameter (the number of contiguous non-PIR HindIII
fragments allowed within one superblock) of between 1 and 20. For all simulations
I mirrored the number of cases and controls from the RA dataset (Okada et al.,
2014).
For comparison, I also investigated the behaviour of a naive test for enrichment
for the null scenario that does not attempt to account for strong local correlation
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in both PCHi-C and GWAS datasets. I computed a 2 × 2 contingency table of
variants according to test and control PIR overlap, and whether a variants posterior
probability of causality exceeded an arbitrary threshold of 0.01, and used Fisher’s
exact test to test for enrichment.
2.6.3 Simulation results
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Fig. 2.10 blockshifter calibration. Each panel represents a simulated genotyping
density: 1,000 genomes (156,082 SNPs); HapMap (44,647 SNPs); Ilumina 550k
(10,241 SNPs). Points represent type 1 error rates (α = 0.05) for the null scenario
(no enrichment of GWAS variants in test specific PIRs) and moderate and strong
enrichment scenarios across 4000 simulated GWAS, with differing blockshifter
‘block’ gap size parameter, n. Error bars represent 95% confidence intervals.
Dashed cyan lines represent the type 1 error rate for Fisher’s test of enrichment of
variants in test and control PIRs under the null scenario.
As expected, the naive application of Fisher’s test leads to substantial inflation
of type 1 error rate, more so in lower density genotyping scenarios (cyan dashed
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lines in Figure 2.10). blockshifter maintains type 1 error rate control, although a
gap size of 5 or more is required to deal with the extended correlation induced
by PMI in lower density genotyping scenarios. As expected blockshifter power
is attenuated, by the reduction in genotyping density. Furthermore, the effect of
applying PMI to impute missing data on blockshifter seems to result in a less
powerful test with sparser, more PMI imputed values resulting in an attenuated
blockshifter enrichment statistic (Figure 2.10). Importantly, PMI data do not
display evidence for an elevated type 1 error rate.
2.7 Tissue specific enrichment of associated variants
with PIRs across 31 traits
I applied blockshifter to analyse the compendium of 31 GWAS summary statistics
for PCHiC tissue specific enrichment. By design blockshifter is a competitive test
for enrichment and requires the selection of tissues or tissue groups to compare. A
natural dichotomy, in terms of haematopoeitic lineage, exists between lymphoid
and myeloid tissues which cluster in two distinct groups as shown in Figure
2.4. Analysis with blockshifter showed that variants associated with autoimmune
disease traits are enriched at PIRs in lymphoid compared to myeloid cells (Figure
2.11a). A non parametric Wilcoxon rank sum test comparing blockshifter Z-scores
for autoimmune traits compared to the rest of the compendium showed that this
trend was significant (Wilcoxon two-sided Padj. = 1.42×10−5). A further analysis
of innate immune cells (monocytes, macrophages and neutophils) compared to
megakaryocytes and erythroblasts showed that autoimmune traits were enriched in
the former (Wilcoxon two-sided padj. = 7.03×10−4). There was some evidence
that blood traits were enriched in myeloid compared to lymphoid PIRs (Wilcoxon
two-sided Padj. = 0.005), however there was no support for this being specific
to megakaryocytes or erythroblasts when the two were compared directly which
might have been expected. There was no enrichment observed for the metabolic
or ‘other’ categories.
Given the observed enrichment of autoimmune GWAS signals in lymphoid
tissues, I performed additional comparisons to see if this could be further localised
(Figure 2.11b). The most significant of these was the enrichment of autoimmune
GWAS signals in PIRs for CD4+ T cells that had been activated, compared to
those that had not (Wilcoxon two-sided Padj. = 2.03×10−6).
2.8 Discussion | 61
CRO
CEL
HB
MCH
MCHC
MCV
MS
PBC
PCV
PLT
PV
RA
RBC
SLE
T1D
UC
−2.5
0.0
2.5
5.0
7.5
−4 −2 0 2
< Erythroblast/Megakaryocyte vs Innate Immune Z Score >
< 
M
ye
loi
d 
vs
 L
ym
ph
oid
 Z
 S
co
re
 >
Trait Category
Autoimmune
Blood
Metabolic
Other
a)
CRO
CEL
HB
MCH
MCHC
MCV
MS
PBC
PCV
PLT
PV
RA
RBC
SLE
T1D
UC
−2
0
2
4
−2 0 2 4
< Megakaryocyte/Erythroblast vs CD4+ Act/Nact Z Score >
< 
C
D
4+
 N
on
 A
ct
 v
s 
C
D
4+
 A
ct
 Z
 S
co
re
 >
Trait Category
Autoimmune
Blood
Metabolic
Other
b)
Fig. 2.11 Scatter plot of blockshifter enrichment Z scores for 31 GWAS traits.
Point colours indicate broad categories of GWAS traits. For clarity, only labels
for blood and autoimmune traits are shown (MS - Multiple sclerosis, CEL -
Celiac disease, RA - Rheumatoid arthritis, PBC - Primary Billiary Cirrhosis,
SLE - Systemic Lupus Erythematosus, T1D - Type 1 Diabetes, CRO - Crohn’s
Disease, UC - Ulcerative Colitis, PV - Platelet Volume, HB - Haemaglobin, MCH
- Mean Corpuscular Haemaglobin, PCV - Packed Cell Volume, MCHC - Mean
Corpuscular Haemaglobin Concentration, RBC - Red Blood Cell Count, MCV -
Mean Corpuscular Volume, PLT - Platelet Count and PV - Platelet Volume). Each
plot represents a set of two competitive comparisons; a) horizontal axis Innate
Immune Cells (Monocytes,Macrophages and Neutrophils) vs Megakaryocytes
and Erythroblasts, vertical axis, Myeloid vs Lymphoid. The blue area represents
enrichment for lymphoid PIRs, and the green enrichment for Megakaryocytes and
Erythroblasts PIRs. Autoimmune GWAS signals show the strongest enrichment in
Lymphoid compared to Myeloid PIRs. b) horizontal axis, Megakaryocytes and
Erythroblasts vs activated/non-activated CD4+ T cells and vertical axis, activated
vs non-activated CD4+ T cells. The blue area represents enrichment for activated
CD4+ T cell PIRs, and the green enrichment for combined PIRs across both
activated and non-activated CD4+ T cell PIRs.
2.8 Discussion
In this chapter I have described the challenges involved in computing meaningful
enrichments for phenotype associated variants with various functional genome
annotations. I have shown that by design PCHi-C annotations exhibit signifi-
cant local structure and this needs to be carefully considered when computing
enrichments. Whilst ‘off the shelf’ solutions exist, none of them explicitly models
the restriction fragment nature of PCHi-C datasets and allows the use of non
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thresholded GWAS summary statistics, stimulating the development of a novel
method.
Whilst extensive catalogues of index variants curated from GWAS exist
(MacArthur et al., 2017; Zheng et al., 2017), due to historical privacy con-
cerns (Homer et al., 2008), the full summary statistics encompassing all analysed
variants for are a given study are harder to obtain. As for most large scale data
analysis projects, a considerable amount of effort was involved in collecting and
subsequently conducting quality control on GWAS summary statistics. In the
case of immune-mediated disease ,this was ameliorated by the existence of Im-
munoBase (https://www.immunobase.org), a publicly available database of curated
summary statistics, with a streamlined data access agreement (Onengut-Gumuscu
et al., 2015).
In the time since this work was completed other publicly available compendia
of summary statistics, with a broader phenotype remit, are gaining momentum.
Whilst the Genome-Wide Repository of Associations between SNPs and pheno-
types (GRASP) database contains summary data for over 2,000 studies, these
are censored such that only variants satisfying P<0.05 are included (Eicher et al.,
2015). This can be problematic in that coverage will therefore be a function of
study size. This when combined with the variable nature of genotyping platforms
will result in highly heterogeneous coverage. Of more utility are efforts, exem-
plified by the GWAS catalogue (MacArthur et al., 2017), to compile complete
summary statistics over a broad range of traits under light touch ‘click-through‘
data access agreements. These efforts, if supported, have the ability to significantly
facilitate integrative types of analysis such as that described here.
Once summary statistics are available, due to nature of the underlying genotyp-
ing platforms utilised, coverage is heterogeneous (Figure 2.7). To a certain extent
some of this is historical, as extensive infrastructure (Das et al., 2016; McCarthy
et al., 2016) has been developed in order to simplify the task of imputing genotype
data to high density reference haplotype datasets. Nevertheless, datasets currently
available do suffer from this heterogeneity. It was therefore necessary to develop
PMI in order to overcome this.
Through simulation I was able to show that blockshifter was increasingly
conservative and that power was attenuated as genotyping density decreased,
increasing the number of PMI imputed SNPs incorporated. One concern is that
two diseases (multiple sclerosis and coeliac disease) with the lowest genotyping
density (Figure 2.11) exhibit the most enrichment. One explanation for this is that
the simulation of GWAS summary statistics is non-trivial under the alternative and
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simulated causal variants were assumed to have GWAS p-values that were above
genome-wide significance. Further work could be undertaken to use more up to
date GWAS simulation frameworks, such as simGWAS (Fortune and Wallace,
2018) to further investigate the performance of blockshifter under sub-genomewide
significant causal variant conditions in order to understand whether this might
cause significant inflation. It should be noted, however, that rheumatoid arthritis
and SLE, two large studies imputed to 1000 Genome reference still exhibited
enrichment supporting the overall finding for enrichment across the ensemble of
immune-mediated/autoimmune diseases studied.
The primary motivation behind the development of blockshifter was to as-
certain whether I could integrate a large PCHi-C dataset with GWAS summary
statistics to obtain biologically relevant enrichments. Given that the chromatin
interactions assayed by PCHi-C are enriched for enhancer elements (Javierre
et al., 2016), failure to replicate, robustly, a global enrichment for GWAS sig-
nals in a relevant tissue specific manner would discourage the further develop-
ment of methods to integrate GWAS and PCHi-C datasets. Generally given the
haematopoieitic focus of the PCHi-C dataset, I detected broadly expected en-
richment patterns with autoimmue disease enrichment in lymphoid rather than
myeloid tissue (Onengut-Gumuscu et al., 2015). In contrast, blood traits such as
mean corpuscular haemoglobin showed enrichment in erythroblast/megakaryocyte
compared to innate immune cells such as macrophages and monocytes. It was
interesting that enrichment was not detected for platelet volume or platelet count,
given the precursor role of megakaryocytes in the genesis of platelets. One ex-
planation is the growing evidence suggesting a role for platelets in both adaptive
and innate immune function (Morrell et al., 2014), as such there might be unap-
preciated overlap in cellular programs underlying megakaryocyte and adaptive
and innate immune tissues, resulting in no overall enrichment in this competitive
setting.

Chapter 3
Integrating GWAS and PCHi-C
data to prioritise causal genes and
tissues
3.1 Foreword
3.1.1 Chapter Summary
In this chapter I develop a method, capture Hi-C omnibus gene score (COGS), to
integrate genetic and chromatin conformational data in order to prioritise causal
genes and tissues for GWAS traits. I employ COGS to prioritise candidate causal
genes across the 17 PCHi-C and 31 GWAS datasets described in Chapter 2.
To characterise its utility I compare COGS prioritisation results using PCHi-C,
conventional Hi-C and proximity-based input methods. To identify putative tissue
specific mechanisms I develop a heuristic framework, hierarchical COGS which I
then apply to the compendium. Focusing on activated and non-activated CD4+ T
cells, I analyse ImmunoChip data across four autoimmune diseases and compare
the effect on COGS performance of fine mapping approaches assuming either
single or multiple causal variants in approximately LD-independent genomic
regions. Finally, I integrate orthogonal functional annotations to refine prioritised
genes and describe a biological validation in IL2RA, by a collaborator, in support
of the approach.
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3.1.2 Attributions
Parts of the work presented in this chapter are included in Javierre et al. (2016), Bur-
ren et al. (2017) and Inshaw et al. (2018) and were carried out collaboratively with
Fraser, Spivakov, Ouwehand and Diabetes and Inflammation Laboratories as part
of the BLUEPRINT/IHEC project (Stunnenberg and Hirst, 2016). Specifically:-
• Ms Ellen Schofield helped me to co-develop https://www.chicp.org (Schofield
et al., 2016), a resource to visualise PCHi-C interaction maps in the context
of GWAS association statistics. Whilst this work is outside of the scope
of this thesis, it was a useful tool in checking the validity of many of the
analyses described in this chapter.
• Dr. Csilla Varnai, Mr. Michiel Thiecke and Dr. Mikhail Spivakov provided
TAD annotations used in COGS input method comparison (Section 3.6.1).
• Dr. Roman Kreuzhuber, under the supervision of Dr. Oliver Stegle carried
out eQTL analysis (Section 3.6.4).
• Dr. Chris Wallace helped with the conceptualisation of COGS (Sections 3.4
and 3.7.1) and supplied GUESSFM results (Section 3.8.4).
• Dr. Antony Cutler, Mr. Arcadio Rubio-Garcia and Dr. Chris Wallace
provided analysed ChIP-Seq, RNA-Seq data and eRNA annotations for
activated and non-activated CD4+ T cells (Section 3.8.5).
• Mr. Daniel Rainbow and Dr. Chris Wallace provided allele specific expres-
sion data and analysis for IL2RA (Section 3.8.6).
3.1.3 Motivation
In the previous chapter I demonstrated that disease associated variants, identified
through GWAS, were enriched in PCHi-C identified PIRs in a tissue specific
manner, thus providing further support for their role in mediating disease risk.
However such a global analysis has limited value in suggesting specific causal
mechanisms for functional follow up.
By definition, each tissue specific PIR, identified by PCHi-C, is paired with a
gene promoter. This motivates further investigation as to whether they can be used
to link variants which causally affect disease risk to their target genes in specific
tissues. Such a data-driven approach to causal gene prioritisation might improve
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the efficacy of downstream functional characterisation, by providing a ranking of
not only causal genes but also relevant tissue contexts.
3.1.4 Software availability
An implementation of the COGS method as described in this chapter is available
from https://github.com/ollyburren/CHIGP under GNU General Public License
v3.0. A more portable and recent R package version, including a vignette, is
available from https://github.com/ollyburren/rCOGS under an MIT licence. Col-
laboratively, I co-developed a browser based tool with Ellen Schofield to visualise
PCHi-C results in the context of GWAS summary statistics (Schofield et al., 2016)
which is publicly accessible at https://www.chicp.org (full source code is made
available from https://github.com/ollyburren/django-chicp).
3.2 Background
In the introductory material I described how GWAS has been successful in iden-
tifying complex disease associated variants (MacArthur et al., 2017). However,
integration with functional annotations has demonstrated that many of these sig-
nals map to tissue specific regulatory sequence elements (Dendrou et al., 2016;
Farh et al., 2015; Maurano et al., 2012; Onengut-Gumuscu et al., 2015) affecting
the regulation of gene expression rather than protein coding sequence. Frequently,
through ‘chromatin looping’, these regulatory elements interact with target gene
promoters over large physical distances, often ‘skipping’ upstream or downstream
intervening gene promoters, presenting a significant challenge for variant inter-
pretation. Whilst targeted functional characterisation of individual GWAS loci
is essential (Claussnitzer et al., 2015; Davison et al., 2012; Smemo et al., 2014),
systematic, data-driven approaches have utility in narrowing the hypothesis space
by prioritising putative causal variants, genes and importantly the tissue contexts
through which they act.
3.2.1 LD and Proximity approaches
In the early days of GWAS, where emphasis was placed on locus discovery and
replication, resources were directed to enlarging sample collections and developing
complimentary methods for efficient and robust data analysis (Clayton and Leung,
2007; Purcell et al., 2007). This, combined with a paucity of information about the
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Fig. 3.1 Publication count each year, between 2001 and 2015, for FTO and IRX3.
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FTO (Frayling et al., 2007; Scuteri et al., 2007) and IRX3 (Smemo et al., 2014) in
obesity.
function of non-coding variants in relevant tissue contexts, led to the application
of expert-based heuristic methods in order to suggest causal candidate genes.
A popular framework has been to use LD or recombination data to compute a
genomic locus within which the causal variant or variants reside, intersecting
these intervals with protein coding gene annotations in order to create lists of
candidate genes. Often, such long lists, are then refined by domain experts in
order to prioritise putative causal genes for functional follow up experiments. As
discussed (Section 3.2), regulatory variation can act over large distances, making
proximity an unreliable indicator for causal gene candidacy. This, combined with
a reliance on literature and expert knowledge, for which knowledge of genes and
their biological contexts is often heterogeneous, can obscure the candidacy of
poorly characterised genes. This can in turn, feedback into the literature, as the
mention of a putative causal disease gene in an influential publication can have
a stimulatory effect on it’s future study (Figure 3.1). This self reinforcement
of the association of a particular gene with a disease can draw focus away from
other candidate genes, inadvertently retarding disease research progress. Such
difficulties in drawing reliable biological insights from GWAS have challenged
the community (Bahcall, 2012) to shift focus away from locus discovery towards
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developing methods that integrate both genetic and genomic information in order
to suggest causal mechanisms in a more data-driven, hypothesis-free fashion.
3.2.2 Population genetics approaches
One of the main data-driven approaches for linking causal variants to target
genes and relevant tissue contexts is to harness population genetic approaches, that
examine how molecular genomic quantitative traits correlate with genetic variation.
Such studies were pioneered in humans, by the analysis of the modulation of gene
expression by genetic variation (Stranger et al., 2007). Typically such expression
quantitative trait loci (eQTL) analyses, begin by the collection of gene expression
measurements for hundreds of genotyped individuals for the cell type of interest,
either using microarray, or more recently, RNA-Seq analysis techniques. This
catalogue of n genotypes and p expression levels can be combined in a series
of univariate linear regressions to identify those variants that are significantly
associated with target gene expression. In the naive setting one could consider
a genome-wide analysis where each available variant is regressed against each
gene (n× p tests). In practice such a strategy is not employed, because of the
significant multiple testing burden incurred. Since target gene proximity is related
to eQTL frequency (Brem et al., 2002) analysis is instead restricted to detecting
local eQTLs (Albert and Kruglyak, 2015), such that analysed variants are limited
to those overlapping a fixed physical window centred on the gene of interest,
resulting in many fewer tests.
In humans the detection of such local eQTL’s in a multitude of tissue con-
texts has been successful, with a recent study, GTEx, robustly detecting one or
more local eQTLs for 86% of protein-coding genes across 44 post-mortem tis-
sue types (GTEx Consortium, 2017). Identifying overlapping eQTL and GWAS
signals provides a powerful and intuitive mechanism for prioritising genes and
tissue contexts for follow up of GWAS results. In the face of ever broadening
tissue catalogues of eQTLs, interpreting such overlaps has proved challenging. For
example, GTEx found that 93% of all common variants are nominally (P< 0.05)
associated with expression of at least one gene in one or more of the tissues that
they studied (GTEx Consortium, 2017). Indeed the application of more robust
statistical methods (Giambartolomei et al., 2014; Zhu et al., 2016) designed to
overcome the effect LD plays in such overlaps, have found relatively limited robust
evidence for overlap (GTEx Consortium, 2017; Guo et al., 2015; Zhu et al., 2016).
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The powerful eQTL paradigm described is extensible to any high throughput
‘omic’ technology that can be used to robustly generate quantitative molecular phe-
notypes. Indeed it is now routinely used to assess a multitude of other functional
annotations such as chromatin accessibility (Alasoo et al., 2018; Tehranchi et al.,
2016). Whilst genotyping need only be carried out once per individual, molecular
phenotyping needs to be repeated for each trait and tissue permutation of interest.
In practice, due to understandable economic considerations this limits not only co-
hort size and thus power to detect variants with more subtle effects, but also those
functioning in specific tissue contexts relevant to disease aetiology (Rockman,
2012).
3.2.3 High throughput molecular genomic approaches
Initial human genome-wide catalogues of chromatin modification elucidated that
regions associated with complex disease were enriched for modifications marking
regions of regulatory activity using correlation between disparate elements in order
to infer target effector genes (Farh et al., 2015; Maurano et al., 2012; Thurman et al.,
2012). As discussed in detail in Chapter 1, advances in high throughput chromatin
conformational capture (Dekker et al., 2002) along with subsequent sequence
capture extensions, have allowed the consideration of specific disease loci in three-
dimensions and the physical linkage of putative causal variants with their target
gene promoters (Dryden et al., 2014; Martin et al., 2015). Further development
of high resolution PCHi-C has facilitated the genome-wide analysis of physical
linkages between GWAS association signals and their target genes (Mifsud et al.,
2015). However, none of these previous studies have combined the statistical fine
mapping methods described in Chapter 1 with PCHi-C data across disease relevant
cell types to infer causal linkages systematically.
3.3 Promoter-capture platform coverage
Throughout this chapter as the source of PCHi-C promoter interacting regions
(PIRs), I use data from Javierre et al. (2016) as described in Chapter 2. The
PCHi-C platform employed uses the same capture library as described in Mifsud
et al. (2015), originally designed to capture the promoters of 89% of Ensembl
protein-coding genes, noncoding RNAs, antisense RNAs, small nuclear RNAs
(snRNAs), microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs) available
at that time. Complete coverage is not possible due to the technical challenges in
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designing probes to capture all promoter containing HindIII fragments, such as
those in regions of the genome where there is a high degree of repetitive sequence.
3.3.1 Capture platform reannotation
Any approach linking putative causal variants to genes via PCHi-C and GWAS in-
tegration will benefit from a thorough and up-to-date integration of gene promoter
locations with HindIII fragment capture design.
I therefore re-annotated the underlying promoter sequence capture platform
(Mifsud et al., 2015) using Ensembl version 75 (Yates et al., 2016) gene anno-
tations. I defined a promoter as the physical location immediately 5’ to a gene
transcriptional start site (TSS). As genes may consist of multiple transcripts this
results in a many-to-many mapping of promoters to fragments. Assignment of
genes to fragments was conducted at the gene level and multiple TSS for the same
gene in the same capture fragment were collapsed.
3.3.2 Distribution of captured transcriptional start sites
In summary 22,076 captured HindIII fragments (baits), containing 31,253 non
redundant promoters were annotated, covering 18,202 protein-coding and 10,928
non-protein coding genes (Table 3.1). This resulted in a 90% coverage of protein
coding space of at least one promoter per gene. There was no evidence to support
a systematic failure to capture genes in specific genomic loci such as telomeric
regions (Figure 3.2).
The underlying resolution of PCHi-C is dependent on the distribution of
HindIII cut sites within the human genome, resulting in a mean and median length
of approximately 9Kb and 7Kb for captured fragments respectively (Figure 3.3a).
As expected I found a relationship between fragment size and the number of
promoters captured, with larger fragments capturing more promoters (Figure 3.3b).
As previously mentioned, a single bait might also contain multiple promoters;
these can include promoters for alternative transcripts for the same gene or more
problematically, promoters for multiple genes. Setting aside non-protein coding
genes, I found that approximately 18% of captured fragments fell into the latter
category of what I term, promiscuous baits. This rises to 33% on the incorporation
of non-coding classes of genes.
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Fig. 3.2 A karyotype coverage plot showing captured (red) and missing (blue)
protein coding gene promoters for the PCHi-C platform employed.
Gene Biotype Overall PCHi-C Bait Coverage (%)
protein coding 20,314 18,202 90
snoRNA 1,457 1,286 88
snRNA 1,916 1,571 82
antisense 5,273 3,782 72
miRNA 3,049 1,532 50
processed transcript 514 249 48
polymorphic pseudogene 45 13 29
sense overlapping 202 58 29
sense intronic 741 145 20
3′ overlapping ncRNA 21 4 19
lincRNA 7,109 1,008 14
IG C pseudogene 9 1 11
misc RNA 2,033 230 11
rRNA 526 42 8
pseudogene 13,920 994 7
IG V gene 138 5 4
IG V pseudogene 187 8 4
Table 3.1 PCHi-C sequence capture by Biotype using Ensembl v75 gene annotation.
‘Overall’ - Total number of features annotated in reference genome. ‘PCHi-C Bait’
- Total number of features captured in PCHi-C bait design.
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Fig. 3.3 Captured HindIII fragment sizes and promoter overlap distributions; a)
distribution of baited fragment sizes with blue and red broken lines indicating
median and mean fragment lengths respectively, b) mean promoter counts for
quantile bins of bait fragments stratified by promotor biotype.
3.4 A method to integrate GWAS summary statis-
tics with PCHi-C maps
3.4.1 Method overview
In order to integrate GWAS data with data linking genomic regions to gene
promoters I developed a gene score metric, Capture Hi-C Omnibus Gene Score
(COGS). In overview this metric uses trait specific sCVPP (Section 1.3.5), in
conjunction with PCHi-C maps in order to assess the evidence that a gene is causal
in specific gene and tissue contexts.
To compute an overall score for a gene I consider evidence for association of
the GWAS trait to variants across three broad sets of genomic features: coding,
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‘virtual’ promoter, and PIRs (derived from, for example, PCHi-C), within a given
approximately LD independent region (Section 2.4.1).
I quantify ‘evidence for association’ using the sCVPP. In a gene/tissue priori-
tisation setting and in the absence of individual level genotyping data the use of
sCVPP is natural albeit at the cost of the significant assumption that there is at
most 1 causal variant (per trait) in any genetic locus under consideration. One
benefit is that sCVPP can, through simple summation, be combined within a given
genetic locus, to estimate posterior probabilities that a given feature overlaps a
causal variant. This property facilitates the integration of GWAS data at a single
basepair resolution, within the larger HindIII regions underlying PCHi-C contact
maps. Another attractive feature of sCVPP is that they are computed from a joint
model of SNPs across an LD block (Wellcome Trust Case Control Consortium
et al., 2012) and thus naturally adjust for LD between variants within that block.
3.4.2 Annotation of coding variants
Whilst PCHi-C data has the prospect of linking non-coding variation to target
genes, any systematic method should take also into account other functional
annotation classes that occur in the coding space. To do this I annotated all
SNPs within dbSNP 138 (Sherry et al., 2001) using VEP (McLaren et al., 2016)
employing gene annotations from Ensembl v75 (Yates et al., 2016). I then filtered
these annotations so that I obtained the set of SNPs that overlapped protein coding
genes. Whilst there is some literature that implies that coding variation may have
regulatory potential (Stergachis et al., 2013), this has proved controversial (Xing
and He, 2015) and I chose to assign function to such variants exclusively within
the gene within which they occurred. I made no distinction between classes of
coding variation as although non-synonymous coding variants by definition alter
protein sequence, there is evidence that synonymous variants can effect profound
changes through, for example the introduction of cryptic splice sites (Rice et al.,
2013). Thus, the final set of coding SNPs (cSNPs) included all exonic variants in
protein coding genes annotated by VEP/Ensembl v75.
3.4.3 Annotation of PCHi-C ‘blindspot’ (‘Virtual Promoter’)
A limitation of the PCHi-C method is that interactions between a captured fragment
and its adjacent HindIII fragments are not able to be reliably called, as signal
is overwhelmed by random Brownian effects (Cairns et al., 2016). In order to
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capture these I created a virtual ‘promoter’ fragment (VPF) by merging each
capture fragment (bait) with those immediately 5’ and 3’ (Figure 3.4b).
3.4.4 Annotation of PIRs
I defined PIRs for a gene as those contributing an interaction exceeding a CHiCAGO
threshold of 5 as recommended by Cairns et al. (2016). In the case where a gene
has multiple baits, due to the presence of multiple TSS, it is possible for the same
PIR to be linked to a gene more than once. In such an instance, I only consid-
ered the highest scoring PIR within a given tissue when applying CHiCAGO
thresholding.
3.4.5 COGS method description
Consider a region of the genome, r that contains nr variants vi,i∈r where i indexes
SNPs across the genome and the notation i∈ r means SNPi is located within region
r. A region can contain intervals, that represent one of three categories of genomic
features previously described: coding SNPs (Section 3.4.2), VPF (Section 3.4.3)
and PCHi-C PIRs (Section 3.4.4). The posterior probability for any feature or set
of features, fr, overlapping r to contain the causal variant under a single causal
variant assumption is
∑
i:vi∈ fr
sCVPPi, (3.1)
where sCVPPi is the single causal variant posterior probability for the ith variant.
Across m regions r1,r2, . . . ,rm there may be at most m causal variants, and I
calculate the posterior probability that sets of features spread across these regions
contain at least one causal variant as one minus the posterior probability there
is no causal variant in any of them, on the assumption that there is complete
independence between the regions,
COGSg = 1−
m
∏
j=1
1− ∑
i:vi∈ fr j
sCVPPi
 . (3.2)
I select the regions such that they are approximately LD independent, and so the
assumption of independence may not strictly hold, for this reason the computed
value is not a true posterior probability and I use the term COGS score instead.
When the set of features are defined as all those linked to a specific gene g, I
denote this COGSg.
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The above framework makes the assumption that features are disjoint (i.e.
non-overlapping), however in practice overlap exists. For example variants in
the coding space will often overlap VPFs due to their proximity to gene bodies
(Figure 3.4b). To overcome this, prior to computing the COGS score, I compute
the union of all features across all categories, that is the smallest set of features
required to cover all categories, and use this as the input into the framework.
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Fig. 3.4 A schematic illustration of the COGS (Capture Hi-C Omnibus Gene
Score) method. a) GWAS summary statistics, for region r, are converted to single
causal variant posterior probabilities (sCVPPnr). b) These are intersected with
three feature sets; VPFs (pink), cSNPs (red) and PIRs (purple) linking to the focal
gene, g (blue). c) Causal feature posterior probabilities are combined through
summation to calculate posterior probabilities for a given feature set to be causal
(Equation 3.1). d) Finally these are summed to compute an overall COGS score
for g to be causal. In most cases features span multiple regions, which assuming
independence are combined to generate an overall COGS score (Equation 3.2).
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3.5 Application of COGS to a GWAS compendium
Initially, in order to simplify the assessment of COGS performance, I considered
the non-redundant set of PIRs linking to a gene, g, across all 17 primary tissues,
along with VPF and cSNPs. It is worth restating that variants overlapping the HLA
region were removed prior to running COGS, due to both its extended LD structure
and known strong and complex association with immune-mediate disease, such
that a single causal variant assumption would not be defensible.
3.5.1 Overall COGS scores for 31 traits
I used COGS to integrate this aggregated contact map with the compendium of
PMI imputed GWAS summary statistics for each of the traits detailed in chapter 2
(Table 2.1). Across all traits, the mean count of protein coding genes for which
COGS scores were generated was 16,910; differences in counts between traits are
expected due to variability in input GWAS summary statistic coverage. Overall,
the majority of gene scores were close to zero, with 99% of genes having a score
less than 0.05 (Figure 3.5).
I created a set of ‘high scoring’ genes for each trait by selecting those with an
overall COGS gene scores greater than 0.5. In total, across all traits, 2,604 unique
protein coding genes were prioritised, with a median of 112 genes prioritised per
trait (Figure 3.6a).
Height had the most genes prioritised, and INS the least. It is established that
the number of GWAS associations discovered relates to sample size, therefore
I looked to see whether there was evidence for a relationship between sample
size and the number of genes prioritised (Figure 3.6B). I observed no correlation
between sample size and prioritised gene count (Spearman’s ρ ≈−0.09,P≈ 0.6).
This is not unexpected as the number of genes prioritised will also be affected by
many other factors, including trait heritability and the relevance of primary blood
cell specific PCHi-C data used.
3.5.2 Are prioritised genes biologically relevant?
Due to the large set of genes prioritised I was motivated to perform a systematic
analysis across all traits in order to provide support for their biological relevance.
One approach, GSEA, can be a useful indicator as to whether a set of empirically
described genes, such as those prioritised by COGS, are enriched for a particular
biological function. I performed a GSEA of prioritised COGS genes over all traits
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Fig. 3.5 A density plot of COGS scores across all traits. For clarity the horizontal
axis is truncated at 0.05, although the observations extend to 1.
using the Reactome (Fabregat et al., 2016) resource as a source of curated gene
sets.
I downloaded the Reactome genesets in gmt format from MolSigDB (v6.2) (Liber-
zon et al., 2015; Subramanian et al., 2005), filtering each gene set so as to only
include those genes for which a COGS score could be computed. I used Fisher’s
test in order to assess whether there was evidence for enrichment of COGS pri-
oritised genes (Overall COGS score > 0.5) compared to background (Overall
COGS score ≤ 0.5) for each of 674 genesets. I selected as significant those
with a Benjamini-Hochberg FDR < 5%, calculated across all gene sets and baits
(Figure 3.7).
As expected, genes prioritised for autoimmune diseases (blue, Figure 3.7)
were enriched in inflammation and immune-response-related gene sets, such as
T cell receptor signaling, whereas genes prioritised for metabolic traits (green,
Figure 3.7) were preferentially enriched for lipid transport and metabolism.
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Fig. 3.6 a) Counts of prioritised COGS protein coding genes (Overall gene score
> 0.5) for 31 GWAS traits. b) GWAS sample size vs number of genes prioritised,
axis are log10 scaled.
As described in the previous chapter, robust GSEA with structured data such
as those encountered when integrating PCHi-C and GWAS is challenging and
thus such analysis is limited. Firstly, there will be correlation between COGS
scores due to LD and because PIRs can be shared between genes. Secondly,
tissues assayed by PCHi-C are derived from haematopoietic lineages, thus biasing
enrichment towards genesets relevant to these tissues. Nevertheless, such an
analysis does provide limited support that genes prioritised by COGS are broadly
of biological relevance to the trait of interest.
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Fig. 3.7 Trait specific enrichment of COGS prioritised genes within Reactome
gene sets. For clarity traits and gene sets for which no significant enrichment
(FDR<5%) was observed have been omitted. To facilitate interpretation, non
significant comparisons are shown in white. Traits are coloured according to
categories defined in Figure 3.5, blue - IMD, red - blood, green - metabolic and
black - other.
3.6 Impact of different gene-variant linking meth-
ods on COGS performance
COGS is a novel method and therefore it is important to compare its performance
under the scenario of different inputs, including PCHi-C, for linking variants to
genes. Such an assessment is challenging, however, as there are no ‘gold standard’
or comprehensive lists of causal disease genes. Indeed, only a handful genes exist
for which functional studies can provide strong evidence for their causality (Cho
and Feldman, 2015; Dendrou et al., 2016; Gregory et al., 2012; Klein et al., 2005).
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There are even fewer that have been characterised convincingly in a non coding
context (Claussnitzer et al., 2015; Dendrou et al., 2009).
3.6.1 A framework for comparing gene-variant linking meth-
ods using GWAS summary statistics
I examined three inputs for linking variants to genes as follows:-
Proximity based intervals: For each protein coding gene, I isolated the set of
HindIII fragments overlapping the relevant TSS and that were captured
on the PCHi-C platform. I extended each fragment 5′ and 3′ by 0.5Mb,
resulting in a set of genomic intervals of approximately 1Mb in size. Whilst
arbitrary such a method will capture most variants in high LD around the
target gene. When multiple TSS for the same gene were captured in different
fragments, I took the union of such intervals in order to obtain one interval
for each gene.
Topologically associated domain (TAD) based intervals: For each protein cod-
ing gene and tissue context (Table 3.2), I defined a TAD based proximity
region as the union of TADs physically overlapping a HindIII containing a
relevant TSS captured on the PCHi-C platform. TADs were obtained from
conventional Hi-C analysis of eight primary cell-types by Csilla Varnai,
Michiel Thiecke and Mikhail Spivakov (Table 3.2).
PCHi-C based intervals: For each protein coding gene and tissue I defined a
PCHi-C interval as the union of all PIRs (CHiCAGO score > 5) across
tissues (for which TAD boundary data was available) called for any PCHi-C
captured protein coding promoter HindIII fragment.
For each of the sets of intervals described above I generated COGS scores
across the eight IMDs included in the GWAS compendium (multiple sclerosis,
coeliac disease, type 1 diabetes, Crohn’s disease, primary biliary cirrhosis, ulcera-
tive colitis, SLE and rheumatoid arthritis), using PMI data sets from which I had
masked cSNPs and those SNPs mapping to the HLA region. PCHi-C and TAD
intervals generated tissue specific scores, and to facilitate their comparison with
proximity derived scores, I took forward the maximum score for a given gene
across all eight tissues considered.
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Tissue TAD Coverage (Gb)
Erythroblasts 1.53
Macrophages 1.68
Megakaryocytes 1.59
Monocytes 1.48
Naive B cells 1.51
Naive CD4+ T cells 1.40
Naive CD8+ T cells 1.51
Neutrophils 1.27
Table 3.2 Topologically associated domain coverage across eight cell types eluci-
dated from classical Hi-C analysis
3.6.2 Comparison of PCHi-C-, proximity- and TAD-based COGS
scores
Figure 3.8 shows COGS scores derived from TAD and proximal derived intervals
compared to those from PCHi-C. I categorised each gene according to whether it
was prioritised (interval method specific COGS score > 0.5) by both, a single or
neither method. For example, Figure 3.8(a), shows the comparison of proximity
(horizontal axis) and PCHi-C derived COGS scores, here the number in the top
right quadrant, 668, is the number of genes prioritised across all eight traits by
both methods.
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Fig. 3.8 Comparison of autoimmune PCHi-C COGS scores and (a) proximity
COGS score from assigning variants to genes within 0.5 Mb of gene promot-
ers (b) Hi-C derived TAD COGS scores, using seven Cell types (Erythroblasts,
Macrophages, Monocytes, Naive B cells, Naive CD4+ T cells, Naive CD8+ T
cells and Neutrophils). Counts of genes in each quadrant are shown, grey to red
colour gradient indicates gene density.
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In general PCHi-C COGS prioritised genes sets were smaller than then those
from the other methods. The naive proximity based COGS score appeared to
be least explicit prioritising 5,731 genes in total, however it had the greatest
overlap with PCHi-C COGS scores. On comparing proximity based and PCHi-C
derived scores, 83 (Figure 3.8(a)) genes were prioritised exclusively by PCHi-C
COGS, suggesting that 12% of PCHi-C prioritised genes are related to interactions
greater than 0.5 Mb. Alternatively, when comparing PCHi-C and TAD derived
COGS scores, 219 (Figure 3.8(b)) genes were prioritised exclusively by PCHi-C
COGS, indicating that approximately 30% of PCHi-C prioritised genes relate to
interactions that span TAD boundaries. To explore this further I looked at the
distance between genes prioritised by TAD and PCHi-C inputs (COGS score >
0.5) and the distribution of distances to the closest TAD boundary (Figure 3.9).
Genes prioritised solely by PCHi-C COGS seemed to be closer to TAD boundaries
compared to those prioritised specifically by the TAD method. However, the
distribution of genes prioritised by both methods is similar indicating that this
phenomenon is potentially due to the imprecise nature of TAD boundary definition,
rather than a true underlying biological phenomenon.
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Fig. 3.9 Box plot showing the distribution of distances between baits and TAD
boundaries for significant (score > 0.5) genes. ’Both’ indicates that gene was
significant using TAD and PCHi-C methods.
In summary, COGS using PCHi-C as input selects genes not found by other
inputs whilst simultaneously prioritising far fewer genes.
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3.6.3 PCHi-C prioritised genes are more likely to be differen-
tially expressed in disease patients
In addition to quantifying the relative size of prioritised gene sets, I wanted to
assess evidence for biologically plausibility. I used data from a study (Peters et al.,
2016) of gene expression data across a range of relevant tissues for individuals
with active inflammatory bowel disease (IBD) and healthy controls, hypothesising
that biological plausibility would be reflected in enrichment of genes differentially
expressed between patients and controls within a prioritised gene set.
To generate a set of differentially expressed genes, I downloaded the data from
ArrayExpress (Kolesnikov et al., 2015) (E-MTAB-3554). The data set consists
of PEER (Stegle et al., 2012) normalised microarray expression values across 49
patients with Crohn’s disease, 42 with ulcerative colitis and 43 healthy controls,
across sorted CD4+ T cells, CD8+ T cells, B cells, Monocytes, and Neutrophils. I
modified an R script from Chris Wallace to compute differential expression using
limma (Ritchie et al., 2015) with a null hypothesis that expression for a given gene
was the same across all three groups within a tissue. As PCHi-C and TAD COGS
scores calculated for the previous comparison are derived by combining over cell
types I selected the union of genes differentially expressed in at least one cell type.
To generate a set of prioritised genes for the IBD component diseases, ulcer-
ative colitis and Crohn’s disease, I used input GWAS statistics from Anderson
et al. (2011) and Franke et al. (2010) with coding and HLA variants removed. I
computed PCHi-C, TAD and proximal gene scores using only cell-types matching
those in Peters et al. (2016).
I used Fisher’s test to examine enrichment for prioritised genes, for each of
the three methods, for genes showing evidence of differential expression between
healthy, and Crohn’s disease (CD) or ulcerative colitis (UC) at a 5% false discovery
rate. I found PCHi-C genes were enriched for differentially expressed genes for
UC (P = 0.002) and CD (P = 0.04). I found no evidence of enrichment in any
data sets using proximal and TAD methods (Figure 3.10).
Whilst such an analysis is not conclusive, it provides further evidence that
integrating PCHi-C data with GWAS through COGS can prioritise biologically
relevant genes, and that this is in some sense more informative, evidenced by
smaller prioritised gene lists and higher enrichment in a biologically relevant
expression dataset than than proximity or TAD based COGS scores.
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Fig. 3.10 Enrichment of prioritised genes in ulcerative colitis and Crohn’s disease
differentially expressed genes from Peters et al. (2016).
COGS identification of biologically relevant genes in Crohn’s disease
The intersect between differentially expressed genes and COGS prioritised genes
identified 67 genes (Table B.1). Whilst there are many candidate genes in this list,
an example on chromosome 3 for ulcerative colitis provides an illustration of the
potential for hypothesis generation by integrative analysis of PCHi-C interaction
maps (Figure 3.11). COGS prioritises BCL6 which has been shown to have potent
effects on Th9 cell development and IL-9 secretion, both important modulators of
inflammation (Bassil et al., 2014). This prioritisation results from putative causal
variants suggested by Anderson et al. (2011) and more recently de Lange et al.
(2017) for Crohn’s disease (CD) that reside in intron 8 of LPP. Whilst previous
studies have implicated a causal role for LPP, PCHi-C results from lymphoid and
myeloid tissues show interactions between this region and the BCL6 promoter
(Figure 3.11).
Expression profiles from Peters et al. (2016) show that whilst LPP is not sig-
nificantly differentially expressed, in monocytes, between CD controls and healthy
volunteers (log(Fold Change) = 0.05, Pad j = 0.46) BCL6 is (log(Fold Change) =
0.22, Pad j = 0.0018), providing further support for its prioritisation.
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Fig. 3.11 Example of COGS prioritised gene on chromosome 3, ‘− log10(P)’
stanza values are taken from de Lange et al. (2017) GWAS of Crohn’s disease,
the recombination block containing the index SNP rs56116661 is shown in red.
‘PCHi-C’ stanza shows significant PCHi-C interactions in Macrophages between
the recombination block containing the index SNP and the promoter of BCL6
gene. The interaction marked in red overlaps rs56116661, with > 0.5 posterior
probability of being the causal variant according to de Lange et al. (2017).
3.6.4 Overlap of COGS prioritised genes with eQTLs
Another line of evidence supporting the functional significance of PCHi-C in-
teractions is the enrichment of eQTL signals in PIRs where the target gene is
shared between the two methods. Roman Kreutzhuber under the supervision of
Oliver Stegle had observed such a tissue specific (Fairfax et al., 2012) enrich-
ment (Javierre et al., 2016), and given the enrichment of GWAS signals in tissue
specific PIRs that I had observed, it was natural to consider the extent of overlap
between COGS prioritised genes and eQTL signals.
I took forward COGS prioritised genes in systemic lupus erythematosus
(SLE) (Bentham et al., 2015) and rheumatoid arthritis (RA) (Okada et al., 2014)
data sets, for which full imputed summary statistics were available. Out of 456
genes that were prioritised for either trait 136 had eQTLs of which four genes
(BLK, RASGRP1, SUOX, and GIN1) showed evidence for possible co-localisation
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in RA and two genes (BLK and SLC15A4) in SLE. Additionally the genes pri-
oritised for RA included 5/9 candidates (C8Orf13, BLK, TRAF1, FADS2 and
SYNGR1) that were identified in a study that combined whole blood eQTLs with
the same RA GWAS data by Mendelian randomisation (Zhu et al., 2016). The rela-
tively large number of GWAS prioritised genes without eQTL support agrees with
previous reports of limited overlap of disease variants with eQTL datasets (Guo
et al., 2015; Huang et al., 2017).
3.7 Comparison of PCHi-C COGS scores between
tissues
Analyses in Chapter 2 have shown that tissue specific PCHi-C interactions show
preferential enrichment for GWAS signals. This motivated me to extend the COGS
framework, such that it would be suitable for jointly prioritising causal genes and
tissue contexts. In Section 3.4.5, I ignored tissue specificity to simplify initial
method development and assessment. However, by restricting the sets of features
available to COGS it is possible for it to operate in a tissue specific manner.
In section 3.4.5 I showed how, under the assumption of at most a single
causal variant within a genomic region r, the posterior probability for a fragment
to contain a causal variant is the sum of sCVPP over SNPs overlapping that
fragment. The fact that the coordinates of each HindIII fragment are known a
priori allows fragment posterior probabilities to be computed and stored for a
given trait prior to computing a specific gene’s COGS score. However, given
that the set of rm regions are selected, not on the basis of alignment with HindIII
fragments, but for approximate LD independence, adjustment is necessary. This
entails the identification and splitting of all fragments overlapping approximate
LD independent region boundaries, which I term ‘LD aware’ HindIII fragments
(Figure 3.12a). Coding variation presents an additional complication, as it needs
to be assessed on a gene-by-gene basis (Section 3.4.2), however again all cSNPs
are known a priori, as such it is simple to compute ‘LD aware’ HindIII fragments
with all cSNPs removed (Figure 3.12b).
With ‘LD aware’ HindIII fragment posterior probabilities for a given trait
precomputed the generation of tissue specific COGS scores is greatly facilitated, as
it is a simple operation of selecting fragment posterior probabilities corresponding
to a gene and tissue of interest for a given region, adding in cSNPs as for the focal
gene, and then combining across regions using Equation 3.2 (Figure 3.12c).
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Fig. 3.12 Computation of feature specific COGS scores. a) The locus shown
consists of three approximately LD independent regions, r1 to r3, which are
intersected with HindIII fragments to create ‘LD aware’ fragments (alternating
grey) with all coding variants (red) removed. b) sCVPP computed using the same
LD independent regions are intersected with these ‘LD aware’ HindIII fragments
to obtain causal fragment posterior probabilities, which only needs to occur once
per trait. c) These fragment posterior probabilities can then be annotated with
any combination of VPF (pink), tissue specific PIRs (purple) and coding variants
(red) from which a feature specific COGS score can be calculated for the focal
gene (blue). In this example, coding variation in an alternative gene (green) is not
considered even though there is overlap with a focal gene PIR.
Such a scheme is fast and flexible, for example, say we wished to compute a
COGS gene score for lymphoid cells without taking into account VPF and cSNP
evidence. In this case I would select the union of PIRs across nine cell types
(nB, tB, FetT, aCD4, naCD4, tCD4, nCD8, nCD4, tCD8 - Figure 3.13) taking
forward the fragment posterior probabilities of the non redundant set of PIRs
with CHiCAGO scores greater than five. As for each trait fragment posterior
probabilities (excluding cSNPs) are stored, the computation of the COGS score
requires a simple lookup of the relevant fragments, which can then be combined
using Equation 3.2.
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3.7.1 A heuristic approach to prioritising sets of tissues
A naive approach to systematically analyse all combinations of feature sets would
require 219− 1 combinations of features for each gene, as there are 17 tissue
feature sets in addition to coding and VPF features. This motivated me to develop
a heuristic approach that utilised the overall relationships between PCHi-C tissues
learned from the data in Chapter 2 through the application of PCA and hierarchical
clustering (Figure 2.4).
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Fig. 3.13 Hierarchical clustering of PCHi-C by CHiCAGO score profile that
broadly reconstitutes the Haematopoietic tree modified from Chapter 2 to include
two non-PCHi-C nodes (red) VPF - ‘Virtual’ promoter fragments and Coding
- focal protein coding variants. PCHi-C tissues (black) are labelled as follows:
Lymphoid; nB - naive B cells, tB - total B cells, FetT - Fetal Thymus, aCD4 -
activated CD4+ T cells, naCD4 - non-activated CD4+ T cells, tCD4 - total CD4+ T
cells, nCD8 - naive CD8+ T cells, nCD4 - naive CD4+ T cells, tCD8 - total CD8+
T cells. Myeloid; Mon - Monocytes, Neu - Neutrophils, Mφ2 - M2 Macrophages,
Mφ1 - M1 Macrophages, Mφ0 - M0 Macrophages, EndP - Endothelial Precursor
cells, MK - Megakaryocytes, Ery - Erythroblasts. The Overall label illustrates
the COGS scores initially computed in Section 3.4.5 and combines both PCHi-C
(black) non PCHi-C (red) features. Nodes, representing collections of clustered
tissues at different hierarchies, are labelled in italics.
In order to incorporate the non PCHi-C featuresets I added to the root of this
tree two additional nodes representing the possibility of a variant to act through
a coding variant or to be present in a VPF (Section 3.4.3), for which tissue
assignment is not possible (marked in red in Figure 3.13).
90 | Integrating GWAS and PCHi-C data to prioritise causal genes and tissues
For a given GWAS I use COGS to compute a score for each binary decision
point or node. For simplicity consider a single region containing a focal gene for
which COGS scores derived from two feature sets F and F ′ are to be compared.
The ratio of these scores is a ratio of likelihoods under different hypotheses or
a Bayes factor (Kass and Raftery, 1995). COGS scores, however incorporate
information across multiple regions that are assumed to be independent of one
another. A COGS score ratio therefore incorporates products of (possibly) depen-
dent probabilities. In order to disambiguate and highlight this I therefore use the
term them psuedo-Bayes Factor (pBF) interpreting these pBF in a similar manner
to Kass and Raftery (1995), such that they represent ‘a summary of the evidence
provided by the data in favour of one scientific theory, represented by a statistical
model, as opposed to another’.
For example (Figure 3.14) at the root or ‘Overall’ node I compute two COGS
gene scores; one considering only coding variants and the other considering only
non-coding variants, that is those located in target gene VPFs or overlapping any
target gene PIR across all 17 primary blood cell types. The ratio of COGS scores
incorporating these different feature sets therefore reflects the strength of evidence
for a single putative causal variant exerting its effect through an alteration of
protein coding sequence, as opposed to a broader non-coding space alternative.
If the evidence for these models is balanced, such that there is equal support
for either, then the pBF ≈ 1, and the method returns an ‘Overall’ hypothesis
label indicating that a coding and non-coding mechanism are statistically not
discriminable (Figure 3.14). Alternatively, if the data supports one of the binary
hypotheses over the other then that hypothesis is returned. I again refer to Kass and
Raftery (1995) for guidance on what magnitude of pBF provides a suitable support
threshold, employing pBF < 13 or pBF > 3, to support a given binary choice
and pBF ≥ 13 or pBF ≤ 3 as ‘balanced’ (inconclusive) evidence to discriminate
between hypotheses.
I apply these tests in a hierarchical manner ‘stepping’ down the tree when
evidence is strong enough to support a decision, or sticking otherwise. For
example if a ’Non-coding’ hypothesis is favoured over ‘coding’ we move to the
‘Non-coding’ node (Figure 3.14) and compute a pBF for the next binary choice,
whether the data favours a causal variant operating through a virtual ‘Promoter’
region or through a PCHi-C identified chromatin looping or ‘Interaction’ event.
This biologically structured and hierarchical examination of the hypothesis space
continues until either 13 ≤ pBF≤ 3, such that no decision is favoured or we reach a
terminal ‘leaf’ node for which further categorisation is not possible (Figure 3.14).
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This hierarchical COGS analysis results in COGS scores at each node, and
I introduce the term lCOGS scores to disambiguate between COGS scores at
terminal ‘Leaf’ nodes from their more general counterparts.
3.7.2 Tissue specific COGS gene prioritisation across 8 immune-
mediated diseases
I applied the hierarchical COGS method described to the compendium of GWAS
traits for protein coding genes where the overall COGS score (including all tissue
PIRs, coding variants and VPF) exceeded 0.5 in order for them to be comparable
with results described in Section 3.5.1. Due to haematopoietic focus of the PCHi-C
interaction data I restricted my analysis to only blood and immune based traits,
as for metabolic and anthropomorphic traits haematopoietic contexts are unlikely
to be truly relevant for discrimination between cell types. I arranged the counts
of genes at each node for each trait into a matrix, and performed hierarchical
clustering using the ‘average’ linkage method on a log10(count+1) transformed
matrix in order to accommodate the large range (0−694) of values encountered
(Figure 3.15).
Generally the number of genes able to be assigned to specific cell types or
leaf nodes was low (IQR 0−2, mean 1.75 ), with mean gene counts ranging from
0.3 in total CD8+ T cells to 9.7 in neutrophils. In comparison non-leaf nodes
counts were higher (IQR 0−4, mean 8.1) with a large proportion driven by non
tissue-specific interactions. This extensive sharing of PIRs across cell-types, could
be due to shared underlying transcriptional programs between related tissue types
or due to the limitations in PCHi-C resolution, with disparate but tissue specific
enhancers sharing a common PIR HindIII fragment. Secondly, in regions of high
LD sCVPP will be shared across many variants, reducing resolution, and thus
making it more likely that collateral PIRs in disparate tissues will contribute to the
final COGS score. Such effects will be compounded by the genetic heterogeneity
and study design of the traits included in the GWAS compendium. With the current
approach it is impossible to disentangle the effect of power, PMI and heritability
from these counts in order to make robust biological inference.
With these caveats in mind, there are notable features that arise from the
hierarchical clustering. The foremost is that generally immune-mediated traits
(blue in Figure 3.15), with the exception of coeliac disease (CEL) appear to
cluster. On explanation might be that CEL may be affected by limited genotype
coverage, and thus a greater reliance on PMI, which is compounded by sample
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Fig. 3.14 A cladogram illustrating the hierarchical method for assigning putative
category labels to genes based on COGS scores for the AHR gene in the context
of RA GWAS summary statistics (Okada et al., 2014). The solid edges denote
the path taken by COGS through the binary decision tree. Each selected node is
labelled with an italicised pseudo Bayes factor. Leaf nodes representing specific
tissues or functional categories are labelled as follows; nB - naive B cells, tB
- total B cells, FetT - Fetal Thymus, aCD4 - activated CD4+ T cells, naCD4 -
non-activated CD4+ T cells, tCD4 - total CD4+ T cells, nCD8 - naive CD8+ T
cells, nCD4 - naive CD4+ T cells, tCD8 - total CD8+ T cells, Mon - Monocytes,
Neu - Neutrophils, Mφ2 - M2 Macrophages, Mφ1 - M1 Macrophages, Mφ0 - M0
Macrophages, EndP - Endothelial Precursor cells, MK - Megakaryocytes, Ery -
Erythroblasts, VProm - ‘Virtual Promoter’ and Coding - variants found in protein
coding regions of target gene. After each label is the leaf node specific gene score
(lCOGS). The method prioritises a causal mechanism in activated CD4+ T cells
for AHR.
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Fig. 3.15 Heatmap of hierarchical COGS analysis using COGS threshold > 0.5.
Rows and columns show traits and node labels respectively (See Figure 3.13), with
individual cells annotated with protein coding gene counts ‘stuck’ at a node for a
trait, with blue(0 genes) to red (235 genes) visually indicating this information
on the log10+1 scale. Additionally rows are annotated with their trait category
and columns with their leaf node status (i.e. whether a single or union of tissues).
Rows and columns are hierarchically clustered using ‘average’ linkage.
size, given that genes are prefiltered on overall COGS score. Indeed in the previous
chapter blockshifter analysis showed that CEL had the second highest enrichment
of GWAS signals in activated CD4+ T cells, where as no genes are specifically
prioritised in that tissue in this analysis, indicating that COGS score thresholding
may be obscuring some of the signal.
Most genes were unable to be mapped to a specific tissue context and instead
were prioritised by the non-specific ‘interaction’ class (mean 95.6). Whilst there
was some specificity this was mostly observed within collections of tissue contexts
(e.g. ‘Myeloid’), rather than at ‘leaf’ nodes, and overall whilst blood and immune
traits do cluster separately, it is challenging to separate them visually. A further
94 | Integrating GWAS and PCHi-C data to prioritise causal genes and tissues
challenge is that a PIR can interact with more than one gene promoter, and as
previously discussed a proportion of captured promoter fragments contain more
than one gene promoter. This leads to the tissue specific prioritisation of multiple
genes, and whether this is due to underlying biology or a limitation of PCHi-C
resolution remains to be elucidated. Overall this suggests pinpointing specific
cellular contexts using PCHi-C input alone is difficult, supporting the inclusion
of additional genomic information prior to functional followup, which I discuss
further in Section 3.8.5.
3.8 Cell context specific COGS analysis of immune-
mediated disease
Notwithstanding the evidence presented for a role for CD4+ T cell chromatin
organisation in immune-mediated disease, differences in DNA methylation of
immune-related genes have been observed in CD4+ T cells from autoimmune
disease patients compared to healthy controls (Coit et al., 2013; Paul et al., 2016).
CD4+ T cells are at the centre of the adaptive immune system and exquisite
control of activation is required to guide a CD4+ T cells fate through selection,
expansion and differentiation into one of a number of specialised subsets (Murphy
and Weaver, 2017). The analysis of gene expression in CD4+ T cells from 20
healthy individuals across a 21 hour activation time course supported early (< 4
hours) modulation of transcriptional programs to be of particular importance, as
this is when a majority of differential gene expression is observed (Burren et al.,
2017).
These multiple strands of evidence for the importance of early CD4+ T cell
activation, coupled with a desire to further understand how disease variants might
operate in a particular cell context specific environment, motivated me to take a
more focused approach to the integration of autoimmmune and autoinflammatory
risk loci with PCHi-C maps. To this end I decided to focus on comparing chromatin
structure between resting and activated CD4+ T cell within the context of IMD.
The focus on IMD also provided the opportunity to use an alternative collection
of association summary statistics and genotype data afforded by the ImmunoChip
platform. This genotyping platform is specifically designed to provide dense
genotype coverage of approximately 180 regions with robust demonstration of
association with one or more IMDs (Cortes and Brown, 2011). The main benefit
of using such a platform is that dense genotyping obviates the need to rely on PMI
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or imputation in order to provide sufficient resolution, albeit at the cost of reduced
genomic coverage.
3.8.1 ImmunoChip study collection description
I gathered publicly available ImmunoChip summary statistics for four IMD studies
from ImmunoBase (Table 3.3), selecting traits on the basis of access to supporting
individual level genotyping data. I fine mapped these traits using the sCVPP
method. I made one important modification by replacing the definition of approx-
imately LD independent regions (Section 2.4.1) with the 187 non-HLA regions
(median size 227Kb with an inter quartile range of between 126Kb and 392Kb)
that were densely genotyped on the ImmunoChip. Across all four diseases the
mean number of variants with summary statistics was 129,006 (IQR 129,499 and
132,323)
Trait Cases Controls Reference
Autoimmune thyroid
disease
2,733 9,364 (Cooper et al., 2012)
Rheumatoid arthritis 11,475 15,870 (Eyre et al., 2012)
Type 1 diabetes 8,000 12,272 (Onengut-Gumuscu et al., 2015)
Celiac disease 12,041 12,228 (Trynka et al., 2011)
Table 3.3 ImmunoChip studies integrated with Javierre et al. (2016) PCHi-C
datasets. All summary statistics were downloaded from ImmunoBase.
3.8.2 Allowing for multiple causal variants within a locus
One drawback of the fine mapping technique employed up to this point (sCVPP)
is that it assumes that within a given locus there are between zero and one causal
variants. When such methods are applied to loci where there are more than one
causal variant the credible intervals may not contain any causal variants with a
much higher than expected likelihood (Hormozdiari et al., 2015).
Where raw genotyping data for a study is available then forward variable se-
lection methods, such as conditional stepwise regression, can be used to elucidate
independent causal variants. Such an approach, first selects a single variant that
best explains the variance of a trait with subsequent ‘steps’ seeking other variants
that explain additional trait variance conditional on this ‘top’ variant. Such an ap-
proach is routinely applied to GWAS and strong evidence for multiple independent
causal variants within a locus has been described (Haiman et al., 2007). Whilst
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this approach is attractive computationally, doubts exist over its validity (Miller,
1984). This is because such a method is not equivalent to explaining which variants
jointly explain the variance of a trait. However, approaches that search such a
potentially large model space exhaustively are only computationally feasible for
simple models incorporating a limited number of variants (Bottolo and Richardson,
2010; Lee et al., 2018) .
An alternative approach is to use Monte Carlo methods to sample the model
space allowing the consideration of multiple causal variants within a genetic region.
One example is GUESSFM that uses a Bayesian evolutionary stochastic search
algorithm to effectively sample the model space, and has been shown to have
consistently better performance than step-wise conditional regression approaches
when variants are correlated due to LD (Wallace et al., 2015).
3.8.3 Comparison of COGS scores between single and multi-
ple causal variant approaches
I obtained, from Chris Wallace, a previous analysis of four ImmunoChip studies
(Table 3.3) using GUESSFM (Wallace et al., 2015). This afforded the opportunity
to gauge the effect of the single causal variant assumption on COGS gene scores by
comparing the genes prioritised by COGS using GUESSFM and sCVPP computed
from summary statistics, that are the usual COGS input.
I limited analysis to PCHi-C contact maps for activated and non-activated
CD4+ T cells for reasons detailed in Section 3.8. COGS requires modification
to deal with GUESSFM output that consists of vector of posterior probabilities
for causal models within a given region, r, such that p = (p1, p2, . . . , p1−q, pq)
over q models, indexed by i, that themselves can incorporate 1 or more variants.
Overall ∑qi=1 pi ≤ 1 and in this scheme it is important not to double count SNPs,
which occurs if COGS is naively applied to marginal posterior probabilities of
SNP inclusion, as the same SNP can be present in multiple models. Thus, it is
no longer feasible to precompute ‘LD aware’ fragment posterior probabilities as
described in Section 3.7.1, but instead I construct indices of variants genotyped
for a given trait and their overlap with sets of features. For example the union of
HindIII fragments incorporating PIRs for activated CD4+ T cells and VPF for a
given gene would entail the union of two lookups in order to identify genotyped
variants. The posterior probability within a region r for this set of features, fr,
to contain one or more variants, is the sum of the posterior probabilities for any
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model containing at least one of these variants
∑
i:i∈ fr
pi, (3.3)
where i ∈ fr indicates that the ith model contains one or more variants that physi-
cally overlaps with the the feature set fr, in this case CD4+ T cell PIRs and VPF.
Evidence across m regions can be combined for a gene, g, using
mCOGSg = 1−
m
∏
j=1
(
1− ∑
i:i∈ frm
pi
)
. (3.4)
Importantly, this score is comparable to COGS scores computed using the
sCVPP method employed in single causal variant COGS analysis.
Disease sCOGS mCOGS Both Total
Type 1 diabetes 16 19 33 68
Coeliac disease 21 2 35 58
Rheumatoid arthritis 16 7 17 40
Autoimmune thyroid disease 8 4 6 18
Total (%) 61 (33%) 32 (17%) 91 (50%) 184
Table 3.4 Protein coding gene count comparison between COGS prioritised genes
(COGS score > 0.5) with different inputs. sCOGS - count of genes prioritised
exclusively using as input sCVPP, mCOGS - count of genes prioritised exclusively
using marginal posterior probabilities for a set of variants to be causal from
GUESSFM analysis of raw genotyping data. Both - count of genes prioritised
using both input methods.
I ran parallel COGS analysis with two inputs, sCVPP and GUESFM, across the
four diseases, calling these sCOGS and mCOGS scores respectively. I restricted
analysis to ImmunoChip regions where data were available for both inputs. These
analyses generated an ‘overall’ COGS score that incorporated evidence from
PCHi-C data contact maps for activated and non-activated CD4+ T cells along
with coding SNP and VPFs. Across all four traits this prioritised (COGS score
> 0.5) 152 and 123 protein coding genes for sCOGS and mCOGS respectively
(Table 3.4). Overall there was modest agreement between the two input methods
with 91 genes prioritised by both methods.
As expected when genes are prioritised by both input methods, COGS scores
are correlated, and overall, across all diseases combined, Pearson’s correlation
coefficient is 0.35 (Figure 3.16). There are, however, clusters of genes prioritised
by one method, where the COGS score in the alternative method is close to zero.
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Fig. 3.16 Comparison of ‘Overall’ COGS scores for sCVPP and mCVPP (using
GUESSFM) fine mapping inputs. ATD - Autoimmune thryoid disease (Cooper
et al., 2012), CEL - Coeliac disease (Trynka et al., 2011), RA - Rheumatoid
arthritis (Eyre et al., 2012) and T1D - Type 1 diabetes (Onengut-Gumuscu et al.,
2015). Only genes prioritised (COGS score > 0.5) by at least one method are
shown. Numbers reflect the counts in each of the relevant quadrants.
One of the aims of COGS is to facilitate functional follow up by ranking genes
at a given locus. For each disease and region pair, I ranked genes using either
sCOGS or mCOGS scores. Out of a total of 79 disease-region pairings examined,
there was an 80% agreement in the highest scoring gene.
I conducted a more detailed analysis of an exemplar region, 19p13.2, in T1D,
for which multiple genes were prioritised using sCOGS input but not mCOGS
(Figure 3.17). In this region strong functional evidence for the causal candidacy
of TYK2 has been reported (Dendrou et al., 2016) and multiple independent
signals within the locus have been previously described (Onengut-Gumuscu et al.,
2015). Both input methods give the highest priority to TYK2 selected rs34536443
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as a likely causal variant in agreement with Onengut-Gumuscu et al. (2015).
Additionally, the sCVPP input prioritises a putative causal variant (rs144309607)
in the virtual promoter region of TYK2, which itself is imputed using the PMI
method. This single alternative signal is sufficient to prioritise five additional genes
through PCHi-C interactions explaining the discrepancy and it is likely that this
sCOGS specific signal is an artefact of the PMI method. The mCOGS approach
also benefits from allowing multiple causal variants: GUESSFM prioritising the
independent coding (missense) signal (rs12720356) in agreement with Onengut-
Gumuscu et al. (2015), amplifying the overall COGS score for TYK2.
The T1D susceptibility region at 16p11.2 shows a reciprocal pattern; mCOGS
prioritises five genes which sCOGS fails to prioritise at a COGS score > 0.5
(Figure 3.18). One explanation for this is that the assumption of a single causal
variant, results in a diffuse signal spread across many variants resulting in lower
overall COGS scores. In contrast, GUESSFM picks two independent signals
(rs151233 and rs151234) amplifying gene scores accordingly.
3.8.4 Cataloguing PCHi-C prioritised genes across immune-
mediated disease
Due to the modest overlap between mCOGS and sCOGS inputs and in the absence
of compelling evidence for the superiority of one input method I ran hierarchical
COGS over the ImmunoChip datasets using both inputs for PCHi-C maps of
activated and non-activated CD4+ T cells, taking forward the union of prioritised
genes. To augment this I added GWAS data for SLE (Bentham et al., 2015) and
RA (Okada et al., 2014) for which imputed summary statistics were available in
order to create a ‘long’ list of immune-mediated disease prioritised genes using the
sCVPP finemapping input method. In total I prioritised 245 unique protein-coding
genes across all datasets and analyses (Figure 3.19).
3.8.5 Integration of functional data with COGS scores
Having generated a long list of genes prioritised from the integration of GWAS,
ImmunoChip and PCHi-C datasets, I sought to understand whether orthogonal
functional genomic data might be used for to refine putative causal mechanisms.
I obtained enhancer RNA (eRNA) annotations, and total RNA sequencing data,
collected and analysed by Tony Cutler and Arcadio Rubio-Garcia from the same
donors for which PCHi-C was performed, for both activated and non-activated
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Fig. 3.17 Comparison of T1D (Onengut-Gumuscu et al., 2015) COGS scores
derived from sCVPP and GUESSFM inputs at the 19p13.2 susceptibility locus.
For clarity only protein coding genes with a COGS score > 0.01 from either
input are shown. The dark green stanza shows the union of interactions with the
TYK2 promoter in activated and non-activated CD4+ T cells, for clarity other
interactions in the region are not shown. The blue ‘GUESSFM’ stanza shows the
marginal posterior probabilities for SNPs to be causal allowing for multiple causal
SNPs. The blue ’mCOGS’ stanza presents the overall COGS scores computed
from GUESSFM model posterior probabilities for a given gene (see ‘Genes’
stanza). Similarly the red stanzas present sCVPP and resultant sCOGS scores
from allowing a maximum of one causal variant.
CD4+ T cells. Briefly, eRNAs are defined as bi-directionally transcribed RNA
species that map to ChIP-Seq derived enhancer regions but do not map to known
gene annotations (Li et al., 2016). This bi-directionality is key to the robust
identification of intronic eRNAs as it allows their separation from pre-mRNA on
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Fig. 3.18 Comparison of type 1 diabetes (Onengut-Gumuscu et al., 2015) COGS
scores derived from sCVPP and GUESSFM inputs at the 16p11.2 susceptibility
locus. Stanzas are described in the legend of Figure 3.17. All activated and
non-activated CD4+ T cells interactions for genes with COGS > 0.5 are shown.
the basis of strand. I applied a stepwise filtration based on the integration of this
data.
Of the 245 putative causal genes prioritised in the previous section (Sec-
tion 3.8.4) 179 were expressed in at least one CD4+ T cell activation state on
the basis of RNA-seq data. Of these, 118 were proximal to a GWAS significant
index variant (p< 5×10−8) through a PCHi-C connection. Within this set of 118
genes, 63 (48%) lay outside of the disease susceptibility region by which they were
prioritised. Examples include, IL6ST (124 kb from 5q11.2 susceptibility region)
in RA (Stahl et al., 2010) and GPR183 (76kb from 13q32.3 susceptibility region)
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Fig. 3.19 Results of running hierarchical COGS across five immune-mediated
diseases. On the left are results using input from imputed GWAS datasets (Ben-
tham et al., 2015; Okada et al., 2014) using sCVPP, on the right are the results
using ImmunoChip datasets (Table 3.3). Labels indicate the prioritised causal
mechanism. When the same gene was prioritised for multiple diseases, I assigned
fractional counts to each node, defined as the proportion of the n diseases for
which the gene was prioritised at that node. Numbers in brackets indicate the
fractional count of genes assigned to a non leaf node.
in T1D (Heinig et al., 2010; Wallace et al., 2012). Overall, the mean distance from
peak GWAS signal to a prioritised gene was 153kb.
Of these 118 genes, 82 were differentially expressed between activation states
(FDR< 0.01) and 48 were prioritised due to an interaction identified only in aCD4
or nCD4. Sixty-three genes were connected via ‘PCHi-C’ to a fine-mapped variant
that overlapped an expressed eRNA (Burren et al., 2017).
3.8.6 Functional validation in IL2RA
One of the genes priortised in multiple immune-mediated diseases that also ap-
peared in all the functional categories previously described (Section 3.8.5) was
IL2RA (Eyre et al., 2012; IMSGC et al., 2013; Jostins et al., 2012; Onengut-
Gumuscu et al., 2015). IL2RA encodes the CD25 protein, a component of the
IL-2 receptor that is essential for high-affinity binding of IL-2, regulatory T cell
survival and T effector cell differentiation and function (Liao et al., 2013). I found
this prioritisation to be driven by an interaction between the IL2RA promoter and
a PIR in intron 1 known to harbour a set of type 1 diabetes putative causal variants
(red group in Figure 3.20) identified in a previous fine mapping study (Wallace
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Fig. 3.20 Genomic and genetic architecture of 10p15.1 type 1 diabetes susceptibil-
ity locus. PCHi-C interactions link the IL2RA promoter to autoimmune disease
associated genetic variation which leads to expression differences in IL2RA mRNA.
GUESSFM SNP groups (‘GFM SNP Groups’ stanza) from (Wallace et al., 2015)
are partitioned by colour. PCHi-C data is for activated (green) and non-activated
(purple) CD4+ T cells, in unambiguous cases PIRs are coloured by GUESSFM
SNP group overlap. Figure adapted from an original prepared by Tony Cutler,
Arcadio Rubio Garcia and Chris Wallace.
et al., 2015). This set of variants (Figure 3.20) is in high LD (r2 > 0.8) with
rs12722495 which has been shown to associate with the surface expression CD25
in memory T cells (Dendrou et al., 2009).
Using a targeted RNA-sequencing approach, and software I helped to de-
velop previously (Rainbow et al., 2015), Daniel Rainbow measured the relative
expression of IL2RA mRNA in five individuals heterozygous across the red group
of SNPs (Figure 3.20 who were also homozygous across most other associated
SNPs, in a 4 hour activation time course of CD4+ T cells. Allelic imbalance was
observed consistently for two reporter SNPs in intron 1 and the 3′ UTR in non-
activated CD4+ T cells in each individual (Figure 3.21a) validating a functional
effect of the PCHi-C derived interaction between this PIR and the IL2RA promoter
in non-activated CD4+ T cells. While the allelic imbalance was maintained in
non-activated cells cultured for 2-4 hours, the imbalance was lost in cells activated
under in vitro conditions. Since increased CD25 expression with rare alleles in the
red group of SNPs has previously been observed on memory CD4+ T cells but not
naive or T regulatory subsets that are also present in total CD4+ T cell population,
we purified memory cells from eight red group heterozygous individuals and
confirmed activation induced allelic imbalance of IL2RA mRNA expression in this
more homogeneous population (Figure 3.21b). One possible explanation for this
is that formation of additional chromatin loops with alternative GUESSFM SNP
groups (blue, magenta, grey, cyan and green Figure 3.20) on activation overcomes
the basal effect of the more constitutive enhancer effect modulated by contact
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within intron 1. Further support for rs61839660 to be causal has subsequently
been reported (Huang et al., 2017; Rainbow et al., 2017). This empirical analysis
confirms that the identified PIR contains a variant which functionally affects the
transcription of the identified target gene (Burren et al., 2017).
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Fig. 3.21 a) Allelic imbalance in mRNA expression in total CD4+ T cells from
individuals heterozygous for the red (Figure 3.20) group of GUESSFM SNPs
using rs12722495 as a reporter SNP in non-activated (non) and activated (act)
CD4+ T cells cultured for 2 or 4 h, compared to genomic DNA (gDNA, expected
ratio = 1). Allelic ratio is defined as the ratio of counts of T to C alleles. ‘x’
represents geometric mean of the allelic ratio over 2–3 replicates within each of 4–5
individuals; p-values from a Wilcoxon rank sum test comparing complementary
DNA (cDNA) to gDNA are shown. ‘+’ shows the geometric mean allelic ratio
over all individuals. b) Allelic imbalance in mRNA expression in memory CD4+
T cells differs between ex vivo (time 0) and 4-h activated samples from eight
individuals heterozygous for red (Figure 3.20) group of GUESSFM SNPs SNPs
using rs12722495 as a reporter SNP. p-value from a paired Wilcoxon signed rank
test is shown
3.9 Discussion
Although GWAS have been successful in discovering a multitude of trait associated
loci, underlying causal mechanisms have proved to be more elusive. Whilst, LD
impedes the identification of causal variants, so their regulatory nature often
complicates functional assessment of causal genes. Often to fill this knowledge
vacuum, researchers resort to more ad hoc rather than data-driven methods for
suggesting causal candidate genes and the tissues in which they might operate.
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The results presented in this chapter suggest that PCHi-C gene prioritisation using
the COGS method developed perform better than the proximity based methods that
have been widely adopted in the field (Section 3.6.1). This increased performance
of PCHi-C COGS was evident, in the smaller total number of genes prioritised,
and the suggestion of causal genes that were not found using either proximity or
TAD based inputs (Section 3.6.2).
I found that by adapting COGS to generate prioritisation scores in a tissue
dependent manner I was able to identify, albeit for only a modest number of
cases, evidence for the importance of specific tissue context and trait combinations
(Section 3.7). Overall hierarchical clustering of these results was inconclusive
using the canonical COGS threshold (COGS>0.5) although I obtained more
robust results that discriminated blood and immune traits when this was lowered
(COGS>0.01). Leaving aside technical considerations, this apparent lack of tissue
specificity might be explained by the fact that the transcriptional programs by
which causal variants modulate disease risk might be active across a wide range of
contexts and therefore difficult to resolve at the individual tissue level.
Of course there are a wide range of technical reasons for these results which
warrant discussion. In order to explore as many traits as possible, I employed an
LD based method, PMI, in order to increase SNP coverage across GWAS datasets.
Using sCVPP derived from PMI as COGS input is likely to lead to a less robust
gene prioritisation for a number of reasons. Consider the instance where a causal
SNP is not directly typed and thus no association summary statistics are directly
available, in such a case the association can only be measured by ‘proxy’ variants
in LD. Generally, as LD between this ‘proxy’ SNP and the causal SNP decays
so too will the association. In this example, PMI will assign the association p-
value of the ‘proxy’ to the untyped causal variant, attenuating the signal, reducing
downstream fine-mapping resolution, ultimately leading to a degradation in COGS
prioritisation. The opposite is also true, if the causal variant is typed, as untyped
variants in LD, by PMI, will be assigned the same p-value. In regions of high LD
this will exacerbate the phenomenon of LD shelving, that occurs when many SNPs
are in high LD with the causal variant, such that they all have similar association
summary statistics (illustrated in Figure 3.17). Whilst such LD shelving is a true
biological phenomenon that is recognised to limit all fine-mapping methods, PMI
amplifies this, resulting in an increased uncertainty in gene prioritisation, that
manifests as a larger number of genes which themselves have lower prioritisation
scores.
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I found the assessment of which input method, sCOGS or mCOGS performed
best challenging due to the lack of a gold standard of confirmed causal genes
underlying disease susceptibility. One might expect that differences in perfor-
mance between the two input methods to be somewhat dependent on how often
the single causal variant assumption is violated. Recently, Asimit et al. (2019)
used a Bayesian multinomial stochastic search method (MFM), to simultaneously
fine-map autoimmune disease susceptibility loci across six autoimmune diseases.
They found that their fine-mapping results within regions with the strongest bi-
ological prior (i.e. containing known genes that regulate T-cell function) and
effect were more likely to be discordant with the more widely applied stepwise
conditional regression approach widely employed. One interpretation of this is
that the phenomena of multiple independent variants within a disease associated
regions is likely to exist genome-wide, but is currently hidden due to insufficient
study power or sample size. With this in mind I would expect sCVPP input to
perform less well than the GUESSFM input for those regions and overall and this
might explain the more modest overlap between the sCVPP and GUESSFM input
methods that I observed.
Underscoring the trade off, when integrating genomic and GWAS data, are
the logistics of data access; sCVPP requires only summary statistics and thus
can integrate a large selection of traits, whilst GUESSFM requires individual
level data limiting its application. It seems likely that using the fine-mapping
results of Asimit et al. (2019) as COGS input might provide a more robust set of
prioritised causal genes than the input methods I have presented although further
work is required to investigate this.
As well as the limitations due to fine-mapping input, a discussion of PCHi-C
limitations and how these might effect causal gene prioritisation is required. The
most serious, involves the blind spot for observing shorter range interactions that
involve HindIII fragments and adjoining baited interactions and I attempted to
capture these as virtual promoter fragments (VPF). This approach whilst reason-
able might result in the inappropriate assignment of variants to a gene given the
expected size of a VPF is approximately 27kb. From imputed GWAS and iChip
COGS prioritisation I found that 38% and 15% of genes were prioritised by VPF
respectively (Figure 3.19), a sizeable fraction of the total number of unique genes
selected. Whilst incorrect assignment of variants to a gene on the basis of VPFs
will result in more genes prioritised adding noise to the gene list, it would not
by itself disadvantage true causal genes from being prioritised. In such cases the
integration of additional sources of genomic information, for example chromatin
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accessibility and gene expression data prior to selecting genes and tissue contexts
for functional followup is essential (Kumasaka et al., 2019; Pickrell, 2014).
A second more pernicious issue is that many baited fragments are promiscuous
in that they contain promoter regions for more than one gene. For these promis-
cuous baits it is impossible to resolve which promoter or promoters are involved
in the chromatin looping, using the current PCHi-C data alone. One approach is
to use gene expression patterns to provide a filter for target genes identified by
specific chromatin interactions, which I discuss in section 3.8.5. Furthermore, my
analysis to date has concentrated on protein coding genes as these have the most
mature and complete annotation, however, research has suggested a role for non
coding genes in the modulation of autoimmune disease susceptibility (Castellanos-
Rubio et al., 2016). The PCHi-C platform used does provide some coverage of
the non protein coding genome, however this is not exhaustive by design and
due to the overlapping nature of the coding and non-coding genome, the issue of
promiscuous baits is worsened.
The introduction of an alternative restriction enzyme that cuts at greater fre-
quency thus resulting in, on average, shorter fragments, might overcome some of
these issues (Chesi et al., 2018). It will however introduce additional challenges;
the shorter fragments will make it more difficult to identify unique sequence for
capture design, exacerbated by the increased number of fragments to be captured,
which in turn will require more sequencing in order to provide adequate sequence
coverage.
Another limitation is the threshold approach to CHiCAGO scores that are used
to call interactions. All of the methods developed so far use a threshold score of
5, so that an interaction with a score of 4.99 will be omitted. I am aware of an
alternative method, based on a Bayesian sparse variable selection approach (Ei-
jsbouts et al., 2019), that will allow the assignment of posterior probabilities to
interactions that might obviate the need for this threshold approach. An extension
of COGS would be required in order to integrate the two posterior distributions
(location of causal variants and PCHi-C contacts) and this is a promising avenue
for future research.
Excluding single cell implementations, all genomic technologies give an av-
erage of the molecular events across the (sometimes mixed) population of cells
being assayed. In the case of immune subsets this is particularly relevant as broad
categories, such as CD4+ T cells will be heterogeneous containing further subdi-
visions that may or may not be relevant for disease biology. It is important to bear
this in mind when considering PCHi-C maps, as without single cell profiling (Tan
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et al., 2018), it is impossible to resolve whether interactions are common across the
assayed tissue type or are specific to, an underlying, and as yet unsorted, subset.
Given the limitations of PCHi-C and the differences between input methods
and thus the veracity of the genes prioritisised, I think it important that further
genomic information is taken into context before embarking on further functional
studies. Ideally such genomic data should be for the same cellular contexts and
if possible the same individual donors for which PCHi-C was performed. In my
analysis the integration of chromatin state and RNA expression data enabled further
filtering allowing, a reduction from 245 putative candidate genes, identified from
combining results using both sCVPP and GUESFM COGS results across immune-
mediated diseases, to 118, found to be expressed in either activated or non-activated
CD4+ T cells (Section 3.8.5). I was able to reduce this further by considering
specific annotations such eRNA overlap and context specific interactions. Not
only did such integration reduce the number of genes but it also has the benefit of
suggesting causal mechanisms amenable to followup functional experiments, and
I described one such example involving the gene IL2RA. These results suggest
an overarching framework to GWAS causal candidate gene prioritisation, that
incorporates an initial scan with blockshifter to identify target tissues of particular
interest followed by detailed finemapping and subsequent integration, using COGS
with relevant tissue types.
The example of IL2RA demonstrates how complicated and subtle the mecha-
nisms by which common variants modulate disease risk. In this associated region,
multiple independent variants that in some cases can be shared and at other times
distinct, between different immune-mediated diseases act to affect the expression
of IL2RA and potentially other causal genes in this region (e.g. RBM17). Results
in this region show the importance of tissue context in disease mechanisms, as
CD4+ T-cell activation was sufficient to overcome the allelic affect observed
for rs61839660 in non-activated cells. This demonstrates the challenges that are
involved in elucidating causal mechanisms in common disease, in that even for
a data set of 17 cell types with known relevance to IMD, only a small minority
of cellular contexts have been assessed. It is therefore almost certain that we are
missing key contexts in which many common variants act in order to modulate
disease risk. Whilst the framework set out here will be useful, I emphasise that the
integration of multiple strands of evidence and empirical techniques are necessary
for the robust identification of causal genes and tissue contexts and ultimately
underlying disease mechanisms.
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My analysis adds to a growing body of evidence that regulatory variation
associated with complex disease is often subtle and context specific. To date, there
has been a focus on methods that integrate GWAS and eQTL data as discussed in
section 3.2.2. Due to logistical, technical and economic barriers, the generation of
well powered catalogues of eQTLs across a range of tissue contexts has proved
challenging. Non-population based techniques, such as PCHi-C, that do not
require a large amount of resource, have utility as they can be used to probe
a larger set of disease-relevant tissues and contexts. Indeed, subsequent to the
work described here many studies have been completed in other disease relevant
tissues including; pancreatic islets cells for type 2 diabetes (Miguel-Escalada et al.,
2018), cardiomyocytes for heart disease (Choy et al., 2018), iPSC osteoblasts for
bone mineral density disorders (Chesi et al., 2018) and iPSC-induced neurons
for neurological disorders (Song et al., 2018). Another promising application
of COGS, that I am developing, is to use pleiotropy between common and rare
mono/oligo-genic disease to suggest novel causal genes in the latter, for example
between IMDs and primary immune deficiency (Thaventhiran et al., 2018).
In summary methods, such as COGS, that link putative causal variation with
target genes, show great promise in prioritising disease mechanisms and tissue
contexts. Along with orthogonal population based methods they provide a pow-
erful and data driven approach to informing the design of, but not replacing,
detailed empirical approaches for the characterisation of the causal molecular
events underlying human disease.

Chapter 4
Shared and distinct genetic
architectures in immune-mediated
disease
4.1 Foreword
4.1.1 Chapter Summary
In this chapter I develop a principal component analysis based framework that
uses GWAS summary statistics to summarise the similarities and differences
in genetic architecture between a set of clinically related diseases. I apply this
framework to a set of immune-mediated diseases (IMDs) in order to generate a
lower-dimensional ‘basis’ that summarises their combined genetic architectures
into a set of ordered principal components (PC). I attempt to characterise PCs
by projecting on summary statistics for a wide range of binary and quantitative
traits. Next, I apply the method to a GWAS of juvenile idiopathic arthritis (JIA)
disease sub-types where cohorts sizes are small, in order to characterise their
shared and distinct genetic architectures. Finally I turn my attention to updating
the proposed framework to allow the projection of individual level genotype data
onto the basis. With this I attempt further characterisation of basis components
using eQTL datasets targeting relevant primary immune cell types.
4.1.2 Attributions
The work presented in this chapter relies on an unpublished case/control cohort
examining the genetics of JIA disease subtypes. Genotype and phenotype data
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was supplied by John Bowes, Sam Smith, Annie Yarwood, Damian Tarasek and
Wendy Thomson and I had no part in study design, recruitment or genotype quality
control.
All UK BioBank GWAS summary statistics were generated by the Neale
Laboratory and were downloaded from http://www.nealelab.is/uk-biobank/.
4.1.3 Motivation
After initial concerns about privacy (Homer et al., 2008), summary statistics
for well powered GWAS are becoming increasingly available in the public do-
main (MacArthur et al., 2017). For immune-mediated diseases that cluster in
individuals or families, there is strong evidence for a shared genetic architec-
ture (Cho and Feldman, 2015; Cotsapas et al., 2011; Onengut-Gumuscu et al.,
2015; Smyth et al., 2008; Zhernakova et al., 2009). Whilst studies and methods
have been developed to exploit this in order identify pleiotropic loci across mul-
tiple diseases (Solovieff et al., 2013), there have been few attempts to integrate
summary GWAS data across multiple phenotypes in more holistic fashion at the
genome-wide scale.
The lack of methods in this areas coupled with the increasing availability of
GWAS summary statistics motivates the development of novel approaches that
are able to generate useful summaries of input traits, that in turn can be used
for disease classification and characterisation (Cortes et al., 2017). Furthermore,
such summaries learned from large well powered GWAS, might facilitate the
characterisation of the genetic architecture of non input traits. This is particularly
attractive in rare or clinically heterogeneous immune-mediated disease where
cohort sizes are typically modest and conventional GWAS approaches are under
powered, as such an approach has the potential to provide insights into the shared
and distinct genetic architectures which might impact therapeutic intervention.
4.1.4 Software Availability
In the course of this work I developed ‘cupcake’, an R library of functions that
encapsulates the methods described in the chapter. This package, is freely available
from https://github.com/ollyburren/cupcake under an MIT license agreement.
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4.2 Background
Immune mediated diseases, whilst diverse, have been found to co-occur both
within individuals and families supporting the presence of a shared genetic archi-
tecture (Somers et al., 2006). For example, between 4-9% of individuals with
type 1 diabetes (T1D) are also affected by coeliac disease (CEL) (Cronin et al.,
1997). Whilst the studies supporting these claims are affected by ascertainment
bias, more recent evidence from GWAS has provided a stronger foundation for
such assertions (Li et al., 2015; Parkes et al., 2013; Zhernakova et al., 2009). This
has lead to concerted efforts to understand both the similarities and differences
between the genetic architectures of IMDs, which can be divided into three main
approaches which I discuss in more detail below.
Cross-phenotype analysis and colocalisation
Soon after the publication of the first large scale multi-trait GWAS (Wellcome
Trust Case Control Consortium, 2007) Smyth et al. (2008) presented a systematic
pairwise analysis between T1D and CEL susceptibility loci, finding convincing
evidence that seven non-HLA loci were common between traits. Two of these
seven loci showed evidence of heterogeneity in effect direction between the two
diseases indicating that the same locus could be both protective and modulate risk
in different disease contexts. However, at this early stage of GWAS development
genotype platform density was low, which precluded inference as to whether
shared loci were a result of shared or distinct causal variants.
Cotsapas et al. (2011) performed a detailed study of seven separate IMDs (CEL,
Crohn’s disease (CRO), multiple sclerosis (MS), psoriasis (PSO), rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE) and T1D) selecting SNPs or
their proxies that were genome-wide significant in one or more disease studies.
They developed the Cross-Phenotype Meta Analysis (CPMA) statistic; using
summary GWAS p-values in order to detect evidence for association of a SNP to
multiple disease phenotypes. On applying CPMA to 107 SNPs, selected due to
genome-wide significance in one or more of the underlying studies, they found
evidence for sharing, between two or more diseases at 42 SNPs. Furthermore
they described 9 SNPs for which they found strong evidence for opposing effects
between diseases at the same locus, indicating that such a phenomenon might be
widespread across IMDs.
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Whilst both Smyth et al. (2008) and Cotsapas et al. (2011), present compelling
evidence for pervasive shared susceptibility loci across IMD, they are limited to
testing each SNP independently and are unable to make inferences about whether
sharing is due to the same or different causal variants.
An alternative approach presented in (Fortune et al., 2015), that overcomes this
is to take a more targeted approach and examine evidence for colocalisation (Gi-
ambartolomei et al., 2014) at associated loci between pairs of traits. In this study
raw genotype data for four autoimmune traits (RA,T1D,CEL and MS), that had
been typed on the ImmunoChip platform was assembled and assessed pairwise
for colocalisation. Out of 90 regions assessed, significant evidence supporting
colocalisation was found at 33. In a related approach Pickrell et al. (2016) used
summary statistics to investigate, genome-wide, the evidence for shared causal
variants across 42 GWAS for a broad range of phenotypes and diseases. They
identified over 300 loci where there was evidence for a shared locus.
Genetic correlation
An alternative approach to quantify the genetic overlap is to enumerate the genetic
correlation between two traits genome-wide. This requires the estimation, for each
trait, of the SNP level heritability, that is the proportion of the variance of the trait
explained by a given SNP (Section 1.3.1).
If raw genotyping data is available and sample sizes are not prohibitively
large the most accurate method of estimating SNP heritability is to apply a linear
mixed model, as implemented in the GCTA software package (Yang et al., 2011).
More recently LD score regression (Bulik-Sullivan et al., 2015), a method which
requires only summary GWAS statistics and can be applied efficiently to very
large GWAS has been developed. At the foundation of LD score regression is the
assumption that causal variant effect sizes are inflated due to LD with each other.
The LD score for a variant j, is defined as
ℓ j =∑
k
r2jk, (4.1)
where r2 is the correlation between variant j and the kth variant. Under a polygenic
model the expected value of z1 jz2 j for the z scores for two traits denoted by
subscript 1 and 2 at variant j is
E
[
z1 jz2 jℓ j
]
=
√
N1N2ρg
M
ℓ j +
ρNs√
N1N2
, (4.2)
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where N1 and N2 are the sample sizes of the traits, Ns is the number of samples
shared between both studies, ρg and ρ are, respectively, the genetic and phenotypic
correlation between the traits and M are the total number of SNPs being considered.
This means that ρg can be estimated by the slope of the regression of z1 jz2 j on LD
score ℓ j. This approach has been used to analyse the genetic correlation between
hundreds of traits (Zheng et al., 2017), including GWAS summary statistics for six
immune-mediated diseases (Figure 4.1), finding significant correlations between
a number of diseases. Whilst such an approach is useful to understand how the
overall genetic architecture of two traits might be related, it can be misleading
and Bulik-Sullivan et al. (2015) illustrate this using the example of the near zero
correlation between both CD with RA even though these diseases are known
to share multiple risk loci. This seemingly paradoxical finding occurs because
although risk variants are shared between CD and RA (Parkes et al., 2013), these
are balanced by variants with opposing effects elsewhere resulting in a negligible
net correlation.
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Fig. 4.1 Genetic correlation computed using LD score regression (Bulik-Sullivan
et al., 2015). Results were downloaded from LDHub (Zheng et al., 2017) on
06/04/2019 and do not include the HLA region. Pairwise comparisons are labelled
with genetic correlation values, and are coloured by Z score if the Bonferroni
adjusted p-value < 0.05
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A drawback from using genetic correlation to infer shared genetic architectures
is that it operates over the whole genome, thus precludes the cataloguing of which
risk variants are shared, opposing and distinct across a number of traits presenting
substantial challenges for biological interpretation.
Genome-wide multi trait approaches
A more holistic approach, disPCA developed by Chang and Keinan (2014), uses
principal component analysis (PCA) in order to summarise a matrix of association
scores across 31 GWAS datasets. Firstly, for each gene, a summary association
statistic, based on genomic distance is computed. The resultant matrix, where
rows and columns reflect GWAS studies and genes respectively, is then column
mean-centred. This transformed matrix is then suitable for PCA, resulting in
loadings for each disease across 31 principal components ordered by the amount
of overall variance each explains. Chang and Keinan (2014), chose to concentrate
on the first two components, explaining a total of 8.69% of the variance. This
analysis demonstrated not only clustering of UC and CD but also SLE with CEL,
which was followed up with pathway analysis using the underlying gene loadings,
although the results as presented are not convincing.
Overall, this approach has limitations, firstly as I have demonstrated in previous
chapters, the assignment of variants to genes on the basis of physical/genetic
location is non-trivial and as such it is challenging to know whether the gene-level
associations they use as input accurately reflect underlying gene biology. Secondly
such gene-level summaries will mask pleiotropy, instead relying on a more diffuse
definition of cross-phenotype association that conflicts with convincing results
that many loci with shared associations are actually due to distinct causal variants
between traits (Fortune et al., 2015). Finally, Chang and Keinan (2014) mention
that their approach fails to take into account the direction of effect of underlying
causal variants, as such antagonistic and shared effects are treated equally. As
discussed in the previous section heterogeneity in effect size and direction between
diseases is likely to be pervasive and thus not accounting for this is likely to
undermine any results from using disPCA.
The approach exemplified by disPCA whilst limited, is of interest as it bridges
an important methodological gap, using PCA as a dimension reduction technique,
to generate interpretable summaries over a genome-wide scale dataset. This invites
the exploration of whether such summaries are of utility as lower dimensional
composite predictors themselves or whether their underlying loadings, that capture
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relationships between SNPs, have further application. The former application,
using summaries as covariates in regression based methods, is well described
in the literature; for example most standard GWAS analysis pipelines make use
of PC scores from ancestral PCA to control for confounding due to population
stratification (Price et al., 2006). However, PCA based dimension reduction
approaches have also been used to create composite phenotypes, that is lower
dimensional summaries, that maximise either the variance or heritability across
multiple phenotypes, which are known, a priori, to be correlated (Avery et al.,
2011; Klei Lambertus et al., 2007). These approaches can provide multiple
benefits, not only in terms of maximising the power for association analysis,
as the top components by definition maximise the variance between traits, but
also in relieving the multiple testing burden when examining multiple related
traits (Aschard et al., 2014).
4.3 Basis disease data preparation
In order to create a detailed map of the genetic architecture of immune-mediated
disease I created a collection of GWAS summary statistics (Table 4.1) across 10
diseases, from publicly available resources including the GWAS catalogue and
ImmunoBase. For inclusion a study needed to fulfil a number of criteria:
Cohort size greater than 10,000 samples: The uncertainty attached to an odds
ratio estimate depends on the total number of cases and controls analysed.
Whilst arbitrary, I felt that a minimum cohort size of this magnitude allowed
the inclusion of cohorts across a wide spectrum of IMD whilst filtering out
studies that might lack power and be unlikely to contribute to the proposed
approach.
Summary GWAS data availability: The approach requires that estimates of the
odds ratios and their significance be available genome-wide. This precludes
the inclusion of studies that, for example, present only summary statistics
for the genome-wide significant loci.
Study performed on cohorts with European ancestry only: Although a popu-
lation agnostic view of the genetic architecture of complex disease is
favoured (DIAGRAM Consortium et al., 2014; Liu et al., 2015; Okada
et al., 2014) there are technical reasons for limiting studies to those of Euro-
pean ancestry in downstream analysis. The main reason is that such a filter
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maximises the number of traits that can be studied but also minimises the
effects of population stratification on downstream analysis. This is because
the contribution to the difference in the estimate of the log odds ratio at a
given SNP and disease cohort is less likely to be confounded due to gross
heterogeneity in allele frequency that are more likely arise to arise when
studies with differences in ancestry are considered. Furthermore, limiting to
a specific ancestry allows the use of reference genotypes in order to estimate
minor allele frequencies and the fine scaled LD architecture between SNPs
for which only GWAS summary statistics are available.
Disease Abbreviation Cases Controls
Primary Biliary Cholangitis PBC 2,764 10,475
Systemic Lupus Erythematosus SLE 4,036 6,959
Coeliac Disease CEL 4,533 10,750
Primary Sclerosing Cholangitis PSC 4,796 19,955
Type 1 Diabetes T1D 5,913 8,829
Multiple Sclerosis MS 9,772 17,376
Crohns’ Disease CD 12,194 28,072
Ulcerative Colitis UC 12,366 33,609
Rheumatoid Arthritis RA 14,361 43,923
Asthma asthma 19,954 107,715
Table 4.1 IMD studies used to construct basis. References for the studies are as
follows; PBC (Cordell et al., 2015), SLE (Bentham et al., 2015), CEL (Dubois
et al., 2010), PSC (Ji et al., 2017), T1D (Cooper et al., 2017), MS (IMSGC et al.,
2011), CD (de Lange et al., 2017), UC (de Lange et al., 2017), RA (Okada et al.,
2014) and asthma (Demenais et al., 2018).
In future sections I refer to the logarithm of the sample estimate of the odds
ratio, βˆ , as this has the convenient property that βˆ ∼ N(β ,σ2
βˆ
). For some studies
σ2
βˆ
was missing, but can be calculated using
σ2βˆ =
(
βˆ
Φ−1(p/2)
)2
, (4.3)
where p is the p-value of the association and Φ−1 is the normal quantile function.
Throughout the text I make liberal use of the abreviations defined in Table 4.1
using the term ‘basis diseases’ to refer to them collectively. Finally, I use the term
‘basis’ as a reference to the resultant eigenvector space from the application of
PCA to ‘basis diseases’ and a synthetic control trait (Section 4.4).
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4.3.1 UK10K as a reference genotype dataset
The employment of a reference genotype dataset as a foundation for downstream
analyses has multiple benefits and I selected the set of genotypes made publicly
available as part of the UK10K project (project consortium, 2015). This study has
made available genotypes, identified through whole genome sequencing, for 3,781
healthy individuals from two British cohorts of European ancestry, namely the
Avon Longitudinal Study of Parents and Children (ALSPAC) and TwinsUK.
The reasons for this choice were because of its size, coverage, availability
and ancestral relevance to the immune disease studies to be analysed. One key
benefit is that the challenge in harmonising effect alleles across input studies is
ameliorated if this is carried out using a set of reference genotypes for which an
accurate estimate of control allele frequencies is available.
4.3.2 SNP selection
The main criteria for selecting SNPs was data availability, the proposed framework
requires that GWAS summary data are available for each SNP across all basis
diseases. The studies selected encompass a relatively large time interval, in
the context of GWAS, and this is reflected in the SNP coverage across studies
(Figure 4.2a). This resulted in a set of 294,573 SNPs for which the relevant data
was available across all 10 traits. I found the category of SNPs found in only one
study was most frequent, driven predominantly by rare SNPs from the Bentham
et al. (2015) study of SLE (Figure 4.2b). A second peak of sharing at six studies,
reflected the fact that SLE, UC, CD, T1D, RA and PSC studies were all imputed
using 1000 genomes data. This exposes the trade off in covering more diseases
at the expense of reduced SNP coverage. I decided that maximising the number
of basis diseases was of greater value than a denser SNP map based on the fact
that the underlying genotyping platforms use a tag SNP approach (Johnson et al.,
2001) in order to capture the most genetic diversity by using as few assays/SNPs
as possible. A sparser SNP map that still allows signal detection, albeit at a lower
resolution is an acceptable trade off if this increases disease coverage, leading to a
richer basis.
I excluded SNPs within the HLA region(chr6:20-40Mb) due to its long and
complex LD structure. Furthermore it is known to harbour SNPs that have a
profound involvement in IMD susceptibility; such large effects have the capacity
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Fig. 4.2 SNP intersection across basis diseases. a) Total number of SNPs across
all studies for which summary statistics were available. b) Sharing of SNPs across
studies.
to overwhelm signal due to loci with more modest effect, potentially limiting my
ability to interpret downstream analyses.
Finally, I filtered the resultant list of SNPs to remove uncommon or palin-
dromic 1 SNPs (MAF<1%) using the UK10K reference genotyping resource
described in section 4.3.1 to obtain a final list of 280,651 SNPs, I refer to this set
of SNPs, used for all downstream analysis as ‘basis SNPs’. Given the filtering
steps employed non-autosomal and mitochondrial SNPs were implicitly excluded
as these results were missing from a majority of input GWAS studies and so were
not taken forward in the initial SNP study overlap step (Figure 4.3).
Having filtered all 10 studies to include only basis SNPs, I next undertook
harmonisation of effect alleles across all studies. This involves adjusting odds
ratios such that effect alleles for all studies are aligned with respect to the same
allele. The choice of what allele to use for alignment is arbitrary and rather than
picking a random input study for such a task I instead aligned all studies to the
common UK10K reference set. My main motivation for doing this was to facilitate
the integration, at a later stage, of UKBB data, which uses the UK10K reference
genotypes for imputations and is therefore automatically harmonised if such a
scheme is employed.
1These are SNPs such as A/T, for which forward and reverse stranded orientations appear
identical. This can result in the miss-assignment of risk alleles undermining any efforts to
harmonise effects across multiple studies.
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4.4 Creating a PCA ‘basis’
In the previous section I described the preparation of a set of harmonised GWAS
summary statistics across ten immune-mediated diseases. I next focused on devel-
oping a framework to provide a lower dimensional summary of the similarities
and differences in the genetic architectures across traits using principal component
analysis (PCA). The output of PCA is a ‘basis’, a transformation of the input
data into a new coordinate system, where each principal axis or component is
orthogonal.
To do this I used the aligned datasets to construct a 10×280,651 matrix of βˆ ,
where rows and columns reflect diseases and SNPs respectively. I added to this
matrix an additional row of zeroes, that constituted a synthetic ‘control’ disease,
modelling a situation where there is no association across any SNPs. I included this
‘control’ disease in order to provide a reference point or ‘baseline’ for downstream
comparative analysis. I use the term M to refer to this 11× 280,651 matrix in
subsequent sections.
4.4.1 PCA basis creation using βˆ
As described in Chapter 1, PCA, is a relatively simple method, that can be used
to construct importance ranked summaries or components of high-dimensional
matrices. For moderately sized matrices, such as M, I was able to use the inbuilt
R function prcomp, in order to conduct PCA. One important consideration prior
to PCA, is whether to adjust variables to have unit variance before analysis, to
prevent variables of different scales dominating the resultant PCA basis. For a
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disease where the underlying study has a large sample size, βˆ more closely follows
the true value of β for that trait, as σ2
βˆ
∝
√
1
N . By scaling diseases to have unit
variance we effectively remove this advantage for larger, better powered GWAS
studies which is not desirable. I therefore chose not scale M prior to PCA. Another
consideration is whether to mean centre βˆ across columns, I chose to do this as
one of the reasons for using βˆ as input is that under the null hypothesis of no
association, E(βˆ ) = 0, and such a transformation enforces this.
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Fig. 4.4 PCA basis using βˆ . a) A scree plot of the variance explained by each
component. b) A biplot of the first two PCs explaining approximately 37% of
the variance in βˆ across all traits examined. Points represent PC scores for a trait
(Trait label abbreviations are defined in Table 4.1).
The resultant PCA of M resulted in 11 principal components (PCs) where
50% of the variance in βˆ between diseases was explained in the first three PCs
(Figure 4.4a). For this naive βˆ basis (Figure 4.4b), I found that PC1 described
a PBC-SLE/PSC axis, whereas PC2 separated PBC from CEL/T1D, with all
other traits clustering around control. Whilst a biplot is a useful summary, it only
captures the total variance explained by the first two PCs (37% variance explained).
An alternative analysis is to convert the matrix of PC scores across all eleven PCs
and traits, into a Euclidean distance matrix. Let pi and qi be the PC scores for the
ith PC for two traits, the Euclidean distance between them across n PCs is
d(p,q) =
√
n
∑
i=1
(pi−qi)2. (4.4)
This distance matrix can then be analysed using an agglomerative hierarchical
clustering methods to look for groups of diseases, encompassing all PCs, that are
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closest in ‘basis’ space and therefore share a similar genetic architecture. I chose
to use the ‘complete linkage’ method, where clusters are defined by the farthest
neighbour with distances derived from Equation 4.4, as implemented in the R
command hclust.
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Fig. 4.5 Complete linkage hierarchical clustering of βˆ PC scores across 11 traits.
This resulted in two main clusters that separated PSC and SLE from the rest
of the traits (Figure 4.5), mostly because of the large effect of PC1. The reported
genetic correlation between PSC and UC (Ji et al., 2017) was not evident in
this clustering, a result that is in conflict with clinical observations that around
75% of individuals with PSC go on to develop IBD. This coupled with the poor
discriminatory performance between control and disease for the top two PC
components, explaining over a third of the variance, undermined the utility of a
basis constructed from raw βˆ .
4.4.2 PCA basis creating using γˆ
In the previous section I used PCA on M, a matrix of aligned βˆ , of diseases
in order to define a subspace, such that diseases with similar βˆ are proximal
when projected into this basis. One source of uninformative variance between the
columns of M is related to the allele frequency, f of a SNP, which relates to the
standard error of βˆ thus
σβˆ =
√
1
2N
√
1
fˆ
+
1
1− fˆ , (4.5)
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under the null hypothesis that β = 0, where fˆ is an estimate of the minor allele
frequency in the cohort for a given basis SNP. Equation 4.5 is derived from the
2×2 table that underlies an odds ratio, where the standard error using the labelling
defined in Figure 1.1 is
√
1
a +
1
b +
1
c +
1
d . Under the assumption that fˆ is the same
across basis traits, which is not unreasonable given that they are all of European
ancestry, this source of variance between studies should be removed as it could
obscure variance due to genuine differences in genetic architecture between basis
diseases. By rearranging equation 4.5, it is possible to estimate the component of
σβ that is due to allele frequency from the available summary statistics by
σˆ f =
√
2Nσβˆ =
1√
fˆ (1− fˆ )
. (4.6)
Such an approach generates σˆ f for each SNP and basis disease pairing, and I
chose to take forward the mean σˆ f per SNP using this to adjust βˆ for each basis
disease by employing
γˆ =
βˆ
σˆ f
, (4.7)
resulting in a new matrix of γˆ which I used to compute a new basis (Figure 4.6).
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Fig. 4.6 PCA basis using γˆ . a) A scree plot of the variance explained by each
component. b) A biplot of the first two PCs.
I found that the basis generated, whilst on a different scale to that generated
using βˆ was very similar resulting only minor differences in the variance explained
across PCs. This is to be expected as the values of γˆ whilst different between
SNPs are constant across input traits. This results in a rescaled basis space where
PC scores for traits are simply rescaled but their relative positions remain the
4.5 Evaluating basis performance | 125
Self Reported Disease Label No. Cases No. Controls
Asthma bb_asthma 39,049 298,110
Rheumatoid arthritis bb_RA 3,730 333,429
Ulcerative colitis bb_UC 1,795 335,364
Malabsorption Coeliac disease bb_CEL 1,452 335,707
Multiple sclerosis bb_MS 1,228 335,931
Crohns Disease bb_CD 1,032 336,127
Systemic lupus erythematosis bb_SLE 366 336,793
Type 1 diabetes bb_T1D 286 336,873
Table 4.2 UK BioBank self-reported phenotypes[https://biobank.ctsu.ox.ac.uk/
crystal/field.cgi?id=20002] matching diseases from which the basis was con-
structed.
same. For GWAS where MAF are greater than 0.1, the standard error due to
sample size is orders of magnitude smaller than γˆ . This means that, in practice,
the influence of MAF on σβˆ is small for the cohort sizes and allele frequencies
usually encountered in GWAS. However in this context which is motivated by a
wish to consider GWAS performed on small cohorts its derivation and inclusion in
the scaling is justified.
4.5 Evaluating basis performance
One approach to examining the relevance of the basis space developed in the
previous section is to interrogate its ability to predict the PC scores for basis traits
from an alternative source of GWAS summary statistics.
One source of summary statistics over thousands of traits is the UK Biobank
(UKBB) (Sudlow et al., 2015). This large cohort has collected both genetic and
phenotypic data over a large range of traits for approximately 500,000 individuals.
Performing high quality GWAS across such a large cohort for so many traits is
technically challenging. To overcome this the Neale laboratory have created soft-
ware tools such as HAIL ( https://github.com/hail-is/hail) and PHESANT (Millard
et al., 2017), which they have used to generate and release publicly the summary
statistics for over 11,000 UKBB traits (http://www.nealelab.is/uk-biobank/). From
this resource I selected eight self-reported diseases (SRD) for which there was a
matching basis trait (Table 4.2).
In general these SRD GWAS contained an order of magnitude fewer cases,
resulting in much less powered GWAS, for example, self-reported T1D covers only
286 cases, compared to the 5,913 included in the basis. The exception is asthma
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which contained nearly double the number of cases included from Demenais et al.
(2018). It is important to note that these diseases, are by definition, self-reported
phenotypes, and as such are likely to be significantly ‘softer’ than those from
which the basis is constructed. By this I mean case/control status is not necessarily
driven by a clinical diagnosis which can result in a misclassification of both case
and control status which further undermines power. I hypothesised that if the
basis reflected true differences in the genetic architecture between input traits, that
these matched SRD, when projected into basis space, should be closer to their
counterparts than other diseases.
4.5.1 Linear regression coefficient conversion to the odds ratio
scale for a binary trait
For computational efficiency, the Neale laboratory have employed a linear regres-
sion approach to all data considered, even if the trait under consideration is binary.
Thus, in order for me to project these data onto the basis, summary statistics
needed to be transformed to the matching log odds ratio scale.
The UKBB summary statistics downloaded from the Neale Laboratory com-
pendium include the total number of samples considered N, as well as N1 the total
number of affected samples (i.e. exhibit the particular self-reported binary pheno-
type). Also reported are ∑Ni XiYi (i.e. XTY ) and ∑
N
i Xi where i indexes individuals
included in the study of each trait. These quantities for each SNP, are sufficient
to compute an odds ratio, under the assumption of Hardy-Weinberg equilibrium
under an additive model. In the case of a binary trait where Y ∈ {0,1}, with 0 and
1 representing whether a given sample is a control or case respectively, the allele
frequency in cases is
fˆcase =
∑Ni XiYi
2N1
. (4.8)
Conversely, the allele frequency in controls is
fˆctrl =
∑Ni Xi−∑Ni XiYi
2(N−N1) , (4.9)
and the estimated odds ratio is therefore
fˆcase(1− fˆctrl)
fˆctrl(1− fˆcase)
. (4.10)
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4.5.2 Comparison of γˆ basis PC scores with matched UKBB
self-reported projections
Using this method I computed βˆ s across all basis SNPs for each of the self-
reported traits using the basis values of σˆ f and equation 4.7 to convert these to γˆ .
Given that the basis was constructed with γˆ aligned with the UK10K reference,
and UKBB genotypes have been imputed using the same reference alleles were
already aligned. Finally I used R function predict, in order to project each of the
selected UKBB SRDs (Table 4.1) onto the γˆ previously described (Section 4.4.2).
The outcome of this is a 9×11 matrix of PC scores, where rows reflect projected
traits and columns the total number of PCs described by the basis.
In order to investigate whether there was support for projected SRDs to have,
overall, similar PC scores to their basis counterparts I used complete linkage
hierarchical clustering of the matrix of PC scores of both basis and projected
diseases (Section 4.4.1).
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Fig. 4.7 Complete linkage hierarchical clustering of γˆ PC scores across 11 traits
(black) and matched UKBB SRDs (red).
I found that such an approach did not support my hypothesis that when pro-
jected, matched basis and UKBB SRD would occupy similar positions in basis
space (Figure 4.7). Instead, all projected UKBB SRD clustered together rather than
with their corresponding matched basis trait. Furthermore the closest clustered
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basis trait was the synthetic ‘control’ trait. These observations, taken together
with the fact that basis trait clustering does not reflect previous studies on shared
genetic architectures of IMD (Cho and Feldman, 2015; Ji et al., 2017; Márquez
et al., 2018), suggests that the basis as constructed is still overwhelmed by sources
of variance between traits not related to their genetic architecture.
4.6 Development of a Bayesian shrinkage method
In the previous sections I described the creation of a basis in order to provide a
low dimensional representation of the shared and distinct genetic architectures of
ten immune-mediated diseases. However, evaluation of the resultant basis showed
that it was not reflective of known disease overlap. The main reason for this
is that the current proposal uses as input, log transformed odds ratio estimates,
with no regard to their significance. Whilst there are arguments, in the form of
the omnigenic model (Boyle et al., 2017), that a large number of variants are
likely to both directly and indirectly influence a trait, most will have such small
effect sizes, such that that large sample sizes would be required for their accurate
estimation. This means that a vast majority of odds ratios estimates for SNPs
included in the basis are ’noisy’ and have large standard errors associated with
them. It seems reasonable that such a large source of variance arising from both
technical and stochastic processes would be expected to overwhelm the basis,
thus obscuring true associations driving similarities and differences between the
genetic architecture of diseases.
One way of taking account of this stochastic variance is to apply a threshold
and only select SNPs exhibiting significant association in one or more traits. Such
an approach whilst attractive due to its apparent simplicity has several drawbacks.
Leaving aside the Winner’s Curse effect (Section 2.2.1), the foremost challenge is
to develop a suitable strategy by which to select such a threshold. If for example
we select only genome-wide significant variants (p< 5×10−8), those variants that
are below but close to this threshold threshold will be unable to contribute to basis
generation even though they may contain useful information. Another difficulty is
how to adequately deal with LD differences across the genome. If a locus is in
strong LD, then by thresholding it is likely that more SNPs are included in the
basis compared to a locus in weaker LD. This means that loci with high LD will
have greater influence on the basis generated, thus creating a bias. To summarise,
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any proposed method should not rely on thresholding and also intrinsically take
into account the differential amounts of LD across the genome.
4.6.1 Method description
One approach that fulfils these criteria is the Bayesian single causal variant fine-
mapping approach introduced in previous chapters that summarises, in the context
of an arbitrary genomic region, the posterior probability for a variant to be causal.
A key facet of this approach is that posterior probabilities are jointly modelled
across all variants within a the genomic region considered. This property is
useful as if regions are selected in such a way that they are approximately LD
independent from each other, the effect of LD can be largely mitigated. Such a
method, when combined over multiple diseases, can be used to assign individual
SNP weights, that can then be used to rescale input odds ratios. These rescaled
odds ratios, weighted or shrunk in proportion to their disease relevance, can be
used to generate a basis that holds promise in overcoming some of the challenges
discussed in the previous section.
To describe the implementation of such a weighting scheme in detail, consider
a genomic region, r that is approximately LD independent from neighbouring
regions. As discussed in the previous chapter if for a particular trait, we have
association p-values, fˆ and βˆ for a set of SNP with r, then we can compute a
single causal variant posterior probability (sCVPP) for each SNP (Section 1.3.5).
The next challenge is integrating sets of sCVPP across multiple diseases. Let i
and j index a matrix of sCVPP across s SNPs and d, diseases, respectively, within
region r. I first compute a disease specific weighting such that
α j =
s
∑
i=1
sCVPPi j. (4.11)
To combine across diseases I compute a disease weighted average for the ith SNP
sCVPP within r as
hi =
∑dj=1α jsCVPPi j
∑dj=1α j
, (4.12)
which once multiplied by γˆ leads to γˆ ′ , a vector of shrunk γˆ of length s for a target
disease.
For ease, given the invariant nature of both σ f and h across diseases, in future
sections I refer to h′i, as the combined weighting of the ith SNP such that
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h′i =
hi
σ f
. (4.13)
I illustrate this process by using the example of seven IMDs (ommiting three
diseases with no association across the region for clarity) across the 2q33.2 region
(Figure 4.8). In this region there is evidence for a strong association proximal
to the gene CTLA4 in both RA and T1D, however LD within the region makes
identifying further associated SNPs in other diseases challenging. By computing
sCVPP, I found some evidence for putative causal variants in other diseases that are
distinct from RA and T1D. In order to combine these sCVPP into a single weight
I consider two things. Firstly, for a given disease the posterior probability that the
2q33.2 region being considered contains a causal variant2, which is reflected in α j.
Secondly, the disease weighted (using α) contribution of a particular SNP to the
total posterior probability for the region, across all diseases. In the example this
results in most of weight being applied to the SNP proximal to CTLA4 previously
identified in T1D and RA, with most other variants receiving almost no weight.
Importantly, putative causal variants in the other diseases such as PSC and CEL
are non-zero weighted, but because there is less evidence for these both at the
sCVPP level and across diseases their weight is attenuated. The application of
these weights results in both a relative down weighting of SNPs unlikely to be
involved in disease susceptibility and a concomitant up weighting on SNPs where
evidence exists for their involvement in disease.
The scheme as described applies only to an approximately LD independent
region r, to apply it genome-wide I use a similar approach to that described in the
previous chapters. Briefly, I split the genome into approximately independent LD
blocks using recombination data from the international HapMap project (Interna-
tional HapMap Consortium et al., 2007). I then compute weightings separately for
each block, concatenating these in order to obtain the complete set of weightings
across all SNPs to be included in the basis.
Whilst the underlying approach was developed for genetic fine-mapping it is
important to note that this is a separate goal from the weighting metric that we
seek. The density of SNPs considered precludes accurate fine-mapping and as
illustrated in the previous chapter we rely on their being up to one causal variant in
a given LD block. In contrast, here we seek a weight that best captures how likely
a given SNP within the region is relevant across all basis diseases being considered.
By performing PCA we summarise information across all basis variants, and thus
2Under the assumption that the causal variant is included in the set of SNPs being considered
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Fig. 4.8 An example of the βˆ weighting scheme across seven selected IMDs in
the 2q33.2 region. The top stanza shows gene positions for GRCh37 as obtained
from Ensembl BioMart. − log10(p) - are the transformed p-values for each study
coloured by disease as follows: blue - Coeliac disease (CEL), pink - Multiple
sclerosis (MS), darkgreen - Primary biliary cholangitis (PBC), red - Primary
sclerosing cholangitis (PSC), orange - Rheumatoid arthritis (RA), lightgreen -
Systemic lupus erythematosis (SLE) and brown - Type 1 diabetes (T1D). This
colouring scheme is repeated for all subsequent relevant stanzas. sCVPP - single
casual variant posterior probabilites for each disease. h - final cross disease
weights. βˆ - The raw estimates of the log(Odds Ratio) across disease. h× βˆ -
weight transformed log(Odds Ratio).
as long as violations of underlying fine mapping assumptions are not systematic
the weighting is justified as these will be distributed over the thousands of regions
and the relatively large number of SNPs being considered.
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4.6.2 Shrinkage evaluation
Using the basis diseases I generated weightings across all 280,651 input SNPs.
The range of h was between 1.2× 10−8 and 0.21 with 99% of weights being
below 0.05. I applied these weightings to M, the matrix of βˆ , by multiplying each
element by its corresponding h′ and used the resultant matrix to compute a basis
as previously described in section 4.4.1.
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Fig. 4.9 Basis PCA using shrunk γˆ . a) A scree plot of the variance explained by
each component. b) A biplot of the first two PCs.
For the resultant basis I found that a much larger proportion (≈ 60%) of the
variance explained was found in the first three principal components compared
with previous basis that used γˆ as an input (Figure 4.9a). Furthermore these PC
scores for the first two input diseases seem to reflect known disease biology. For
example PC1 seems to discriminate auto-inflammatory diseases such as CD, UC
and PSC from those categorised as more classical autoimmune diseases such as
SLE, PBC and T1D (McGonagle and McDermott, 2006).
I evaluated the resultant basis, as before (Section 4.5), using matched UKBB
SRD with the proposed Bayesian shrinkage scheme applied prior to projection
onto the basis (Figure 4.10).
I found that this basis produced PC scores for projected SRD UKBB traits that
were more similar to their basis counterparts than between other diseases. The
only exception to this was for RA which appeared to match more closely with
the synthetic control trait. One possible explanation for this is that the projected
studies are all self-reported and symptoms of RA are more often confused with
other conditions such as osteoarthritis than other projected traits.
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Fig. 4.10 Complete linkage hierarchical clustering of weighted βˆ PC scores across
11 basis traits (black) and matched UKBB self-reported traits (red).
4.7 Estimating the variance of projected PC scores
In the previous section I proposed a framework, based on a Bayesian weighting
method, for generating a basis which was supported by widespread co-clustering
of matched basis and UKBB SRD diseases. Whilst PC scores for diseases used to
construct the basis are fixed, as these same diseases are used to construct the basis,
scores for projected diseases will have an associated sample variance. Efficiently,
and accurately estimating this variance is important as it is required in order to
make inference about whether individual or sets of projected traits are significantly
different from one another.
4.7.1 Analytical variance estimation
In order to consider the variance associated with projecting a trait onto a basis
PC, consider the simple case of a single approximately LD independent region
containing s variants, indexed by i. To project the ith SNP onto the kth basis PC,
requires first taking the product of between βˆi and the corresponding weights (h′i)
and PC loading (lik).
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qik = βˆih′ilik. (4.14)
When performed across all s variants this results in vector qk = {q1k . . .qs−1,k,qsk}.
The variance of qik, Var(qik), depends on the variance of βˆ , and h′i and lik which
are treated as constants such that
Var(qik) =
(
h′ilik
)2 Var(βˆi)
=
(
hi
σ f
lik
)2
σ2Nσ
2
f
= (hilik)
2σ2N , (4.15)
where σ2N and σ2f are the component of the standard error of βˆ due to sample
size and MAF respectively. The variance-covariance matrix of Var(qk) requires
taking into account the linkage disequilibrium between SNPs. To do this I use
the fact that the correlation matrix of genotypes, Σ, which can be estimated from
a set of reference genotypes such as the UK10K, is the same as the variance-
covariance matrix of standardised βˆ , Z, where each element is a z-score such that
z = βˆσβˆ
(Burren et al., 2014). Letting Vk =
(√
Var(qik), i = 1, . . . ,s
)
the variance-
covariance matrix, Xs×sk associated with projecting the s variants, onto the k
th PC
in the simplified region can be approximated as:
Xk = (Vk ◦σ fˆ )T (Vk ◦σ fˆ )◦Σ, (4.16)
where vector σ fˆ is the component of the standard error due to allele frequency
across s SNPs and ◦ denotes element-wise multiplication. The variance associated
with the projection onto the kth PC over the vth region is then the the sum over all
elements of Xk
Var(Pkv) = 1Xk1T , (4.17)
where 1 is row vector of 1s of length s.
This result can be extended genome-wide by making the assumption of inde-
pendence between regions, which is reasonable if the regions have been selected
to be approximately LD independent. Then the total variance for a particular PC
is simply the sum of the variance for that PC across the total number of LD blocks,
r, to be considered,
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Var(Pk) =
r
∑
v=1
Pkv. (4.18)
Whilst such a scheme takes into account the component of variance due to
minor allele frequency, σ2
fˆ
it does not take into account the component due to
sample size, σ2N . This is beneficial as under the reasonable assumption that study
design is fixed across all projected SNPs, this quantity is constant allowing the
computation of the variance associated with the projection of any case/control
study design. I approximate σ2N as
σ2N =
N1 +N0
N0N1
, (4.19)
where N1 and N0 are the case and control size of the projected study respectively.
This means that the variance of projecting an arbitrary trait, t onto the the kth PC is
N1 +N0
N0N1
×Var(Pk), (4.20)
where N1 and N0 are the case and control size of t GWAS respectively. This setup
provides the benefit that the value Var(Pk) needs only be estimated once for a given
basis, mitigating the computational overhead associated with having to empirically
estimate the variance associated with projecting many traits onto the basis.
4.7.2 Empirical variance estimation
In the previous section I presented an analytical result that makes both implicit and
explicit assumptions about LD independence, due to its reliance on the approx-
imation of Σ from a reference genotype set and approximately LD independent
genomic regions. In order to validate the result I next developed simulations for
evaluating the variance of a projected trait under different conditions.
Simulation under H0
The first condition I examined was the projection of a synthetic GWAS trait under
the null hypothesis of no association. Under this condition, E(βˆ ) = 0, and an
estimate of βˆ for a single SNP can be obtained from βˆ = N(0,σ2
βˆ
), where
σ2βˆ ≈
1
2N
(
1
fˆ
+
1(
1− fˆ )
)
, (4.21)
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where N is the simulated sample size under consideration, and fˆ is the estimated
minor allele frequency obtained from UK10K reference genotype resource. In
order to simulate sets of βˆ under H0 under differing sample sizes robustly we must
incorporate LD. Thus the simulation of βˆ s for a given LD block involves sampling
from a multivariate normal,
βˆ ∼MVN
(
0,
(
σβˆσ
T
βˆ
)
◦Σ
)
. (4.22)
For a given sample size this is done for each LD block, and the results con-
catenated to create a vector of βˆ under H0, which can be re-scaled and projected
onto the basis.
Under the assumption that PC scores from this simulation will be distributed
normally it is possible to estimate approximately, the number of simulations
required for a reasonable empirical estimate of the PC score variance. This
involves setting a target variance, σ2, and then simulating PC scores such that
PCscore ∼N(0,σ2), 1,000 times for each value of n, where n = {200,500,103,2×
103,104,105} reflecting the number of simulations performed, and setting σ2 =
0.1, a reasonable estimate given the observed basis PC scores (Figure 4.9). At
each n I computed the coefficient of variation (CV) σˆµˆ where σˆ and µˆ are estimates
for the standard error and mean computed over the 1,000 simulations for a given n.
CVs had a range from 5% where n = 200 to 0.2% where n = 105. I took forward
an n = 500 as this gave a CV of 3% that balanced the stability of the variance
estimate with the increasing computational burden associated with larger values
of n. Using the proposed framework I simulated and projected GWAS summary
statistics under H0 across sample sizes ranging from 1,000 to 15,000 individuals.
Simulation under H1
The previous simulations are generated under the null hypothesis of no association
across any SNPs. In application such a strong assumption will be violated and
therefore I also wanted to assess how appropriate both analytical and simulated
PC score variance were compared to those obtained from actual GWAS data.
To do this I used imputed genotypes for T1D from WTCCC (Wellcome Trust
Case Control Consortium, 2007) supplied by Chris Wallace. I carried out QC,
filtering out SNPs with poor imputation scores, violating HWE (ZHWE > 5), and
not overlapping the set of basis SNPs. This left approximately 286,000 variants
across 5,271 individuals (1,929 cases and 3,342 controls). I used this set of variants
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to create a basis as described previously (Section 4.6.2) with the T1D trait excluded.
This is because additional correlation between βˆ s between a basis and projected
traits would be introduced which is not due to a shared disease architecture but
instead because of sample sharing. This correlation is non negligible when there
is a large degree of sample overlap between traits such as occurs for Cooper et al.
(2017) and Wellcome Trust Case Control Consortium (2007) GWASs (Discussed
further in Section 4.9.5).
In order to estimate the variance associated with the projection PC scores I
employed a bootstrap methodology (Efron, 1979). Let N1 and N0 be the number
of cases and controls for which the variance of PC scores are to be estimated. In
the first step I sample N1 case and N0 control genotypes to form a ‘source’ set of
genotypes. To perform a bootstrap estimate of the PC variance for a particular
case/control configuration I sample with replacement N1 case and N0 control
genotypes from this ‘source’ set, which I use to conduct a case/control GWAS
(using 1958 birth cohort codings for regional locations as a covariate). Finally
the resultant βˆ are projected onto the basis in the usual fashion to derive PC
scores which are stored. I repeated both steps 500 times for a given value of N0
and N1 allowing a robust estimation of the variance PC scores under different
GWAS case and control size scenarios. Unlike the H0 framework I was limited
by the underlying WTCCC study size in the configurations that can be assessed,
I therefore assessed matched numbers of cases and controls for sample sizes of
500,1000 and 1900.
A further source of variance not related to disease genetic architecture might be
introduced by population substructure. Whilst the bootstrap above does incorporate
geographical birth location as a covariate in order to mitigate this, the sampling
regime as described has the potential to preferentially select cases or controls
from a particular region. To obviate this I performed the bootstrap a second time
making sure that geographic location proportions amongst cases and controls were
preserved after sampling.
4.7.3 Variance estimate evaluation
The results of simulations and bootstraps indicate that the analytical estimates of
the variance of PC scores were well calibrated (Figure 4.11). Empirical estimates
of the variances under H0, both H1 with and without population stratification
were aligned with analytical estimates and well within 95% confidence intervals
supporting their utility in downstream analysis.
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Fig. 4.11 Variance estimation of PC score method comparison. Crosses represent
analytical variance estimates under H0 (Section 4.7). Points represent empirical
computation of variance over 500 simulations of projected summary stats under
H0 (Section 4.7.2). Triangular points represent projection variances from 500
bootstraps at different sample size configurations under H1 (Section 4.7.2), with
squares representing where geographical location has been taken into account in
the sampling strategy.
4.7.4 Assessing the significance of trait projections
Having a reliable method for estimating the variance associated with trait projec-
tion into the basis space is useful as it can be used to assess whether a particular
PC score for an axis is significantly different from the control trait, where no
associations are expected. In subsequent sections I use δkt = Pkt −Pk,control to
centre projections about control where, as before k indexes the number of PCs.
After such a transform, a standard normal Z-score can be computed for the the kth
PC as
Zkt =
δkt√
Var(Pk)
. (4.23)
4.8 Annotation of basis principal components
I next sought to better understand the biology that might underlie individual basis
PCs. One mechanism for doing this is to project GWAS summary statistics for a
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diverse range of traits onto the basis and catalogue PC and trait combinations that
are significantly different from the ‘control’ basis trait PC score.
4.8.1 Projection of UKBB self-reported trait GWAS
One source of traits is the previously mentioned the UKBB (Sudlow et al., 2015).
In addition to the seven self-reported traits already projected (Section 4.5) there are
further traits with binary outcomes for which summary statistics are available from
the Neal laboratory compendium. I chose to take forward three main categories
covering self-reported medical conditions (UKBB code 20002, n = 282) cancer
(UKBB code 20001, n = 28) and treatment/medications3 (UKBB code 20003,
n = 542), which are all self-reported.
I downloaded summary statistics for all of the categories mentioned from the
Neale Laboratory compendium, filtering to obtain summary statistics for SNPs
included in the basis. After converting to the odds ratio scale (Section 4.5.1) and
applying weights (Section 4.6) I projected all 854 traits onto the basis. I used the
analytical variance estimations (Section 4.7) of PC score projections to assign
significance to combinations of traits and principal components. To select combi-
nations for further study I used the Benjamini–Hochberg procedure (Benjamini
and Hochberg, 1995) to adjust p-values for multiple testing over all trait and PC
combinations, selecting those with a false discovery rate (FDR) less than 5%
for downstream analysis. In total across all traits I took forward 210 significant
trait-PC combinations, compassing 108 unique traits in order to annotate basis
components (Figure 4.12). I decided to exclude PC11 from downstream analysis,
due to the small amount of overall variance it explains, and the fact that this likely
composed of a large proportion of stochastic variance.
PC1 This component is effective at discriminating between autoinflammatory
diseases, including CD and UC with negative δ values, and those of a more
classical autoimmune phenotype such as RA and SLE whereδ is positive
(Figure 4.13). Gastroenteritis/Dysentry has the most positive δ values, how-
ever it is likely that this is a false positive result, given that the number of
cases is small (n=104), and such a result contradicts clinical observations
that link gastroenteritis to an increased risk of developing IBD (García Ro-
dríguez et al., 2006). Self reported medication δ values tend to correlate
3This category contains data on any regular treatments taken weekly, monthly, etc. It does not
include short-term medications (such as a 1 week course of antibiotics) or prescribed medication
that is not taken, or over-the-counter medications, vitamins and supplements.
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Fig. 4.12 Summary of significant UKBB SRD traits that on basis projection
were found to have significant (FDR<5%) δ values. Colours represent the three
categories; Cancer (n = 28), Disease (n = 282) and Medications (n = 542).
with diseases for which they are indications. For example Asacol and
Mesalazine (Figure 4.14, negative δ ) are used in the treatment of IBD,
whereas Methotrexate and Thyroxine (Figure 4.14, positive δ values) prod-
ucts are used in the treatment of RA and Hypothyroidism respectively. This
pattern repeats across most of the PC components, providing reassurance
of the SRD projections. Also of interest is the significantly negative δ for
basal cell carcinoma, this agrees with the finding that both non-melanoma
and melanoma skin cancer rates are elevated in individuals with IBD (Long
et al., 2012). Whether this risk is related to treatment with thiopurines and
immunosuppressants, the genetic architecture of IBD, or combination of
both remains to be elucidated.
PC3 On this component δ values for significant SRD traits on this PC are all neg-
ative, and I found no diseases with significant positive scores. Furthermore
I found no nosological relationship between δ s indicating that this compo-
nent captures a more common genetic architecture found across all IMDs.
Notable exceptions to this are MS and Asthma which have non significant
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Fig. 4.13 Heatmap of significant UKBB SRD projections. PC score distance from
control (δ ) is indicated by colour. An asterix indicates δ is significant at FDR<5%.
For clarity, PC11 is omitted as it explains a negligible amount of variance between
basis traits making its interpretation challenging.
positive δ values. Interestingly, treatment response to anti-TNF therapy, a
mainstay biological treatment for many immune-mediated diseases, mirrors
this pattern. For example it is routinely used in the treatment of RA, which
has a significantly negative δ values, whilst it is not efficatious in the treat-
ment of asthma (Holgate et al., 2011). Indeed in multiple sclerosis which
has the most positive δ values, anti-TNF therapy is a contraindication and
can exacerbate disease symptoms (Cho and Feldman, 2015; Gregory et al.,
2012).
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Fig. 4.14 Heatmap of significant UKBB self-reported medication. PC score dis-
tance from control (δ ) is indicated by colour. An asterix indicates δ is significant
at FDR<5%. A large number of asthma medications are significantly associated
with PC10, and so it it is omitted to facilitate interpretation. For clarity, PC11 is
omitted as it explains a negligible amount of variance between basis traits making
its interpretation challenging.
PC5 This PC is defined by two basis traits, PSC and PBC that are not part of the
self-reported UKBB set, having positive δ values. I found that, ursodeoxy-
cholic acid, that is used to treat both PSC and PBC had the most positive δ
values out of all projected traits. This observation supports the notion that
this PC represents a Coelic disease and PBC/PSC axis. The observation
that hepatocellular carcinoma (HCC), also correlates with the δ values of
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PSC and PBC provides further support, as the cirrhosis endemic in both
diseases is associated with increased in risk of HCC development (Lindor
et al., 2009).
PC9 and PC10 Both of these PCs seem to separate asthma and allergic diseases
from the other IMDs. I found that δ values between diseases and related
treatments were strongly correlated. This was especially evident for PC10
where a more negative PC score captures the genetic architecture of allergic
disease (e.g. asthma, Hayfever and Anaphylaxis), as well as a more general
component of IMDs. I found that 34 out of 40 (85%) medications with a
significantly negative δ values, were for treatments for allergy or asthma.
4.8.2 Projection of UKBB blood count GWAS
The study by Astle et al. (2016), presents a comprehensive genetic association
analysis of 36 blood cell count phenotypes across 173,430 individuals of European
ancestry which suggests a causal relationship between certain blood cell pheno-
types and immune-mediated disease. Thus projecting summary GWAS statistics
from this study onto the basis presents an opportunity to investigate whether
the proposed framework is able to uncover similar relationships. Furthermore
such cell type specific relationships might shed light on the causal tissue contexts
underlying basis PCs.
Basis projection
I downloaded4 GWAS summary statistics for all 36 traits, filtering each for SNPs
intersecting the basis and aligned the alleles such that they were concordant with
the basis. This resulted in a 36×280,651 matrix on which I applied the proposed
shrinkage (Section 4.6) prior to projection onto the basis space.
In order to select significant blood trait δ values I concatenated those aris-
ing from this analysis with those derived from the UKBB self-reported binary
traits (Section 4.8.1) taking forward those with a FDR < 5%, for further anal-
ysis. I focused on the 13 main blood cell indices on which Astle et al. (2016)
conducted Mendelian randomisation analysis (Table 4.3), which found significant
relationships between IMD risk and counts for eosinophils (Asthma and CEL),
lymphocytes (Asthma, CEL and MS) and neutrophils. For eosinophil counts
(EO#) they found a positive relationship between Asthma, RA, T1D and CEL
4http://www.bloodcellgenetics.org/
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Trait Abreviation
Lymphocyte Count LYMPH#
Neutrophil Count NEUT#
Eosinophil Count EO#
Basophil Count BASO#
Monocyte Count MONO#
Mean Corpuscular Haemaglobin MCH
Hematocrit (fraction of blood volume occupied by red cells) HCT
Red Cell Distribution Width RDW
Reticulocyte (immature red blood cells) Count RET#
Immature Fraction of Reticulocytes IRF
Platelet Count PLT#
Mean Platelet Volume MPV
Platelet Distribution Width PDW
Table 4.3 Table of 13 main blood measurements analysed by Astle et al. (2016)
risk, whereas across the four PCs with at least one significant δ value I found
conflicting evidence (Figure 4.15). For example for PC4, EO# has a negative δ ,
concordant with Asthma and RA but not T1D and CEL. Overall EO# PC scores
show a strong concordance with Asthma but not other basis traits. For lympho-
cyte counts (LYMPH#) Astle et al. (2016), demonstrated a positive relationship
between this trait and MS, with a lower count indicating protection from Asthma
and CEL. Whilst PCs with significant δ values for this trait showed strong overlap
with Asthma, CEL and MS were discordant. Finally, I found overlap for all PCs
with significant δ values for neutrophil count (NEUT#) with Asthma, in agreement
with Astle et al. (2016), who found a positive relationship between Asthma risk
and NEUT#.
Overall I found these results difficult to interpret outside of the established
association between (EO#) and asthma (Bousquet et al., 1990). The disappointing
overlap with projected blood traits and the causal overlaps suggested by Astle
et al. (2016), is perhaps, unsurprising as there are many technical differences
between the two approaches. For example, there is a large difference in both
the number and ascertainment method as to which SNPs were included in both
analysis method. Whilst the basis is restricted to considering the subset of SNPs
present across all studies, Astle et al. (2016) considered IMD SNPs that were a
priori in high LD with one or more sentinel SNPs associated with one or more
of the 13 main blood traits (MAF>0.01%). Such a bias in terms of both SNPs
considered and how they were ascertained is likely to lead to differing results
regardless of the analytical method used.
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Fig. 4.15 Results of projection of 13 main blood count traits from Astle et al.
(2016), see Table 4.3 for trait abbreviations. PC score distance from control (δ ) is
indicated by colour. An asterix indicates δ is significant at FDR<5%.
4.8.3 Projection of whole blood eQTL data
One approach to characterising the biology underlying basis components is the
integration of genetic data influencing gene expression in a relevant tissue type as
this has the potential to link the genetic regulation of the expression of specific
genes to a component. Recently, Võsa et al. (2018) performed a meta-analysis
of whole blood eQTL data on a total of 31,684 healthy individuals of European
ancestry. I sought to project this dataset onto the basis in order provide a richer
characterisation of basis components.
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I downloaded summary statistics from http://www.eqtlgen.org/cis-eqtls.html
for cis eQTLs, from testing for association between a given gene’s expression
(across 19,960 genes expressed in blood) and each SNP within a 1Mb region
from the gene centre. To this I added summary statics downloaded from http:
//www.eqtlgen.org/trans-eqtls.html for what Võsa et al. (2018) term trans-eQTLs,
that result from association testing between a given gene’s expression and each
SNP from a curated list of 10,317 trait-associated SNPs outside of a 5Mb region
from the gene centre.
For each gene, I filtered summary statistics to obtain only those for SNPs
included in the basis. Given that the summary statistics available are predominantly
centred on a given gene this leads to large amounts of missing data, where an
eQTL summary statistic is not present for most basis SNPs. Over 19,942 genes for
chromosomes included in the basis, the mean number of variants with summary
statistics was 1,804 (IQR 1,742-1,861). I set effect sizes for variants where
summary statistics were not available to zero under the reasonable assumption
that untested or unreported variants were likely to have negligible effects sizes
on target gene expression. After aligning effect alleles and performing Bayesian
shrinkage I projected all genes onto the basis, resulting in a total of 11 component
scores for each of 19,942 genes for which at least one basis SNP was available.
I generated Z scores using empirical mean and variance estimates across all
gene projections for a given PC such that
Zkg =
Pkg− P¯k√
Var(Pk)
, (4.24)
where Pkg, is the PC score for the kth component associated with projecting a gene,
g onto the basis (Figure 4.16).
I devised a gene set enrichment strategy in order to assess whether com-
ponents were associated with specific biological gene-sets through eQTLgen
gene projections. To do this I downloaded Reactome (Fabregat et al., 2016),
KEGG (Kanehisa and Goto, 2000) and HALLMARK gene-sets in gmt format
from http://software.broadinstitute.org/gsea/msigdb (Liberzon et al., 2015). I cre-
ated a gene ‘universe’ by selecting the unique set of identifiers for protein coding
genes for which PC scores were available across all components. I used this to
filter pathways such that genes without a PC score were removed, this resulted
in pathways containing very few genes, to counter this I only took forward those
with more than 10 genes for downstream analysis. Given that for a component,
genes can have both positive and negative PC scores, using the raw PC scores for
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Fig. 4.16 Heatmap of significant gene projections from Võsa et al. (2018). Colour
indicates difference from control PC score, ’*’ denotes significant at FDR < 5%.
enrichment might be misleading as these effects might be antagonistic, resulting
in no net enrichment. A more robust approach is to compare the variance of PC
scores between genes within a set and their complement. To do this I used the
var.test function in R which implements an F-test on the ratio of variances
of PC scores of genes in the two groups. I used this approach to assess each of
the filtered gene-sets in order to identify those with evidence of large PC score
variance.
As might be expected I found that gene-sets with relevance to both adaptive
and innate immunity showed evidence of enrichment (Figure 4.17) across all basis
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Fig. 4.17 Heatmap of variance enriched pathways from projection of variance
enriched pathways from projection of Võsa et al. (2018). Colour indicates
log(F-statistic) from an F-test of equality of variances , ’*’ denotes significant at
FDR < 1%.
components. Specifically, PC1 was characterised by both inflammatory pathways
(e..g NOD like receptor signalling and integrin cell surface interactions (de Lange
et al., 2017)) and those involved in adaptive immunity (e.g. b-cell receptor sig-
nalling), supporting its role in describing an autoinflammatory/autoimmune axis.
Pathway associations with other components were less clearly defined, with more
generalised roles for metabolism (e.g. fatty acid metabolism), cytokine signalling
(IL2/STAT5 signalling) and T and B cell signalling. When projecting on UKBB
SRD (Section 4.8.1) I observed an association between Asthma and the medication
used in its treatment on PC10, the association of the coagulation/complement sys-
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tem provides further support for this as the importance of this biological pathway
with respect to Asthma has previously been reported (de Boer et al., 2012).
4.9 Using the basis to characterise JIA
In the previous sections I proposed a framework for creating a basis that facilitates
the comparison of the genetic architecture of clinically and/or phenotypically
related disease by creating a low dimensional summary using publicly available
GWAS summary statistics. Such a representation appears to mirror disease nosol-
ogy, with for example PC1 discriminating between auto-inflammatory and more
autoimmune diseases (Section 4.6.2). In an extension, by projecting new datasets
into basis space, demonstrated using UKBB SRDs, I was able to show that basis
was able to cluster these on the basis of shared genetic architectures (Figure 4.10).
In this section, I expand on this application, describing how it can be used to
better understand the genetic difference underpinning a clinically heterogenous
disease, using juvenile idiopathic arthritis (JIA) as a motivating example.
4.9.1 JIA disease subtypes
JIA is the most common cause of chronic childhood rheumatic disease, with
heterogeneous arthritides occuring prior to the age of 16 years and persisting for
at least 6 weeks (Ravelli and Martini, 2007). This heterogenity has led to the
International League of Associations for Rheumatology (ILAR) criteria, which
divides JIA into subtypes on the basis of clinical features (Petty et al., 2004) and
comprises seven main disease subtypes (Table 4.4).
In previous work Hinks et al. (2017), investigated the HLA region in order to
suggest genetic associations that were common or distinct between subtypes. This
analysis was by design restricted to examining disease overlap using SNPs within
the HLA region, but nevertheless suggested an overlap between polyoligoarthritis
(PO), extended oligoarthritis (EO) and rheumatoid factor negative (RF-), the
most common disease subtypes. In addition to this Ombrello et al. (2017), using
a cohort of 770 children, found no evidence for a shared genetic architecture
between systemic JIA (Sys) and the other JIA disease subtypes, supporting the
observation that Sys is a distinct disease. However, the method employed to
examine overlap was limited to examining either targeted regions (Prahalad et al.,
2013) or those covered by ImmunoChip genotyping platform (Hinks et al., 2013)
and so was not a full genome-wide analysis.
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Subtype Abbreviation Case# Phenotype
Psoriatic PsA 150
Psoriasis/ dactylitis/
onycholysis
Enthesitis-related ERA 185
Ankylosing spondilytis/
Sacroiliac joint tenderness/
inflammatory lumbosacral pain/
HLA-B27
Polyoligo RF+ RF+ 199
Five or more joints and
Rheumatoid factor positive
Systemic Sys 283 Daily fever
Extended oligo EO 394
Five or more joints after
6 months
Polyoligo RF- RF- 573
Five or more joints and
Rheumatoid factor negative
Persistant oligo PO 650 Four or fewer joints
Table 4.4 JIA disease subtype cohort description. Disease subtypes and their
clinical phenotypes and are derived from (Hinks et al., 2017). Case# indicates the
number of individuals with a particular ILAR classification of JIA disease subtype
for which genotype data was available for analysis in this thesis.
4.9.2 JIA subtype GWAS analysis
I obtained quality controlled genotype, data from collaborators at The University
of Manchester, for samples for all seven ILAR coded subtypes of JIA (Table 4.4)
and 5,181 shared controls. I had no input into the collection, recruitment or
processing of genotyping calls. I was supplied with a matrix of PC scores derived
from PCA of the genotype matrix, performed by the Manchester group in order to
estimate and thus control for subtle ancestry specific effects that might confound
subsequent analysis.
I used this data to perform a case/control GWAS of JIA subtypes limited to the
variants contained in the basis using the same 5,181 controls for analysis across
all subtypes. Briefly, I used the R package snpStats (Clayton and Leung, 2007) to
fit a logistic model, for each of the subtypes using sex and as recommended by the
Manchester group the first three PCs obtained from PCA of the genotype matrix
as covariates.
4.9.3 Projection of JIA subtype GWAS
The GWAS performed in the previous section resulted in a set of summary statistics
for each of the 7 subtypes. After aligning effect alleles with the basis, I applied the
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weights as previously described to βˆ , and projected each subtype onto the basis.
This projection resulted in a 7×11 matrix of projected PC scores (Figure 4.18).
The most striking difference that I observed was on PC3 where scores for all
subtypes except ERA and systemic JIA were significantly different to the ‘control’
basis trait.
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Fig. 4.18 Control centred projected PC scores across 7 JIA subtypes. The y
axis represents the difference between the ‘control’ PC score and the projected
PC scores for a given trait (δ ). For clarity faded lines indicate 95% confidence
intervals for the projection, calculated using the method proposed in section 4.7
PC3 discriminates ERA and Systemic JIA from other subtypes
In section 4.7 I introduced a method for analytically computing the variance of a
PC score for a projected trait. This showed that whilst PC3 δ values for RFneg, PO,
EO, RFpos and PsA were significant even after employing Bonferroni multiple
testing correction, both ERA and Sys were not (Table 4.5).
Comparison with HLA focused Hinks et al. (2017) subtype analysis
Whist I observed striking differences at PC3 it is important to consider other
PCs in order to get an overall view of the similarities and difference between the
genetic architecture of JIA disease subtypes. To do this I applied the hierarchical
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Trait Cases Z p-value padj.
RFneg 573 -7.0 3.4×10−12 2.6×10−10
PO 650 -6.7 2.1×10−11 1.6×10−9
EO 394 -5.7 1.5×10−8 1.2×10−6
RFpos 199 -4.3 1.6×10−5 1.2×10−3
PsA 150 -3.9 1.2×10−4 9.0×10−3
ERA 185 0.0 ≈ 1 ≈ 1
Sys 283 1.4 0.16 ≈ 1
Table 4.5 Table of significance compared to control traits for JIA subtypes on PC3.
The Adj. p value column represents the Bonferroni corrected values across all 11
PCs and disease subtypes.
clustering approach previously described (Section 4.5.2) to the matrix of PC scores
for the 7 projected JIA subtypes. This analysis (Figure 4.19a) suggested three
clusters, the largest of which contained RFneg, EO, PO and PSA with a further
cluster containing ERA and systemic subtypes. Interestingly RFpos appeared to
exhibit only limited overlap with other disease subtypes.
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As previously mentioned Hinks et al. (2017), used genetic correlation, con-
ducted using (GATK), across the HLA region in order to characterise the pairwise
genetic overlap between disease subtypes. For comparison with the approach
detailed here I applied the hierarchical clustering approach to the matrix of genetic
correlations presented in Hinks et al. (2017). It should be noted that whilst there
is significant overlap between the individuals included between the two studies
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they are not identical. Interestingly, I found that my analysis identified a similar
cluster containing RFneg, EO, PO and PSA albeit with a slightly modified fine
grained structure, even though the basis approach explicitly excludes the HLA
region from consideration. In Hinks et al. (2017), the clustering of PO, EO and
RFneg is mostly likely explained by the shared susceptibility allele at HLA-DRB1
amino acid glycine 13. Conversely whilst a histidine at HLA-DRB1 amino acid 13
protects from these subtypes it increases risk of developing the RFpos subtype,
perhaps explaining why RFpos clusters separately. Hinks et al. (2017) suggest
that PsA might be susceptible to misclassification, and therefore might comprise
a mixture of PO, EO and RFneg subtypes. The similarities between the results
obtained by the two approaches indicate that at least for PsA, EO, PO, RFneg,
there is a common genetic architecture that exists outside of the major HLA-DRB1
locus and that non-HLA loci are at least in part responsible for a shared genetic
architecture between these traits.
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Fig. 4.20 Heatmap of JIA subtype projections, cells are labeled with δ values and
coloured by Z score if they exceed Bonferonni significance.
This leads to the question as to whether their are additional components,
exclusive of PC3, that have significantly different PC scores for JIA subtypes
(Figure 4.20). Finding significance is heavily dependent on sample size (Equa-
tion 4.20), as such I found that EO and RFneg, subtypes with the greatest number
of cases, had the most components with significant δ values, after Bonferroni
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correction. Interestingly, both Sys and ERA had no significant δ values for any
component, whilst some of this is no doubt due to sample size, I note that the
smallest disease subset, PsA is significantly associated with PC3. Such an obser-
vation is also supported by the analysis of Ombrello et al. (2017), who found that
using polygenic risk scores built from combinations of the most common subtypes
(PO,RFneg and RFpos), had no predictive power when applied to a cohort of
systemic JIA patients.
In summary, the projections of JIA subtypes into basis space that I observed
appear to have some support from alternative studies (Hinks et al., 2017; Ombrello
et al., 2017). However, the results do raise the important question as to what,
biologically or clinically, the principal components represent. Furthermore, when
comparing between subtypes (rather than with control) care needs to be taken
due to the fact that input summary statistics are computed using a shared pool of
control subjects, which I discuss further in Section 4.9.5.
4.9.4 Annotating PCs related to JIA
The characterisation of components as described previously (Section 4.8) is valu-
able as it can be used to gain knowledge about how individual components relate to
JIA disease subtypes. For PC1 all JIA subtypes have positive δ values indicating
a tendency towards autoimmunity however, only PO, RFneg and RFpos show
significance (FDR<0.05). The ERA subtype has clinical and genetic (through
the presence of HLA-B27) similarities with adult-onset ankylosing spondyli-
tis (Colbert, 2010). However, I observed significantly different PC1 scores (t-test
p = 0.01) between UKBB SRD ankylosing spondylitis (N = 1,058) and ERA
with a tendency of ERA towards an autoimmune phenotype. One explanation
for this might be a tendency for the misclassification of other forms of JIA to
the ERA subtype based on a reliance on the the presence of HLA-B27 (MAF
approx 7%). Unfortunately summary statistics for a large AS GWAS outside of
UKBB, such as that presented in International Genetics of Ankylosing Spondylitis
Consortium (IGAS) et al. (2013) are not publicly available, precluding validation
of this finding.
Returning to PC3 which separates Sys and ERA from other disease subtypes,
I previously described (Section 4.8.1) how this component also separated self-
reported MS and asthma from other IMDs and a possible link with anti-TNF
therapy. However a more complicated picture emerges when JIA is taken into
account, as whilst there is limited evidence for the efficacy of anti-TNF treatments
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Fig. 4.21 Forest plot showing the context of JIA subtype projections for PC1.
Coloured points indicate the difference in trait scores with synthetic control,
marked with a red dotted line. Error bars indicate 95% confidence intervals. For
clarity basis trait PC scores (purple) have been merged with overlapping UKBB
traits. Whilst non-basis UKBB traits have been filtered to show only those that
are significantly different from control at FDR < 5%, other traits are included
regardless, these are shown with dashed error bars.
in treating systemic JIA (Russo and Katsicas, 2009), beneficial outcomes have
been observed in children with ERA (Gmuca et al., 2017; Weiss et al., 2018).
I did not observe a specific overlap between PsA and self-reported Psoriasis
for components with significant δ s, perhaps due to the misclassification within the
PsA subtypes suggested by Hinks et al. (2017). Forest plots for all PCs such as
the example in Figure 4.22 are available in Appendix C.2.
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Fig. 4.22 Forest plot showing the context of JIA subtype projections for PC3. For
further details see Figure 4.21 legend.
4.9.5 Comparing JIA subtypes PC scores in the presence of
shared controls
Up to this point I have focused on a statistical method for comparing a projected
disease PC score with a synthetic basis control trait, where no effect is assumed
at each basis SNP. A natural approach to testing the significance of principal
component scores between sets of traits is the t-statistic which involves computing
the the pooled mean and variance of the sets of PC scores to be compared. This
is complicated when comparisons involve study designs that utilise a common
pool of samples, where pooled variance will be underestimated if independence is
assumed. Lin and Sullivan (2009) show that the correlation between study effect
estimates with shared samples can be estimated as follows:
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Corr(βˆk, βˆl) =
(
nkl0
√
nk1nl1
nk0nk0
+nkl1
√
nk0nl0
nk1nk1
)/√
nknl = ρkl, (4.25)
where nk1, nk0, and nk (or nl1, nl0, and nl) are, respectively, the number of cases,
the number of controls, and the total number of subjects in the kth (or lth) study
and nkl0 and nkl1are the total number of controls and cases that overlap. Let
X = {x1, . . . ,xnx−1,xnx} and Y = {y1, . . . ,yny−1,yny}, be vectors of the PC scores
for two groups of traits for a given PC. The variance of the difference between the
means of the two groups is
Var(X¯− Y¯ ) = ∑
nx
i Var(xi)
n2x
+
∑nyj Var(y j)
n2y
− 2
nxny
∑
i, j
Cov(xi,y j), (4.26)
where, by (Equation 4.25), Cov(xi,yi) = ρkl
√
Var(xi)Var(yi). This allows the
computation of a t-statistic t = X¯−Y¯√
Var(X¯−Y¯ ) that is appropriately adjusted for shared
cases or controls.
I applied this method to examine, for PC3 the difference in projected PC scores
between two sets of JIA subtypes, with one set containing ERA and sys, and the
other containing all other subtypes. As expected I found this to be particularly
significant (p = 1.66× 10−9), even taking into account shared controls. For
comparison, the application of a pooled variance approach without taking into
account shared controls was inflated (p = 4.58×10−10), and whilst this makes
no difference to the conclusion for this comparison, for more subtle comparisons
sample sharing will affect type 1 error.
4.10 Projecting individual genotypes onto the basis
Up to this point I have considered the projection of effect size estimates only,
however extending the method to allow as input individual genotypic data allows
other applications and datasets to be applied to the method. This is because the
PC scores for each PC component derived from such an application apply to an
individual rather than a specific trait. For example if we project on the genotype
data for a set of individuals for whom we also have gene expression data we might
look for evidence for the correlation between individual level PC scores and gene
expression.
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4.10.1 Computation of posterior odds ratios
The projection of individual level genotype data into the basis space requires the
conversion of specific genotypes onto the odds ratio scale. To do this I used a
Bayesian framework developed by Chris Wallace inspired by the work of Aitkin
and Chadwick (2003). This framework assumes that, at any SNP, we wish to
estimate the individual odds ratio as determined by the allele frequency in controls,
and a single case. In subsequent sections I use Bin(n, p) to represent a binomial
distribution of n trials with a probability of success p and Beta(α,β ) to represent
a Beta distribution with shape parameters α and β .
I assume that genotypes in controls follow a Bin(2, f0) distribution, where f0 ∼
Beta(α0,β0). I also assume a large number of controls, such that the parameters
(α0,β0) may be estimated by maximum likelihood (equal to maximum a posteriori
estimates assuming a flat prior on f0). Assuming f0 has been estimated as fˆ0 the
observed frequency of a specific allele in n0 control subjects, and Hardy-Weinberg
Equilibrium, I equate the estimated and theoretical expectation and variance of f0
E( f0) = fˆ0 =
α0
α0 +β0
V ( f0) =
fˆ0(1− fˆ0)
2n0
=
α0β0
(α0 +β0)2(α0 +β0 +1)
and solve for
α0 = (2n0−1) fˆ0
β0 = (2n0−1)(1− fˆ0)
If f1 is the allele frequency in cases, with prior distribution Beta(α1,β1),
and we observe a single case G ∼ Bin(2, f1), then the posterior distribution of
f1|G∼ Beta(α1 +G,β1 +2−G).
To estimate (α1,β1), I set prior limits on the log odds ratio, Ω. First I assume
that
E(logΩ) = E (log( f0)+ log(1− f1)− log(1− f0)− log( f1))
= ψ(α0)−ψ(β0)−ψ(α1)+ψ(β1)
= 0 (4.27)
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where we make use of the relations that if f0 ∼ Beta(α0,β0), then
1− f0 ∼ Beta(β0,α0), (4.28)
and
E(log( f0)) = ψ(α0)−ψ(α0 +β0) (4.29)
where ψ() denotes the digamma function. Second, we assume that
Pr(|logΩ|> log2) =
∫ 1
0
Pr(l( f0)< f1 < u( f0)) f ( f0)d f0
= 1− ε (4.30)
where l( f0) and u( f0) are the lower and upper limits on f1 corresponding to
Ω= 12 and 2, respectively, and ε is the small probability that f1 lies outside these
limits, i.e. we assume large odds ratios are a priori unlikely. I used the R function
uniroot to optimise conditions (4.27)– (4.30) to estimate (α1,β1) and therefore
generate a function to convert individual genotypes to the odds ratio scale, given
only allele frequencies in control subjects.
4.10.2 Effect of parmameters on posterior log(OR) estimates
The Bayesian framework depends upon two parameters, control sample size and
the prior probability that an odds ratio exceeds a target log odds ratio, Ω, of 2
(See previous section). To analyse the effect of altering these parameters I first
examined the behaviour of the framework over a range of control sample sizes
(Figure 4.23a). Reflecting the larger variance of odds ratios at small control sample
sizes and minor allele frequencies, I observed a small attenuation in posterior odds
ratios with decreasing control sample size, although across the broad range of
sample sizes this made relatively little difference. More generally the selection
of a lower control sample size leads to more conservative estimates of posterior
odds ratio estimates. I next examined how the prior probability for odds ratios
to exceed 2 might affect posterior odds ratio estimations (Figure 4.23b). As
P(| log(OR)|> log(2)) decreases I observed that the relationship between allele
frequency and posterior odds ratios depends much more strongly on the prior than
on sample size.
Reflecting on these observations I decided to take forward the empirically
obtained curves from using a sample size of 2,500 and P(| log(OR)|> log(2) =
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Fig. 4.23 Effect of parameters on posterior log(OR) values computed through
the proposed Bayesian framework. Effect of a) Control sample size (n0) and b)
P(| log(OR)|> log(2)), with sample size fixed at 2,500.
0.01 on the basis that this would generate conservative estimates for posterior odds
ratios for downstream analysis.
4.10.3 Projection of JIA disease subtype genotype data into
basis space
I applied the proposed method to raw genotype data for the JIA case cohort
previously described (Table 4.4). This involved aligning genotypes such that
reference and alternate alleles matched those used to construct the basis. Then
on a per individual basis I computed an estimate of the logarithm of the posterior
odds ratio, βˆ , for each genotype across each variant included in the basis. This
required two variables, the raw genotype for the individual at that variant and
the allele frequency of the alternate allele, for the latter I used allele frequency
estimates from the UK10K reference cohort for consistency with the basis. Such
a computation involves using the curves previously obtained with the selected
parameters (Section 4.10.2) such that given an observed genotype and control
allele frequency, the required posterior log odds ratio can be simply looked up.
After applying the standard basis shrinkage to βˆ across all basis SNPs I projected
each individual into basis space.
One approach to the assessment of the PC scores obtained from the proposed
genotype level method is to investigate how they compare to those obtained from
projecting βˆ estimates from case/control GWAS (Section 4.9.3). In order to
prepare a comparable summary I took the mean PC score, across individuals
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Fig. 4.24 Comparison of JIA subtype PC δ values derived from genotype (top
panel) and summary data approaches (bottom panel).
for each JIA subtype and plotted them along side the summary method results
((Figure 4.24) Whilst the scaling of PC scores for the genotype method was
much reduced compared to the summary statistic method, the overall patterns
across disease subtypes was conserved (Figure 4.24) offering support for the
proposed framework. I found that a t-test of individual PC3 scores for ERA and
Systemic were significantly different from other subtypes, P = 4.61×10−3 and
P = 1.96×10−8 respectively, matching the significant difference observed when
performing a similar analysis using summary PC scores (Section 4.9.5).
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4.10.4 Evaluating individual level eQTL data using the basis
In the previous section I outlined a method for computing posterior odds ratios
given the genotypes for a set of individuals. This approach extends the basis
considerably, allowing the projection of any measured phenotype for which raw
genotype data is available. An obvious target are eQTL studies in relevant tissue
types where genotypes and gene expression data are available. I wished to explore
whether projecting the genotypes for such a study might have utility in assigning
genes to basis PCs, and therefore provide insights into IMD disease pathogenesis,
not achievable through the previously proposed approaches.
I obtained raw genotype and expression data from Raj et al. (2014), a published
eQTL study of CD4+ T cells, and CD14+ monocytes; immune cell subtypes that
have been implicated in IMD pathogenesis. In order to match the ancestry of pro-
jected genotypes with cohorts used to construct the basis, I took forward data only
for individuals with American-European ancestry from Raj et al. (2014) for use in
downstream analysis. After genotype harmonisation with the basis I computed
posterior log odds ratios across all basis SNPs for 209 and 211 individuals with
Monocytes CD4+ T cells expression data respectively. In total I included 178
individuals for which expression values were available for both cell types. I began
by projecting posterior odds ratios for each individual onto the basis obtaining a
total of 2,343 PC scores across the eleven basis PCs. In order to assess whether
there was a relationship between an individuals score and gene expression I fitted
a linear regression model for each of the 19,323 genes whose expression was
measured in the study, such that
Y ∼ β0 +β1Xk + ε, (4.31)
where Y is a vector of normalised expression values for a given gene and cell type
across all individuals and Xk is a corresponding vector of PC scores for the kth
component, β0, β1 and ε are intercept, coefficient and normal error terms (ε ∼
N(0,σ2ε )) respectively. Such an approach resulted in the computation of 212,553
linear models across all 11 basis PCs. For each linear model the significance of
the β1 coefficient can be assessed using a t-statistic, under the null hypothesis
that β1 = 0 (i.e. there is no relationship between individual component score
and gene expression). Using this approach I found that across PCs for both cell
types there was little support for the association of gene expression for either cell
type across any basis PC component. Indeed, at FDR<5% only two genes were
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significant across all cell types and PCs examined (Table 4.6), neither of which
shows evidence for involvement in IMD aetiology.
Fig. 4.25 Quantile-quantile normal plots for p-values obtained from regressing
an individual’s PC score with expression data from Raj et al. (2014). Colours
represent cell-types; CD14+ (Monocytes) - coral and CD4+ - turquoise.
Whilst such an observation is disappointing, there could be a number of
explanations for this. Firstly, variants that effect gene expression are nominally
found in proximity (cis) to their target gene (Brem et al., 2002; GTEx Consortium,
2017) and whilst evidence for trans-eQTLs are emerging, their robust detection
requires sample sizes 200 times larger than that analysed here (Võsa et al., 2018).
This means that for a given gene a majority of input SNPs will be non-informative,
instead adding stochastic noise, and it is likely that this noise will be sufficient
to overcome any true signal arising from variants with genuine associations with
expression.
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PC Probe Gene βˆ1 p padj
PC6 8073207 FAM83F 30.22 2.5×10−6 0.048
PC10 8152280 LRP12 49.25 1.1×10−6 0.022
Table 4.6 Gene expression from Võsa et al. (2018) significantly associated with
a basis principal component. PC - The basis principal component associated.
βˆ1 - regression coefficient estimate, p - raw p-value, padj - Benjamini-Hochberg
adjusted p-value
4.11 Discussion
In this chapter I have proposed a PCA framework to construct a basis that can
capture, in a summarised form, the shared and distinct genetic architectures across
a set of input diseases using summary GWAS statistics. The comparison of GWAS
summary statistics between related diseases is not novel (Cho and Feldman, 2015;
Cotsapas et al., 2011; Gutierrez-Arcelus et al., 2016), but is commonly conducted
by examining individual associations signals between between pairs of disease
associations. Such approaches are attractive as they simplify the comparison of
effect sizes and putative causal variants which in turn can be used to suggest causal
mechanisms. Genome-wide approaches such as genetic correlation can identify
relationships between diseases (Bulik-Sullivan et al., 2015) but they do so in a
pairwise fashion, and can miss relationships in the presence of opposing balanced
correlation structures (Section 4.2). In contrast, the unsupervised approach pre-
sented here partitions and summarises the relationships between diseases in an
holistic fashion, analysing the relationships between all available basis disease
associations simultaneously. Whilst this learned basis is of interest, the projection
of other traits into basis space is of great utility as it allows not only the charac-
terisation of specific PCs that in turn can suggest biological insights, but also the
partitioned (by PC) comparison between traits.
The application of PCA to feature extraction and dimension reduction over
GWAS summary statistics has been attempted previously (Chang and Keinan,
2014), however my approach is markedly different in that I considered effect size
and direction. I found that re-weighting input odds ratios prior to PCA was of great
importance and failure to do so created a basis that was overwhelmed by stochastic
noise at unassociated variants or possibly through more systematic noise due to
study specific signals unrelated to underlying disease genetic architectures. The
PCA of summary statistics for 10 IMDs that used a novel re-weighting method that
I developed was able to discriminate between auto-inflammatory and autoimmune
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diseases, in agreement with a clinical taxonomy suggested by (McGonagle and
McDermott, 2006), providing support for the efficacy of the approach.
The basis obtained forms a compact summary of the relationships between
input diseases The projection of external data onto the basis is especially useful
as it allows the transfer of knowledge derived from diseases, with large sample
size and resultant power, onto other phenotypes, which themselves can be, of very
limited sample size. I found this particularly useful for biologically annotating
individual PCs using UKBB data over a wide range of traits. Reassuringly,
PC scores between UKBB SRD and matched basis diseases were most similar.
Furthermore UKBB SR medication data showed a strong relationship with the
diseases and corresponding treatments. I note that these results are concordant with
the observations of Wu et al. (2019), who for example, found a strong relationship
between RA and immuno-suppressant drugs using a polygenic risk score (PRS)
approach.
On extending the approach to consider the more quantitative, intermediate
phenotypes of blood count and eQTL data from Astle et al. (2016) and Võsa et al.
(2018) respectively, my results were less clear. In comparison to the Mendelian
randomisation analysis results described by Astle et al. (2016), I found only modest
overlap.
For my analysis involving blood eQTLs (Võsa et al., 2018) I was limited
somewhat by data availability, as summary statistics were only available across
all genes for a limited subset of SNPs. To overcome this I made the assumption
that effect sizes at missing SNPs were zero, and whilst this is a strong assumption,
its effect can be somewhat ameliorated by considering a within study empirical
significance measure. Whilst I was able to find significant PC scores for genes
and pathways that corresponded to basis and other projected traits (e.g. integrin
cell surface interactions and IBD (de Lange et al., 2017) and PC1) many were
associated with more than one PC, mirroring the situation previously described
where biological concepts are shared across multiple PCs. One possibility is
that PCs are capturing different facets of the same biological concept (e.g. B-
cell receptor activation pathway) with opposing effects across PCs and therefore
diseases, however further work is required to describe this fully. Further work
might consider alternative methods to achieve sparser PCs, such that biological
concepts are concentrated across fewer components.
I examined in detail the application of the basis to provide insight into the
genetic architecture of basis-related diseases, that due to their rarity or clinical
heterogeneity, might lack sufficient power. Using JIA as example to investigate
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this, I projected disease subtypes onto the basis, hypothesising that despite the
small input sample size a PC score comparison might shed light as to whether
genetic architecture might be responsible for the observed clinical heterogeneity.
PC3 δ values were able to effectively discriminate Sys and ERA, which were
statistically indistinguishable from the basis ‘control’ from other JIA subtypes,
which all had significant negative δ values. This was unlikely to be completely
driven by sample size due to the significance of PsA, the smallest subtype cohort.
Whilst the studies of Hinks et al. (2017) and Ombrello et al. (2017) provide some
support for the observed genetic heterogenity between subtypes.
In light of the projection of UKBB traits, which suggest that PC3 is a more
general component for which a majority of diseases except Asthma and MS
have significant δ s. This is of some interest as PC3 scores for traits suggested
a link between the efficacy of anti-TNF therapy. Whilst the effect of rs1800693
is well documented as a major factor in the exacerbating disease symptoms in
MS (Gregory et al., 2012), via splicing of TNFRSF1A, this was not responsible for
this observation as basis loadings for SNPs were minimal for the region 12p13.31
(median PC3 loading rank across all SNPs in the region was 210,673). Such an
example provides an illustration as to how the approach could provide insight into
disease pathology, although further work would be required to understand how
robust such assertions might be.
I extended the framework to allow the projection of individual level genotype
data into the basis space, using a Bayesian framework. This projection of posterior
βˆ onto the basis has overlap with the calculation of single trait polygenic risk
scores (PRS) (Chatterjee et al., 2016), where rather than weighting allele counts
by raw (or regularised) effect sizes ascertained from a single trait ‘discovery’
GWAS, posterior log odds ratios are weighted by the loadings obtained from the
basis. In this way we obtain multi-trait PRS stratified by PC for each individual
projected. The results from the application of this method to individual genotype
data from the JIA disease subtype cohort, matched those generated using summary
GWAS data, providing support for the framework. However on application to an
eQTL dataset of relevant tissues, I was unable to find any convincing relationships
between individual-level PC score and gene expression, even in light of the
multiple examples of colocalisation between eQTL datasets and IMD GWAS
signals that have previously been described in overlapping tissue contexts (Guo
et al., 2015; Zhang et al., 2015). Although this appears contradictory to recent
studies that highlight a significant role for trans-eQTLs (Boyle et al., 2017; Liu
et al., 2018; Võsa et al., 2018), it seems most likely that the main reason I was
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unable to confirm this was because of lack of power in the Raj et al. (2014) data
set used. Further work will be required to examine whether larger studies eQTL
studies in relevant tissues are able to provide more insight into PC characterisation.
One important consideration was the best approach to missing data, that arises
from the heterogeneity of genotyping platforms and downstream imputation across
SNPs with the GWAS I wished to consider. Whilst there are methods to deal
with missing data using PCA, these are often computationally taxing and assume
that data is missing at random (Ilin and Raiko, 2010). I chose to include a wider
range of basis traits at the cost of decreased SNP coverage. I made this choice
because I felt this would lead to a richer basis under the expectation that phenotypic
heterogeneity is driven by differences in underlying genetic architecture. There
is evidence to support this, for example T1D, where SNPs proximal to genes
involved in pancreatic β -cell function (e.g. GLIS3, BCAR1 and INS) are shared
with type 2 diabetes but not other IMDs (Aylward et al., 2018; Fortune et al.,
2015).
Whilst there are a myriad of further extensions that might be applied to the
approach described, one of the most obvious is extending the number of traits used
either to create or be projected on to the basis. For the former, given that summary
statistics for well powered GWAS for a range of phenotypes are now routinely
available (MacArthur et al., 2017), the possibility of creating a richer basis en-
compassing a much wider range of diseases and phenotypes that are not limited
to IMD is possible. Such a resource might have utility in not only partitioning
diseases, through PCs related to specific genetic architectures but also framing
diseases in their overall context. This latter application might have utility in the
development of new disease taxonomies that are based on molecular rather than
clinical phenotypes. In addition to creating a richer basis, the identification and
projection of additional rare forms of IMD holds promise. This could be extended
over rare disease subtypes for which data is available, for example teasing apart
antibody specific forms of eosinophilic granulomatosis with polyangiitis (Lyons
et al., 2018) and perhaps using the basis to better understand the genetic architec-
ture of even rarer diseases of the immune system where roles for both common
and rare variants are suggested, such as Primary Immunodeficiency (Thaventhiran
et al., 2018).

Chapter 5
Discussion
In this thesis I have developed methods for integrating genomic datasets at different
resolutions in order to develop a better understanding of immune-mediated disease
susceptibility. The COGS method (Chapter 3), concerned with suggesting causal
variants, genes and tissue contexts using PCHi-C data and GWAS summary
statistics, operates at the highest resolution, making use of the single base-pair
resolution of SNPs. In contrast blockshifter (Chapter 2) acts at a lower resolution,
employing a genome-wide approach, in order to suggest relationships between the
disease specific genetic architectures and overall tissue specific, three dimensional
chromatin organisation. Chapter 4 takes this further, describing a framework
acting at a genome-wide and multi-trait scale, initially to summarise the genetic
relationships between a set of clinically related diseases, but which has relevance
to understanding the genetic basis of a wide range of both binary and quantitative
human phenotypes.
5.1 Linking themes
5.1.1 Effect of single causal variant assumptions
Common to all three chapters is the use of Bayesian fine-mapping methods to as-
sign posterior probabilities for a variant to be causal, predicated on the assumption
of a single causal variant within an associated locus. In practice it is likely that
this key assumption is often violated, and results from Asimit et al. (2019) suggest
a sobering picture where the presence of multiple disease causing variants within
a single locus might be currently underestimated.
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The effect of violating this assumption is dependent on the locus and disease
specific genetic architectures, but I envisage two main scenarios. In the most
benign scenario, consider a locus in which there are multiple causal variants in
low LD, but with heterogeneous effect sizes such that one ‘lead’ variant possesses
a much larger association signal than the others. Setting aside technical reasons,
such a situation could arise if the variant has a higher effect size or is more common
in the population than the other causal variants. In such a case it is likely that
the majority of the causal variant posterior probability is assigned to this ‘lead’
variant, thus masking the other causal variants in the locus.
As described in Asimit et al. (2019), a more worrying but rarer scenario
consists of two causal variants, that whilst not being highly correlated with each
other, are in LD with a third variant that itself is not causal. As, via LD, this
third variant captures both causal variant associations, under single causal variant
assumptions, it will misleadingly be assigned a high posterior probability for
causality.
Such scenarios are of most relevance to the methods developed in Chapter 3
that operate at the highest resolution. The effect of the first scenario on COGS
prioritisation will likely be more benign, as the prioritisation will be performed on
the ‘lead’ signal at the expense of other causal variants within the locus. As a result
genes and tissues, whilst of relevance to disease biology, are possibly incomplete,
obscuring more subtle causal mechanisms. In contrast, scenario two is likely to
result in a misleading prioritisation, as posterior probability is assigned to variants
which are unrelated to disease pathogenesis, and as such could lead to genes and
tissues unsuitable for informing downstream functional studies. Although this
effect is likely to be mitigated by the size of the underlying HindIII fragments
and the correlation between the states of neighbouring fragments. Whilst the
ability to resolve these scenarios, once the single causal variant assumption is
relaxed, is linked to underlying sample size, it might provide an explanation for
the modest overlap of prioritised genes obtained for single and multiple causal
variant fine-mapping inputs to COGS that I observed.
I expect the single causal variant assumption to have a more limited effect
on the other, lower resolution approaches presented. Considering blockshifter, I
would argue that this limitation although important at individual loci is somewhat
averaged out at the genome-wide scale, and this is further ameliorated by the
competitive nature of the test, where enrichment is computed not with respect to a
null distribution, but as the comparison of two sets of tissues, similarly affected by
underlying assumptions.
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Whilst the shrinkage method underpinning the analyses in Chapter 4 is synthe-
sised from the single causal variant fine-mapping approach, its goals are somewhat
different in that it seeks to amplify effect sizes for SNPs which are likely to as-
sociated with disease whilst attenuating those that are more likely due to more
stochastic processes. In such a situation picking a non-causal variant that encapsu-
lates information about a multiple number of causal variants does not significantly
disadvantage the method, under the assumption that input studies of shared ge-
netic ancestry are selected. Indeed, for this application, where SNP coverage is
limited it is more likely that a second key assumption, that the causal variant(s)
are genotyped, is most likely violated, which I discuss in the next section.
5.1.2 Data availability
Another theme that runs through this thesis is that of data availability, mainly
pertaining to GWAS datasets. This can be subdivided into two separate consid-
erations: the public availability of full GWAS summary statistics for published
studies, and due to the rapid technological advances in this area, the heterogeneous
nature of SNP coverage between different traits.
With regards to the public availability of GWAS summary statistics, great
strides have been made over the time since the commencement of this work. For
example the work detailed in Chapters 2 and 3, required a considerable effort
in order to compile a set of summary statistics over 31 traits. This fractured
availability of GWAS summary statistics is in part historical and founded on
somewhat overblown concerns about patient anonymity (Homer et al., 2008).
Thankfully we are reaching a stage where online resources that aggregate and
curate and make publicly available, full GWAS summary statistics across the whole
range of human quantitative traits and disease phenotypes are being realised. For
example The GWAS Catalog1 (MacArthur et al., 2017), has taken this community
requirement seriously and now provides access to the full summary statistics
of over 750 studies/traits. However, given that in total they have curated data
information about ‘lead’ SNPs for nearly 4,000 publications, clearly further work
is required.
Critical to such efforts are not only suitable funding mechanisms that recognise
the community benefit of such resources, but also the support of funders and peer-
reviewed publications to encourage researchers to submit full summary statistics
repository as part of the manuscript submission process. Such an approach,
1https://www.ebi.ac.uk/gwas/home
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exemplified by ArrayExpress (Kolesnikov et al., 2015) and GEO (Clough and
Barrett, 2016) for gene expression data, would not only provide better coverage
of a diverse range of phenotypes but would present additional opportunities, for
example they might provide a starting point for the development of light-touch
meta-data standards for efficiently describing GWAS studies. Such standards need
not be onerous but, for example, could incorporate guidelines on reporting effect
sizes and the allele to which they pertain, enabling researchers to rapidly examine
heterogeneity of effect direction at a given SNP or locus.
The differential SNP coverage between studies, presents a more technical chal-
lenge, and for the chapters concerned with PCHi-C integration a quote attributed
to Charles Babbage springs to mind:
Errors using inadequate data are much less than using no data at all.
Here ‘inadequate data’ is relevant to the use of the PMI methodology I developed
in order to fill in instances where variants were not genotyped in the original study,
and as the sobriquet suggests, this imputation method should not be conflated
with the more rigorous procedures used to infer missing genotypes (Howie et al.,
2009) or association statistics (Pasaniuc et al., 2014). Such an approach was
necessary, as not only was the fine-mapping procedure I employed predicated
on coverage of the causal variant, but also such resolution is required when
integrating genomic annotations for reasons of sufficient coverage of individual
features. For blockshifter I was able to simulate the effect of PMI on outcome,
demonstrating that it decreased power to detect true enrichment, such that its
effect on downstream results would be relatively benign. The affect on COGS
prioritisation was more complicated and I showed that PMI, for certain loci could
have marked effects on gene prioritisation, and in my final analysis I opted to use
only dense ImmunoChip summary statistics, or those studies of IMD for which
conventional imputation was performed (Bentham et al., 2015; Okada et al., 2014).
For the PCA framework, I argued that, given the design of genotyping plat-
forms, the effect of a sparse SNP map on my results would be minimal as most
common variation would be effectively tagged. This tension between data avail-
ability and the desire to cover as rich a set of diseases/phenotypes as possible is
relevant throughout this thesis. Whilst a researcher, invested in a particular disease
or phenotype might find this unacceptable, I took the view that covering as many
traits as possible would lead to greater insight. On reflection this is somewhat
application specific. It is reasonable to cast the net widely when attempting to elu-
cidate relevant tissue contexts, or genetic relationships between diseases, whereas
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a greater focus on specific diseases and fine-mapping strategies is reasonable when
attempting a more detailed prioritisation of potential causal mechanisms using
PCHi-C facilitated COGS at a specific locus.
5.1.3 The importance of orthogonal functional evidence
Undoubtedly, whilst the use of PCHi-C data in this thesis is novel there are
multiple technical and biological reasons why it is no panacea for the elucidation
of causal mechanisms in complex disease. A chief limitation is that resolution is
restricted to the restriction fragment level and thus far removed from the theoretical
single base-pair scale of genetic association studies. This limitation not only
precludes the identification of causal variants but also introduces the possibility
that multiple gene regulatory elements, acting on different target genes and in
heterogeneous tissue contexts are contained within a single fragment. Leaving
aside the technical challenges of employing alternative, ‘frequent-cutter’ restriction
enzymes strategies, an alternative method to overcome such challenges is to
integrate orthogonal high resolution genomic data in an attempt to triangulate
promising regulatory sequences containing putative causal variants. In this thesis
I used an informal hierarchical method, first using COGS to prioritise genes,
before descending to the individual promoter interacting fragment level to look for
overlap with tissue matched annotations such as eRNAs, using this as a prospective
filter to suggest promising candidates for functional followup (Table B.2). Clearly
given the investment required in such downstream studies the examination of
all sources of available evidence is prudent. Indeed in a number of regions LD
prevents the statistical identification of causal variants, whilst large sample sizes
and/or GWAS studies across different ethnicities has the potential to overcome
this situation, such approaches are resource intensive. Thankfully, new high-
throughput functional screens requiring only few donors are being developed to
overcome some of these situations. For example massively parallel reporter assays
(MPRA) (Melnikov et al., 2012) have been used successfully to interrogate the
enhancer potential of regulatory sequences containing putative causal SNPs for red
blood cell traits (Ulirsch et al., 2016). However such approaches are technically
challenging and their reliance on plasmid transfection currently precludes the
assessment of certain IMD tissue contexts such as monocyte lineages. Another
technique which shows great promise is the use of CRISPR activation assays;
where a strong transcriptional activator such as VP64 is tethered to a catalytically
dead Cas9 which in conjunction with specific guide-RNAs can be targeted to
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specific regulatory sequences. The motivation for such manipulations is they
allow the assessment of the activity of a regulatory sequence in a tissue-context
agnostic manner, as the proximal localisation of the transcriptional activator to
the regulatory element will drive expression of the element and its target gene,
irrespective of cellular context. Such an approach has been used to interrogate the
IL2RA region, discussed in detail within this thesis, corroborating the contribution
of rs61839660 to IMD disease risk discussed in Chapter 3 (Simeonov et al., 2017).
5.1.4 A new taxonomy
The importance of taxonomies for organising data in the biological sciences have
been recognised since, 1758, when Carl Linnaeus proposed a systematic classifi-
cation of plants and animals based on the detailed observations of many different
organisms. Indeed, disease taxonomies such as The International Classification of
Diseases (ICD) are the very heart of modern medicine, however these are beginning
to lag behind a growing body of molecular phenotypes, obscured by similarities
in clinical disease presentation, that can be important for efficiently treating dis-
ease (Mirnezami et al., 2012). To address this, new initiatives are being developed
that can capture such rich, molecular phenotypes, in an extensible and flexible
manner. One example is the Human Phenotype Ontology (HPO) (Köhler et al.,
2017), which, whilst initially targeting rare disease, is being extended to cover
more common diseases, providing not only detailed clinician-lead taxonomies but
also facilitating relationships across disease domains. The development of such
new taxonomies is intimately linked to the elucidation of the molecular phenotypes
that underlie disease susceptibility as these will ultimately determine the spectrum
of disease covered by a particular classification. The methods and analysis pre-
sented in Chapters 2 and 3 can be viewed as very early stage prioritisation methods
for uncovering such molecular phenotypes by suggesting promising genes, tissue
contexts and biological pathways that through careful functional validation, might
lead to novel disease classifications.
Chapter 4 presents a promising approach for disease classification based on
shared and distinct genetic architectures. In application to IMD, what emerges
is a spectrum of risk encompassing auto-inflammatory diseases such as IBD at
one extreme and classic autoimmune diseases such as SLE at the other. The
presence of blurred lines between different but clinically related diseases is not
unexpected (Cleynen et al., 2016; McGonagle and McDermott, 2006), however
the ability to ‘learn’ orthogonal partitions of risk across common clinically related
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diseases affords the opportunity to project rarer phenotypes in order to uncover
unappreciated genetic similarities and differences. Whilst this is of some interest,
characterising the biology that each component relates to will greatly increase
utility of the method, whether for suggesting novel therapeutic avenues (or those
to avoid) or to realise a deeper molecular classification of particular disease.
However the approach, as presented here, suffers somewhat from the overlap of
concepts between components which makes relating them to biological processes
challenging. Some of this overlap could be biological, for example the same
variants in a particular biological pathway exerting antagonistic effects in different
diseases and further work looking at PC loadings and variants will be required to
investigate this.
A natural extension is to consider methods, such as VARIMAX (Jackson,
2014), for transforming the principal components in order to promote sparsity
in underlying loadings, which might result in greater discrimination of concepts
across components. In practice given that the total number of components is small
(n = 11) it is unlikely that this will have a profound effect, given that orthogonality,
and thus variance explained, between components is to be preserved. It might be
promising to investigate alternative matrix factorisation methods, where underlying
assumptions of orthogonality are relaxed. Given the computational burdens of
such techniques I would expect a filtering of SNPs, based on weightings would be
propitious prior to their employment.
5.2 Further Work
5.2.1 PCHi-C facillitated gene prioritisation in alternative con-
texts
In chapter 3 I prioritised putative causal genes and tissue contexts based on
PCHi-C maps of 17 haematopoietic cell types. As detailed above, there were a
number of limitations both at the level of causal variant identification and PCHi-C
resolution, and I outlined the importance of using multiple, orthogonal lines of
evidence to assess prioritised causal mechanisms, prior to functional validation.
One extension that might improve the robustness of such a prioritisation would
be the incorporation of such alternate sources of evidence directly into the COGS
methodology. Given its Bayesian foundations a promising avenue for future
extensions could be the consideration of more informative priors, based on the
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intersection of orthologous genomic datasets with GWAS association signals. As
previously introduced in Chapter 2, fgwas (Pickrell, 2014) uses such an approach
in order to suggest novel associations as well as identify genomic annotations of
interest, and involves the computation of such informative priors simultaneously
across multiple annotations for a given trait or disease. This invites a combined
approach where fgwas is used to compute fine-mapping posterior probabilities
in the context of relevant genomic annotations (e.g. ChIP-Seq), which are then
used as an input to COGS to suggest causal genes. Such an analysis could provide
pilot data indicating whether additional effort to mediate, with functional data, the
beta binomial priors adopted in the multi-causal variant GUESSFM (Bottolo and
Richardson, 2010; Wallace et al., 2015) approach would be worthwhile.
Another promising application of PCHi-C is in the identification of causal
mechanisms underlying monogenic causes of disease. As detailed in the Chapter 1
rare variation in non-coding regions can result in profound phenotypic effects (Let-
tice et al., 2003). Given the availability of whole genome sequences (WGS) and
extensive phenotypic information for a wide range of rare diseases (Ouwehand,
2019), PCHi-C could be applied in a number of ways in order to further understand
the causal mechanisms underlying rare diseases. For example WGS data could
be mined for the presence of compound heterozygotes, where PCHi-C data is
used to ‘connect’ a heterozygous regulatory sequence deletion with a deleterious
protein truncating single nucleotide variant in the same gene. Alternatively, if a
rare disease is characterised by specific tissue defects (especially those with rele-
vance to Haematopoietic cell lineages), tissue-specific COGS scores from related
complex diseases (e.g. IMD and primary immune deficiency) could be used to
suggest causal genes underlying the rare disease. Here the notion is that both rare
and common diseases share causal genes, but differ in the level of penetrance
and expressivity. Such applications, whilst in their infancy are beginning to bear
fruit (Thaventhiran et al., 2018).
5.2.2 Further exploration of basis polygenic risk scores
With the advent of genomic technologies, we are now able to measure, with
unprecedented resolution and accuracy, molecular phenotypes in a scalable fashion,
ushering in an era of ‘genomic medicine’. Genetics is forming the vanguard of
such an approach, through the development of polygenic risk-scores (PRS), which,
in their simplest manifestation, are formed from a weighted sum of a set of risk
variants present within an individual (Chatterjee et al., 2016; Wray et al., 2007).
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Such approaches are not new and have been applied in the field of livestock
breeding for many years, but, with the advent GWASs of large sample size, are
now being applied to human disease (Wray et al., 2019). In certain settings,
for example breast cancer, PRS, are beginning to be assessed for their utility
in augmenting more traditional risk profiling measures such as family history
and highly penetrant mutations in BRCA1/2 so as to provide a clinical screening
mechanism for identifying individuals at high risk of developing disease and
whether this might manifest as a particularly aggressive disease subtype (e.g.
oestrogen receptor negative breast cancers) (Mavaddat et al., 2019). Setting
aside technical issues, for example, the applicability of such GRS across different
populations, their translation into a clinical setting is challenging. Firstly, the
predictive power of a PRS is tied to the narrow-sense heritability of the trait,
which for example in breast cancer is approximately 40%, but can extend to
90% for example, in ankylosing spondylitis. Even in such diseases which are
highly heritable, their application could lead to a prevention paradox (Rose, 1981),
where only a small number of cases come from high risk individuals where
such a PRS might be discriminatory, thus undermining their use in a clinical
setting. Ultimately, the clinical utility of a disease-specific PRS, will be shaped
by the existence and availability of interventions that modulate risk in individuals
identified as being at high risk. For example knowing that a young child is at high
genetic predisposition of being obese is likely to have more clinical utility than
such an observation in an adult patient (Hunter and Drazen, 2019).
In my opinion for the reasons set out above, the applicability of PRS to in-
dividual disease prediction/screening in a clinical setting for IMD is somewhat
limited, and their maximum utility most probably lies elsewhere, for example in
disease stratification. In such a setting individuals are stratified as to their risk
of developing a particular IMD, and high risk individuals are then targeted for
detailed longitudinal study. In chapter 4, I made a brief reference to the parallels
between such PRS and the PCA basis developed. In the context of individual
genotype projections, basis PC scores are derived from linear combinations of
individual allele counts giving an individual PC score for each component and
can thus be interpreted as partitioned multi-trait PRS. Further exploration of the
presented method is, I think justified, given the results observed for JIA subtypes.
One potential application might be to use the basis to interrogate disease prognosis
in Crohn’s disease, as a previous within-cases GWAS presented evidence such
a process might be orthogonal to disease susceptibility (Lee et al., 2017), and
further analysis might yield additional, clinically relevant insights. The benefit of
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this cohort is that participants were recruited at phenotypic extremes under the
expectation this would maximise genetic discrimination, and as such might exist
at the extremes of the distributions for polygenic risk. The projection of both sum-
mary and individual data from this study on to the basis thus framing them in the
context of multiple IMDs, could help to shore up such evidence of orthogonality,
and also lead to additional insights into previously unexamined overlaps in IMD
genetic architectures with disease prognosis. One further application might be
to use the basis to further explore the genetic architecture of rare diseases, that
manifest an immune-mediated component, for example common variable immune
deficiency (Li et al., 2015). Such an analysis could suggest, not only common
molecular aetiologies with prexisting IMDs, but might give some insight into the
interplay between common and rare variants underlying disease pathogenesis.
5.3 Concluding Remarks
For a majority of common human disease we are now firmly in the ‘post-GWAS’
era. Whilst ever larger sample sizes, coupled with new sequencing technologies
will extend the collection of associated loci and causal variants, focus is now
turning towards elucidating underlying causal mechanisms (Visscher et al., 2017).
As set out in this thesis and elsewhere identifying causal variants, their target
effectors and relevant tissue contexts is challenging. Such an effort is justified,
however as the rewards, are likely to be substantial, encompassing the identification
of novel therapeutic targets, and the development of disease classifications built
on firm genetic and molecular foundations. Only once these are realised will the
large amounts of time and resources invested in GWAS over the last decade be
fully justified.
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A.1 Summary of PCHi-C datasets
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Cell type Label
Biological
replicates
Unique
captured read
pairs
Detected
interactions
Megakaryocytes MK 4 653,848,788 150,203
Erythroblasts Ery 3 588,786,672 144,771
Neutrophils Neu 3 736,055,569 131,609
Monocytes Mon 3 572,357,387 151,389
Macrophages M0 Mφ0 3 668,675,248 163,791
Macrophages M1 Mφ1 3 497,683,496 163,399
Macrophages M2 Mφ2 3 523,561,551 173,449
Endothelial
Precursors
EndP 3 420,536,621 141,382
Naive B cells nB 3 629,928,642 171,439
Total B cells tB 3 702,533,922 183,119
Fetal Thymus FetT 3 776,491,344 145,577
Naive CD4+ T
cells
nCD4 4 844,697,853 192,048
Total CD4+ T
cells
tCD4 3 836,974,777 166,668
Non-Activated
Total CD4+ T
cells
naCD4 3 721,030,702 177,371
Activated Total
CD4+ T cells
aCD4 3 749,720,649 188,714
Naive CD8+ T
cells
nCD8 3 747,834,572 187,399
Total CD8+ T
cells
tCD8 3 628,771,947 183,964
Total 11,299,489,740 708,007
Table A.1 Summary of PCHi-C datasets used in this study. Adapted from Javierre
et al. (2016). ‘Total detected interactions’ represents unique interactions captured
in at least one cell type.
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Trait Label Reference
Multiple sclerosis MS IMSGC et al. (2011)
Celiac disease CEL Dubois et al. (2010)
Type 1 diabetes T1D Barrett et al. (2009)
Crohn’s disease CRO Franke et al. (2010)
Primary Billiary Cirrhosis PBC Cordell et al. (2015)
Ulcerative colitis UC Anderson et al. (2011)
Systemic Lupus Erythrematosus SLE Bentham et al. (2015)
Rheumatoid arthritis RA Okada et al. (2014)
Type 2 diabetes T2D Morris et al. (2012)
Haemoglobin HB Soranzo et al. (2009)
Mean corp. haemoglobin MCH Soranzo et al. (2009)
Packed cell volume PCV Soranzo et al. (2009)
Mean corp. haemoglobin conc. MCHC Soranzo et al. (2009)
Red blood cell count RBC Soranzo et al. (2009)
Mean corpuscular volume MCV Soranzo et al. (2009)
Platelet count PLT Gieger et al. (2011)
Platelet volume PV Gieger et al. (2011)
Body Mass Index BMI Locke et al. (2015)
Low density lipoprotein LDL Teslovich et al. (2010)
Tryglycerides TG Teslovich et al. (2010)
High density lipoprotein HDL Teslovich et al. (2010)
Total Cholesterol TC Teslovich et al. (2010)
Insulin sensitivity INS Manning et al. (2012)
Insulin sensitivity BMI adj. INS BMI Manning et al. (2012)
Glucose sensitivity GLUCOSE Manning et al. (2012)
Glucose sensitivity BMI adj. GLUCOSE BMI Manning et al. (2012)
Height HEIGHT Wood et al. (2014)
Diastolic blood pressure BP DIA ICBP et al. (2011)
Systolic blood pressure BP SYS ICBP et al. (2011)
Lumbar spine bone mineral dens. LSBMD Estrada et al. (2012)
Femoral neck bone mineral dens. FNBMD Estrada et al. (2012)
Table A.2 Table of GWAS studies used in Chapters 2 and 3
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Table B.1 Genes significantly (FDR<5%) differentially expressed between UC/CD
and healthy controls with PCHi-C COGS scores > 0.5. Genes are ordered by
COGS score.
Gene Name COGS score DE pad j Disease
FAIM3 1.000 0.000 UC
COX4I1 1.000 0.036 UC
RPS24 1.000 0.011 CD
IKZF1 0.999 0.001 CD
ACSS1 0.999 0.017 UC
CHD1 0.988 0.032 CD
CD274 0.987 0.002 CD
ROPN1L 0.944 0.042 UC
ADO 0.941 0.006 CD
TFAM 0.939 0.001 CD
ETS1 0.934 0.001 UC
MIDN 0.927 0.011 CD
SBNO2 0.926 0.000 CD
IPMK 0.922 0.028 CD
RQCD1 0.914 0.038 UC
STK32B 0.894 0.022 UC
CTDSP1 0.877 0.008 UC
ADAM10 0.854 0.006 UC
MYC 0.836 0.034 CD
FCGR2A 0.836 0.021 UC
FCRLA 0.835 0.018 UC
SGMS1 0.835 0.000 UC
CD244 0.823 0.003 CD
PIM3 0.822 0.001 UC
BCL6 0.811 0.001 UC
RTP2 0.800 0.043 UC
RASGRP1 0.795 0.005 CD
IKZF3 0.793 0.000 UC
LYRM7 0.771 0.001 UC
DGKD 0.758 0.004 CD
CHRNE 0.737 0.041 UC
ARRB2 0.717 0.001 UC
PIP4K2C 0.686 0.009 UC
Continued on next page
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Gene Name COGS score DE pad j Disease
ADAM9 0.684 0.000 UC
GATA3 0.679 0.031 UC
PAPD7 0.659 0.007 UC
MFF 0.658 0.020 UC
IGF2 0.649 0.049 UC
STK36 0.634 0.013 UC
GPX4 0.631 0.000 CD
BEST1 0.627 0.001 CD
ATG4D 0.626 0.017 CD
AGAP2 0.621 0.017 UC
SMAD3 0.612 0.013 CD
MRPL4 0.599 0.017 CD
MARCH9 0.594 0.003 UC
MAN2A2 0.591 0.038 CD
GALC 0.589 0.001 CD
CDK4 0.588 0.014 UC
MLC1 0.575 0.031 CD
DSE 0.573 0.000 UC
BCL2 0.565 0.015 UC
FBL 0.561 0.001 UC
C9orf37 0.543 0.001 UC
DPP7 0.542 0.047 UC
SSNA1 0.542 0.000 UC
PHPT1 0.542 0.007 UC
CCDC183 0.542 0.012 UC
ABCA2 0.542 0.021 UC
SCAMP3 0.529 0.020 CD
TTC1 0.523 0.045 UC
ZBTB49 0.520 0.047 UC
CD55 0.517 0.002 UC
FYB 0.508 0.008 CD
ATF6 0.504 0.003 UC
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Table B.2 Activated and non-activated CD4+ T cell PCHi-C COGS prioritised genes (COGS > 0.5) across 6 IMD studies. All diseases were
based on ImmunoChip studies (IC) apart from SLE which only used a genome-wide (GW) study. Note that RA prioritisation is based on
both IC and GW studies. Context indicates labelling by the hierarchical COGS method where prioritisation is based on; INT = interaction,
CODE = coding SNP, NCODE = interaction + promoter, PROM = promoter, NACT = Non activated CD4+ T cells, ACT = Activated CD4+
T cells and OVERALL = interaction + promoter + coding SNP. ‘Expr’ (Expression) and ‘eRNA’ columns reflect differential expression
of target genes and enhancer RNAs between non activated CD4+ T cells respectively; ND = Not detected, ‘+’ = Up , ‘-’ = Down , ‘=’
= No change and are relative to activation. Locus and SNP are the most proximal disease-matched susceptibility region and index SNP
respectively as curated in ImmunoBase. A list of COGS scores for all genes analysed is available as a supplementary table in Burren et al.
(2017).
# ENSG Name Disease Analysis COGS Context Expr eRNA Locus SNP p-value
1 ENSG00000160087 UBE2J2 SLE GW 0.60 INT + ND
2 ENSG00000157870 FAM213B RA GW 0.75 PROM = = 1p36.32 chr1:2523811 7.8E-14
3 ENSG00000142606 MMEL1 RA GW 0.76 PROM ND = 1p36.32 chr1:2523811 7.8E-14
4 ENSG00000134242 PTPN22 ATD IC 0.57 CODE + ND
5 ENSG00000134242 PTPN22 RA IC 0.66 CODE + ND
6 ENSG00000134242 PTPN22 RA GW 0.68 CODE + ND
7 ENSG00000134242 PTPN22 T1D IC 0.82 CODE + ND
8 ENSG00000134247 PTGFRN RA GW 0.98 INT + ND 1p13.2 rs2476601 6.6E-170
9 ENSG00000134256 CD101 RA GW 0.98 INT - ND 1p13.2 rs2476601 6.6E-170
10 ENSG00000116830 TTF2 RA GW 0.97 INT + ND 1p13.2 rs2476601 6.6E-170
11 ENSG00000134253 TRIM45 RA GW 0.97 INT ND ND 1p13.2 rs2476601 6.6E-170
12 ENSG00000160712 IL6R RA GW 0.56 NACT - ND 1q21.3 rs2228145 3.7E-09
Continued on next page
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13 ENSG00000162706 CADM3 SLE GW 0.90 CODE ND ND
14 ENSG00000143226 FCGR2A RA GW 0.52 PROM ND ND
15 ENSG00000143226 FCGR2A RA IC 0.59 PROM ND ND
16 ENSG00000143226 FCGR2A SLE GW 0.96 PROM ND ND 1q23.3 rs1801274 1.0E-12
17 ENSG00000132185 FCRLA RA GW 0.60 INT = ND
18 ENSG00000132185 FCRLA RA IC 0.69 INT = ND
19 ENSG00000132185 FCRLA SLE GW 0.89 INT = ND 1q23.3 rs1801274 1.0E-12
20 ENSG00000162746 FCRLB RA GW 0.61 INT ND ND
21 ENSG00000162746 FCRLB RA IC 0.69 INT ND ND
22 ENSG00000162746 FCRLB SLE GW 0.89 INT ND ND 1q23.3 rs1801274 1.0E-12
23 ENSG00000081721 DUSP12 RA GW 0.60 ACT = ND
24 ENSG00000081721 DUSP12 RA IC 0.69 INT = ND
25 ENSG00000081721 DUSP12 SLE GW 0.89 ACT = ND 1q23.3 rs1801274 1.0E-12
26 ENSG00000198821 CD247 RA GW 0.53 PROM - +
27 ENSG00000116701 NCF2 SLE GW 1.00 CODE - ND
28 ENSG00000116750 UCHL5 CEL IC 1.00 ACT = ND 1q31.2 rs2816316 6.7E-25
29 ENSG00000116747 TROVE2 CEL IC 1.00 ACT + ND 1q31.2 rs2816316 6.7E-25
30 ENSG00000136634 IL10 T1D IC 0.67 PROM + + 1q32.1 rs3024493 2.0E-08
31 ENSG00000142224 IL19 T1D IC 1.00 INT ND + 1q32.1 rs3024493 2.0E-08
32 ENSG00000162891 IL20 T1D IC 0.67 INT ND + 1q32.1 rs3024493 2.0E-08
33 ENSG00000162892 IL24 T1D IC 1.00 INT + + 1q32.1 rs3024493 2.0E-08
Continued on next page
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# ENSG Name Disease Analysis COGS Context Expr eRNA Locus SNP p-value
34 ENSG00000162894 FAIM3 T1D IC 1.00 INT - + 1q32.1 rs3024493 2.0E-08
35 ENSG00000162896 PIGR T1D IC 1.00 INT ND + 1q32.1 rs3024493 2.0E-08
36 ENSG00000162897 FCAMR T1D IC 0.67 INT ND + 1q32.1 rs3024493 2.0E-08
37 ENSG00000152518 ZFP36L2 CEL IC 0.82 INT - -
38 ENSG00000115421 PAPOLG CEL IC 1.00 INT = ND 2p16.1 rs13003464 4.3E-16
39 ENSG00000162924 REL RA IC 0.59 NCODE + ND 2p16.1 rs34695944 1.7E-15
40 ENSG00000162924 REL RA GW 0.93 NCODE + ND 2p16.1 rs34695944 1.7E-15
41 ENSG00000162924 REL CEL IC 1.00 INT + ND 2p16.1 rs13003464 4.3E-16
42 ENSG00000233404 FLJ20373 CEL IC 0.77 INT ND ND 2q12.1 rs990171 1.2E-16
43 ENSG00000115590 IL1R2 CEL IC 0.77 INT + ND 2q12.1 rs990171 1.2E-16
44 ENSG00000115598 IL1RL2 CEL IC 0.62 INT + ND 2q12.1 rs990171 1.2E-16
45 ENSG00000152127 MGAT5 SLE GW 0.99 INT + ND
46 ENSG00000115232 ITGA4 CEL IC 0.99 INT - ND 2q31.3 rs1018326 3.1E-16
47 ENSG00000151690 MFSD6 RA GW 0.86 INT = ND 2q32.3 rs13426947 7.2E-10
48 ENSG00000189362 TMEM194B RA GW 0.95 ACT + ND 2q32.3 rs13426947 7.2E-10
49 ENSG00000138386 NAB1 SLE GW 0.72 CODE + ND
50 ENSG00000138378 STAT4 RA GW 0.52 INT + ND 2q32.3 rs13426947 7.2E-10
51 ENSG00000138378 STAT4 RA IC 0.53 INT + ND 2q32.3 rs13426947 7.2E-10
52 ENSG00000138378 STAT4 CEL IC 0.99 INT + ND 2q32.3 rs6715106 8.4E-09
53 ENSG00000173559 NABP1 RA IC 0.58 INT + ND 2q32.3 rs13426947 7.2E-10
54 ENSG00000173559 NABP1 RA GW 0.60 INT + ND 2q32.3 rs13426947 7.2E-10
Continued on next page
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55 ENSG00000173559 NABP1 CEL IC 0.99 INT + ND 2q32.3 rs6715106 8.4E-09
56 ENSG00000119004 CYP20A1 T1D IC 0.66 INT + + 2q33.2 rs3087243 7.4E-21
57 ENSG00000173166 RAPH1 T1D IC 0.83 INT + + 2q33.2 rs3087243 7.4E-21
58 ENSG00000178562 CD28 T1D IC 0.81 INT = + 2q33.2 rs3087243 7.4E-21
59 ENSG00000187118 CMC1 RA GW 0.94 INT = ND 3p24.1 rs3806624 8.6E-09
60 ENSG00000163512 AZI2 RA GW 0.56 INT - ND 3p24.1 rs3806624 8.6E-09
61 ENSG00000206559 ZCWPW2 RA GW 0.56 INT ND ND 3p24.1 rs3806624 8.6E-09
62 ENSG00000136068 FLNB RA GW 0.50 NACT = ND 3p14.3 rs35677470 1.7E-07
63 ENSG00000163687 DNASE1L3 RA GW 0.65 CODE ND ND
64 ENSG00000163687 DNASE1L3 RA IC 0.82 CODE ND ND
65 ENSG00000114850 SSR3 RA GW 0.80 INT = ND
66 ENSG00000163659 TIPARP RA GW 0.78 INT - ND
67 ENSG00000197980 LEKR1 RA GW 0.75 INT = ND
68 ENSG00000213186 TRIM59 CEL IC 1.00 NACT = ND 3q25.33 rs1353248 9.8E-09
69 ENSG00000114209 PDCD10 SLE GW 0.54 INT = ND
70 ENSG00000163536 SERPINI1 SLE GW 0.54 INT - ND
71 ENSG00000145495 MARCH6 RA GW 0.61 INT = ND
72 ENSG00000145491 ROPN1L RA GW 0.83 INT ND ND
73 ENSG00000154122 ANKH RA GW 0.67 INT - ND
74 ENSG00000134352 IL6ST RA GW 1.00 INT + ND 5q11.2 rs7731626 7.3E-24
75 ENSG00000134352 IL6ST RA IC 1.00 INT + ND 5q11.2 rs6859219 4.0E-16
Continued on next page
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76 ENSG00000153922 CHD1 RA IC 0.62 INT + ND 5q21.1 rs39984 9.3E-08
77 ENSG00000153922 CHD1 RA GW 0.64 INT + ND 5q21.1 rs39984 9.3E-08
78 ENSG00000153922 CHD1 SLE GW 0.67 INT + ND
79 ENSG00000174132 FAM174A SLE GW 0.62 INT - ND
80 ENSG00000113532 ST8SIA4 SLE GW 0.53 INT + ND
81 ENSG00000145723 GIN1 RA GW 0.61 INT - ND 5q21.1 rs39984 9.3E-08
82 ENSG00000145723 GIN1 RA IC 0.62 INT - ND 5q21.1 rs39984 9.3E-08
83 ENSG00000145725 PPIP5K2 RA GW 0.61 INT = ND 5q21.1 rs39984 9.3E-08
84 ENSG00000145725 PPIP5K2 RA IC 0.62 INT = ND 5q21.1 rs39984 9.3E-08
85 ENSG00000113552 GNPDA1 CEL IC 0.90 INT + +
86 ENSG00000197043 ANXA6 RA GW 0.76 INT - ND
87 ENSG00000197043 ANXA6 SLE GW 1.00 INT - ND 5q33.1 rs7708392 3.8E-13
88 ENSG00000113328 CCNG1 SLE GW 1.00 INT - ND 5q33.3 rs2431697 8.0E-28
89 ENSG00000170584 NUDCD2 SLE GW 1.00 INT + ND 5q33.3 rs2431697 8.0E-28
90 ENSG00000072571 HMMR SLE GW 1.00 INT - ND 5q33.3 rs2431697 8.0E-28
91 ENSG00000137265 IRF4 CEL IC 0.95 CODE + ND
92 ENSG00000157593 SLC35B2 RA GW 0.56 PROM + ND 6p21.1 rs2233424 1.4E-19
93 ENSG00000146232 NFKBIE RA GW 0.76 OVERALL + ND 6p21.1 rs2233424 1.4E-19
94 ENSG00000178233 TMEM151B RA GW 0.60 PROM ND ND 6p21.1 rs2233424 1.4E-19
95 ENSG00000272442 RP11-
444E17.6
RA GW 0.58 PROM ND ND 6p21.1 rs2233424 1.4E-19
Continued on next page
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96 ENSG00000112159 MDN1 RA IC 0.53 INT + + 6q15 rs72928038 8.2E-07
97 ENSG00000112159 MDN1 ATD IC 0.88 INT + + 6q15 rs72928038 1.2E-07
98 ENSG00000112159 MDN1 T1D IC 0.99 INT + + 6q15 rs72928038 6.4E-14
99 ENSG00000057657 PRDM1 RA GW 0.55 INT + ND 6q21 rs9372120 7.6E-10
100 ENSG00000118503 TNFAIP3 RA GW 0.79 ACT + ND 6q23.3 rs17264332 3.9E-20
101 ENSG00000118503 TNFAIP3 RA IC 0.83 ACT + ND 6q23.3 rs17264332 3.9E-20
102 ENSG00000118503 TNFAIP3 CEL IC 0.98 ACT + ND 6q23.3 rs17264332 5.0E-30
103 ENSG00000146425 DYNLT1 RA GW 0.98 ACT = + 6q25.3 rs2451258 2.7E-11
104 ENSG00000146425 DYNLT1 CEL IC 0.75 INT = ND 6q25.3 rs182429 8.5E-16
105 ENSG00000164674 SYTL3 RA GW 0.98 ACT + + 6q25.3 rs2451258 2.7E-11
106 ENSG00000164674 SYTL3 CEL IC 0.75 INT + ND 6q25.3 rs182429 8.5E-16
107 ENSG00000203711 C6orf99 CEL IC 0.74 INT ND ND 6q25.3 rs182429 8.5E-16
108 ENSG00000164691 TAGAP RA GW 0.98 INT + + 6q25.3 rs2451258 2.7E-11
109 ENSG00000164691 TAGAP CEL IC 1.00 OVERALL + ND 6q25.3 rs182429 8.5E-16
110 ENSG00000060762 MPC1 ATD IC 0.53 INT - ND
111 ENSG00000249141 RP11-
514O12.4
ATD IC 0.58 NCODE ND ND
112 ENSG00000026297 RNASET2 ATD IC 0.67 NCODE = ND
113 ENSG00000213066 FGFR1OP RA GW 1.00 NACT = ND 6q27 rs1571878 5.0E-35
114 ENSG00000106546 AHR RA GW 0.96 ACT + ND
115 ENSG00000155849 ELMO1 RA IC 0.67 NCODE + ND 7p14.1 rs79758729 9.2E-07
Continued on next page
B
.2
Prioritised
C
O
G
S
genes
from
B
urren
etal.(2017)
|
217
# ENSG Name Disease Analysis COGS Context Expr eRNA Locus SNP p-value
116 ENSG00000155849 ELMO1 CEL IC 0.74 NCODE + ND 7p14.1 1kg_7_37384979 2.1E-08
117 ENSG00000136273 HUS1 SLE GW 0.66 INT + ND 7p12.2 rs4917014 6.4E-14
118 ENSG00000042813 ZPBP T1D IC 0.91 INT ND ND 7p12.2 rs10272724 4.8E-09
119 ENSG00000164500 C7orf72 T1D IC 0.91 INT ND ND 7p12.2 rs10272724 4.8E-09
120 ENSG00000185811 IKZF1 SLE GW 0.74 INT = ND 7p12.2 rs4917014 6.4E-14
121 ENSG00000185811 IKZF1 T1D IC 0.99 INT = ND 7p12.2 rs10272724 4.8E-09
122 ENSG00000132436 FIGNL1 SLE GW 0.70 INT + ND 7p12.2 rs4917014 6.4E-14
123 ENSG00000105810 CDK6 RA GW 0.96 OVERALL + ND 7q21.2 rs4272 5.0E-09
124 ENSG00000147316 MCPH1 SLE GW 0.51 INT + ND 8p23.1 rs2736340 6.3E-20
125 ENSG00000155189 AGPAT5 SLE GW 0.58 INT + ND 8p23.1 rs2736340 6.3E-20
126 ENSG00000147324 MFHAS1 SLE GW 0.66 INT = ND 8p23.1 rs2736340 6.3E-20
127 ENSG00000171056 SOX7 SLE GW 0.54 ACT ND ND 8p23.1 rs2736340 6.3E-20
128 ENSG00000258724 SOX7 SLE GW 0.54 ACT ND ND 8p23.1 rs2736340 6.3E-20
129 ENSG00000254093 PINX1 SLE GW 0.54 ACT + ND 8p23.1 rs2736340 6.3E-20
130 ENSG00000154319 FAM167A SLE GW 0.55 PROM ND ND 8p23.1 rs2736340 6.3E-20
131 ENSG00000154319 FAM167A RA GW 0.56 PROM ND ND 8p23.1 rs2736337 3.1E-13
132 ENSG00000136573 BLK RA GW 0.52 PROM - ND 8p23.1 rs2736337 3.1E-13
133 ENSG00000136573 BLK SLE GW 0.53 PROM - ND 8p23.1 rs2736340 6.3E-20
134 ENSG00000255394 C8orf49 SLE GW 0.76 INT ND ND 8p23.1 rs2736340 6.3E-20
135 ENSG00000154328 NEIL2 SLE GW 0.76 INT = ND 8p23.1 rs2736340 6.3E-20
136 ENSG00000079459 FDFT1 SLE GW 0.54 INT = ND 8p23.1 rs2736340 6.3E-20
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137 ENSG00000255046 RP11-
297N6.4
SLE GW 0.54 INT = ND 8p23.1 rs2736340 6.3E-20
138 ENSG00000164733 CTSB SLE GW 0.54 INT - ND 8p23.1 rs2736340 6.3E-20
139 ENSG00000205883 DEFB135 SLE GW 0.57 NACT ND ND 8p23.1 rs2736340 6.3E-20
140 ENSG00000136997 MYC RA GW 0.70 INT + + 8q24.21 rs1516971 1.3E-10
141 ENSG00000095261 PSMD5 RA GW 0.73 INT = + 9q33.2 rs10985070 5.0E-11
142 ENSG00000056558 TRAF1 RA GW 0.89 NCODE + + 9q33.2 rs10985070 5.0E-11
143 ENSG00000119397 CNTRL RA GW 0.85 INT - + 9q33.2 rs10985070 5.0E-11
144 ENSG00000134460 IL2RA RA GW 1.00 PROM + + 10p15.1 rs706778 4.6E-14
145 ENSG00000134460 IL2RA RA IC 1.00 PROM + + 10p15.1 rs706778 4.6E-14
146 ENSG00000134460 IL2RA ATD IC 1.00 NCODE + + 10p15.1 rs706779 2.7E-07
147 ENSG00000134460 IL2RA T1D IC 1.00 NCODE + ND 10p15.1 rs41295121 4.9E-08
148 ENSG00000134453 RBM17 RA IC 0.67 ACT + + 10p15.1 rs706778 4.6E-14
149 ENSG00000134453 RBM17 RA GW 0.77 ACT + + 10p15.1 rs706778 4.6E-14
150 ENSG00000134453 RBM17 ATD IC 0.99 INT + + 10p15.1 rs706779 2.7E-07
151 ENSG00000134453 RBM17 T1D IC 1.00 NCODE + ND 10p15.1 rs41295121 4.9E-08
152 ENSG00000170525 PFKFB3 RA GW 0.65 NCODE + ND 10p15.1 rs10795791 3.0E-06
153 ENSG00000212743 DKFZP667-
F0711
RA GW 0.75 PROM = + 10p15.1 rs947474 4.1E-10
154 ENSG00000212743 DKFZP667-
F0711
CEL IC 0.76 OVERALL = + 10p15.1 rs2387397 1.9E-08
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155 ENSG00000212743 DKFZP667-
F0711
T1D IC 0.86 NACT = ND 10p15.1 rs41295121 4.9E-08
156 ENSG00000065675 PRKCQ ATD IC 0.54 INT - + 10p15.1 rs706779 2.7E-07
157 ENSG00000107485 GATA3 RA GW 1.00 PROM = = 10p14 rs3824660 2.0E-08
158 ENSG00000107485 GATA3 SLE GW 0.68 INT = ND
159 ENSG00000128815 WDFY4 SLE GW 0.88 CODE = ND
160 ENSG00000150347 ARID5B RA GW 0.69 INT + + 10q21.2 rs12764378 4.5E-10
161 ENSG00000150347 ARID5B SLE GW 0.99 INT + + 10q21.2 rs4948496 1.0E-10
162 ENSG00000185507 IRF7 SLE GW 0.69 NCODE = ND 11p15.5 rs4963128 4.9E-09
163 ENSG00000099834 CDHR5 SLE GW 0.84 OVERALL ND ND 11p15.5 rs4963128 4.9E-09
164 ENSG00000185940 KRTAP5-
5
T1D IC 1.00 INT ND ND 11p15.5 rs72853903 6.2E-10
165 ENSG00000205864 KRTAP5-
6
T1D IC 1.00 INT ND ND 11p15.5 rs72853903 6.2E-10
166 ENSG00000129965 INS-IGF2 T1D IC 1.00 PROM ND ND 11p15.5 rs72853903 6.2E-10
167 ENSG00000254647 INS T1D IC 1.00 PROM ND ND 11p15.5 rs72853903 6.2E-10
168 ENSG00000180176 TH T1D IC 1.00 PROM ND ND 11p15.5 rs72853903 6.2E-10
169 ENSG00000184281 TSSC4 T1D IC 1.00 INT + ND 11p15.5 rs72853903 6.2E-10
170 ENSG00000026508 CD44 SLE GW 0.83 INT + + 11p13 rs2732549 1.2E-23
171 ENSG00000135362 PRR5L RA GW 0.68 INT = ND
172 ENSG00000178105 DDX10 RA GW 0.71 ACT + ND 11q22.3 chr11:107967350 1.4E-08
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173 ENSG00000110367 DDX6 CEL IC 0.51 INT = ND 11q23.3 rs10892258 1.7E-11
174 ENSG00000134954 ETS1 CEL IC 1.00 INT - = 11q24.3 rs11221332 5.3E-16
175 ENSG00000134954 ETS1 SLE GW 0.80 ACT - ND 11q24.3 rs7941765 1.3E-10
176 ENSG00000134954 ETS1 RA GW 0.99 ACT - ND 11q24.3 rs73013527 1.2E-10
177 ENSG00000151702 FLI1 CEL IC 0.71 INT - = 11q24.3 rs11221332 5.3E-16
178 ENSG00000118971 CCND2 SLE GW 0.79 INT + ND
179 ENSG00000139531 SUOX RA GW 0.62 PROM = ND 12q13.2 rs773125 1.1E-10
180 ENSG00000065361 ERBB3 T1D IC 0.65 PROM ND ND 12q13.2 rs11171739 9.7E-11
181 ENSG00000135506 OS9 RA GW 0.57 PROM - ND 12q13.2 rs773125 1.1E-10
182 ENSG00000135439 AGAP2 RA GW 0.51 INT - ND 12q13.2 rs773125 1.1E-10
183 ENSG00000135452 TSPAN31 RA GW 0.51 INT + ND 12q13.2 rs773125 1.1E-10
184 ENSG00000111252 SH2B3 CEL IC 0.70 CODE + ND
185 ENSG00000111252 SH2B3 T1D IC 0.84 CODE + ND
186 ENSG00000134882 UBAC2 T1D IC 0.86 INT - + 13q32.3 rs9585056 5.2E-09
187 ENSG00000134882 UBAC2 CEL IC 0.67 INT - -
188 ENSG00000125245 GPR18 T1D IC 0.86 INT - + 13q32.3 rs9585056 5.2E-09
189 ENSG00000125245 GPR18 CEL IC 0.67 INT - -
190 ENSG00000169508 GPR183 T1D IC 0.86 INT + + 13q32.3 rs9585056 5.2E-09
191 ENSG00000169508 GPR183 CEL IC 0.67 INT + -
192 ENSG00000185650 ZFP36L1 RA GW 0.97 INT + ND 14q24.1 rs1950897 8.2E-11
193 ENSG00000165409 TSHR ATD IC 1.00 INT ND ND 14q31.1 rs2300519 1.3E-38
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194 ENSG00000165417 GTF2A1 ATD IC 1.00 INT = ND 14q31.1 rs2300519 1.3E-38
195 ENSG00000197406 DIO3 T1D IC 0.76 INT ND ND 14q32.2 rs56994090 1.1E-11
196 ENSG00000172575 RASGRP1 RA IC 0.96 INT = + 15q14 rs8043085 1.4E-10
197 ENSG00000172575 RASGRP1 RA GW 1.00 NCODE = + 15q14 rs8032939 1.9E-18
198 ENSG00000172575 RASGRP1 T1D IC 0.91 INT = ND 15q14 rs12908309 4.3E-08
199 ENSG00000175779 C15orf53 T1D IC 0.81 INT ND ND 15q14 rs12908309 4.3E-08
200 ENSG00000175779 C15orf53 RA IC 0.96 INT ND + 15q14 rs8043085 1.4E-10
201 ENSG00000175779 C15orf53 RA GW 1.00 INT ND + 15q14 rs8032939 1.9E-18
202 ENSG00000140332 TLE3 RA GW 0.82 INT + ND 15q23 rs8026898 3.6E-19
203 ENSG00000182108 DEXI T1D IC 0.51 INT = ND 16p13.13 rs193778 4.4E-10
204 ENSG00000182108 DEXI RA GW 0.85 INT = ND 16p13.13 rs4780401 4.1E-08
205 ENSG00000038532 CLEC16A T1D IC 0.55 INT = ND 16p13.13 rs193778 4.4E-10
206 ENSG00000038532 CLEC16A RA GW 0.90 INT = ND 16p13.13 rs4780401 4.1E-08
207 ENSG00000175643 RMI2 SLE GW 0.60 INT - ND 16p13.13 rs9652601 7.4E-17
208 ENSG00000175643 RMI2 T1D IC 0.97 NCODE - ND 16p13.13 rs193778 4.4E-10
209 ENSG00000185338 SOCS1 T1D IC 0.85 NCODE + ND 16p13.13 rs12927355 3.0E-22
210 ENSG00000178279 TNP2 T1D IC 0.59 INT ND ND 16p13.13 rs12927355 3.0E-22
211 ENSG00000178257 PRM3 T1D IC 0.59 INT ND ND 16p13.13 rs12927355 3.0E-22
212 ENSG00000122304 PRM2 SLE GW 0.52 ACT ND ND 16p13.13 rs9652601 7.4E-17
213 ENSG00000122304 PRM2 RA GW 0.62 ACT ND ND 16p13.13 rs4780401 4.1E-08
214 ENSG00000233232 NPIPB7 T1D IC 0.66 PROM ND ND 16p11.2 rs151234 4.8E-11
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215 ENSG00000261832 CLN3 T1D IC 0.66 PROM ND ND 16p11.2 rs151234 4.8E-11
216 ENSG00000188603 CLN3 T1D IC 0.66 PROM - ND 16p11.2 rs151234 4.8E-11
217 ENSG00000184730 APOBR T1D IC 0.99 OVERALL - ND 16p11.2 rs151234 4.8E-11
218 ENSG00000176046 NUPR1 T1D IC 0.66 NACT ND ND 16p11.2 rs151234 4.8E-11
219 ENSG00000157423 HYDIN SLE GW 0.64 INT ND ND
220 ENSG00000103091 WDR59 T1D IC 0.95 INT = ND 16q23.1 rs8056814 3.0E-19
221 ENSG00000186187 ZNRF1 T1D IC 0.95 INT + ND 16q23.1 rs8056814 3.0E-19
222 ENSG00000168928 CTRB2 T1D IC 1.00 PROM ND ND 16q23.1 rs8056814 3.0E-19
223 ENSG00000168925 CTRB1 T1D IC 1.00 PROM ND ND 16q23.1 rs8056814 3.0E-19
224 ENSG00000131148 EMC8 SLE GW 0.97 ACT + ND 16q24.1 rs11644034 9.6E-18
225 ENSG00000131148 EMC8 RA GW 1.00 ACT + ND 16q24.1 rs13330176 1.4E-12
226 ENSG00000131143 COX4I1 SLE GW 0.97 ACT = ND 16q24.1 rs11644034 9.6E-18
227 ENSG00000131143 COX4I1 RA GW 1.00 ACT = ND 16q24.1 rs13330176 1.4E-12
228 ENSG00000140968 IRF8 SLE GW 0.99 ACT + ND 16q24.1 rs11644034 9.6E-18
229 ENSG00000140968 IRF8 RA GW 1.00 ACT + ND 16q24.1 rs13330176 1.4E-12
230 ENSG00000174327 SLC16A13 SLE GW 0.98 ACT ND ND 17p13.2 rs2286672 2.9E-09
231 ENSG00000132522 GPS2 SLE GW 0.98 ACT = ND 17p13.2 rs2286672 2.9E-09
232 ENSG00000261915 RP11-
542C16.2
SLE GW 0.98 ACT ND ND 17p13.2 rs2286672 2.9E-09
233 ENSG00000215041 NEURL4 SLE GW 0.99 PROM = ND 17p13.2 rs2286672 2.9E-09
234 ENSG00000072818 ACAP1 SLE GW 0.99 PROM - ND 17p13.2 rs2286672 2.9E-09
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235 ENSG00000170175 CHRNB1 SLE GW 0.97 ACT - ND 17p13.2 rs2286672 2.9E-09
236 ENSG00000174282 ZBTB4 SLE GW 0.98 INT - ND 17p13.2 rs2286672 2.9E-09
237 ENSG00000259224 SLC35G6 SLE GW 0.98 INT ND ND 17p13.2 rs2286672 2.9E-09
238 ENSG00000181222 POLR2A SLE GW 0.98 INT = ND 17p13.2 rs2286672 2.9E-09
239 ENSG00000239697 TNFSF12 SLE GW 0.98 INT = ND 17p13.2 rs2286672 2.9E-09
240 ENSG00000248871 TNFSF12-
TNFSF13
SLE GW 0.98 INT ND ND 17p13.2 rs2286672 2.9E-09
241 ENSG00000161955 TNFSF13 SLE GW 0.98 INT ND ND 17p13.2 rs2286672 2.9E-09
242 ENSG00000161956 SENP3 SLE GW 0.98 INT + ND 17p13.2 rs2286672 2.9E-09
243 ENSG00000161960 EIF4A1 SLE GW 0.99 INT + ND 17p13.2 rs2286672 2.9E-09
244 ENSG00000129226 CD68 SLE GW 0.99 INT ND ND 17p13.2 rs2286672 2.9E-09
245 ENSG00000129255 MPDU1 SLE GW 0.99 INT + ND 17p13.2 rs2286672 2.9E-09
246 ENSG00000129194 SOX15 SLE GW 0.99 INT ND ND 17p13.2 rs2286672 2.9E-09
247 ENSG00000129245 FXR2 SLE GW 0.98 ACT = ND 17p13.2 rs2286672 2.9E-09
248 ENSG00000268503 AC007421.1 SLE GW 0.98 ACT ND ND 17p13.2 rs2286672 2.9E-09
249 ENSG00000129214 SHBG SLE GW 0.98 ACT ND ND 17p13.2 rs2286672 2.9E-09
250 ENSG00000141510 TP53 SLE GW 0.98 ACT = ND 17p13.2 rs2286672 2.9E-09
251 ENSG00000141499 WRAP53 SLE GW 0.98 INT - ND 17p13.2 rs2286672 2.9E-09
252 ENSG00000179148 ALOXE3 SLE GW 0.98 INT ND ND 17p13.2 rs2286672 2.9E-09
253 ENSG00000179094 PER1 SLE GW 0.97 ACT = ND 17p13.2 rs2286672 2.9E-09
254 ENSG00000161405 IKZF3 RA IC 0.55 PROM + ND 17q12 chr17:38031857 2.3E-12
Continued on next page
224
|
# ENSG Name Disease Analysis COGS Context Expr eRNA Locus SNP p-value
255 ENSG00000161405 IKZF3 RA GW 0.66 PROM + ND 17q12 chr17:38031857 2.3E-12
256 ENSG00000186075 ZPBP2 T1D IC 0.51 PROM ND ND 17q12 rs12453507 1.0E-08
257 ENSG00000186075 ZPBP2 RA IC 0.60 PROM ND ND 17q12 chr17:38031857 2.3E-12
258 ENSG00000186075 ZPBP2 RA GW 0.71 PROM ND ND 17q12 chr17:38031857 2.3E-12
259 ENSG00000120068 HOXB8 SLE GW 0.54 INT ND ND
260 ENSG00000170689 HOXB9 SLE GW 0.52 INT ND ND
261 ENSG00000184557 SOCS3 RA GW 0.58 PROM + ND
262 ENSG00000087157 PGS1 RA GW 0.55 PROM = ND
263 ENSG00000175354 PTPN2 RA GW 0.73 ACT + ND 18p11.21 rs8083786 6.3E-18
264 ENSG00000175354 PTPN2 T1D IC 0.91 ACT + ND 18p11.21 rs1893217 1.2E-15
265 ENSG00000099625 C19orf26 SLE GW 0.59 INT ND ND
266 ENSG00000099624 ATP5D SLE GW 0.59 INT = ND
267 ENSG00000167470 MIDN SLE GW 0.59 INT + ND
268 ENSG00000099622 CIRBP SLE GW 0.59 INT = ND
269 ENSG00000267303 CTD-
2369P2.12
RA GW 0.58 CODE ND ND
270 ENSG00000161847 RAVER1 RA GW 0.58 CODE = ND
271 ENSG00000105397 TYK2 RA IC 1.00 CODE = ND
272 ENSG00000105397 TYK2 T1D IC 1.00 CODE = ND
273 ENSG00000105401 CDC37 RA GW 0.96 INT + ND 19p13.2 chr19:10771941 8.6E-10
274 ENSG00000180739 S1PR5 RA GW 0.96 INT - ND 19p13.2 chr19:10771941 8.6E-10
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275 ENSG00000130734 ATG4D RA GW 0.96 INT - ND 19p13.2 chr19:10771941 8.6E-10
276 ENSG00000129347 KRI1 RA GW 0.96 INT + ND 19p13.2 chr19:10771941 8.6E-10
277 ENSG00000129355 CDKN2D RA GW 0.97 INT + ND 19p13.2 chr19:10771941 8.6E-10
278 ENSG00000129353 SLC44A2 RA GW 0.96 INT - ND 19p13.2 chr19:10771941 8.6E-10
279 ENSG00000129351 ILF3 RA GW 0.96 PROM + ND 19p13.2 chr19:10771941 8.6E-10
280 ENSG00000105063 PPP6R1 SLE GW 0.79 PROM = ND
281 ENSG00000133265 HSPBP1 SLE GW 0.79 PROM + ND
282 ENSG00000160469 BRSK1 SLE GW 0.91 PROM ND ND
283 ENSG00000133247 SUV420H2 SLE GW 0.78 ACT - ND
284 ENSG00000267531 AC020922.1 SLE GW 0.78 ACT ND ND
285 ENSG00000233493 TMEM238 SLE GW 0.92 INT = ND
286 ENSG00000108107 RPL28 SLE GW 0.93 INT = ND
287 ENSG00000108106 UBE2S SLE GW 0.92 INT + ND
288 ENSG00000187902 SHISA7 SLE GW 0.92 INT ND ND
289 ENSG00000063241 ISOC2 SLE GW 0.92 INT + ND
290 ENSG00000197483 ZNF628 SLE GW 0.79 INT = ND
291 ENSG00000090971 NAT14 SLE GW 0.91 INT = ND
292 ENSG00000179954 SSC5D SLE GW 0.91 INT ND ND
293 ENSG00000179943 FIZ1 SLE GW 0.78 INT = ND
294 ENSG00000171443 ZNF524 SLE GW 0.78 INT - ND
295 ENSG00000213015 ZNF580 SLE GW 0.78 INT = ND
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296 ENSG00000171425 ZNF581 SLE GW 0.78 INT = ND
297 ENSG00000173581 CCDC106 SLE GW 0.81 INT ND ND
298 ENSG00000175063 UBE2C CEL IC 0.54 INT - ND
299 ENSG00000101470 TNNC2 CEL IC 0.54 INT ND ND
300 ENSG00000124104 SNX21 CEL IC 0.54 INT = ND
301 ENSG00000198026 ZNF335 CEL IC 0.92 PROM = ND
302 ENSG00000062598 ELMO2 CEL IC 0.54 INT = ND
303 ENSG00000159110 IFNAR2 RA GW 0.84 INT - ND 21q22.12 rs2834512 2.1E-08
304 ENSG00000100099 HPS4 SLE GW 0.66 INT - ND
305 ENSG00000100104 SRRD SLE GW 0.66 INT + ND
306 ENSG00000100109 TFIP11 SLE GW 0.65 INT + ND
307 ENSG00000187045 TMPRSS6 CEL IC 0.55 INT ND =
308 ENSG00000187045 TMPRSS6 RA IC 0.64 ACT ND ND 22q13.1 rs909685 1.4E-16
309 ENSG00000187045 TMPRSS6 T1D IC 0.86 INT ND ND 22q12.3 rs229533 1.8E-08
310 ENSG00000100385 IL2RB CEL IC 0.55 INT + =
311 ENSG00000133466 C1QTNF6 T1D IC 0.69 PROM = ND 22q12.3 rs229533 1.8E-08
312 ENSG00000166897 ELFN2 CEL IC 0.55 INT - =
313 ENSG00000100060 MFNG CEL IC 0.55 INT - =
314 ENSG00000100321 SYNGR1 RA GW 0.69 PROM ND ND 22q13.1 rs909685 1.4E-16
Appendix C
C.1 Relationship between PCA and SVD
Consider a n× p matrix X , where the columns are mean centred. The Principal
components of X can be computed by performing eigen-decomposition on the
variance-covariance matrix of X such that
X T X
n−1 =V DV
T , (C.1)
where V is a p× n matrix where each column represents an eigenvector, that
defines a principal component and D is a n× p diagonal matrix of eigenvalues
that reflect the square-root of the variance explained by each component.
Consider the singular value decomposition X
X =UΣV T , (C.2)
where U is the square left singular matrix (n×n), Σ is a diagonal matrix of the
singular values of X (n×n) and V is the right singular matrix of X (p×n). From
this it follows that
X T X =UΣV ,
=
(
UΣV T
)T
UΣV T ,
=VΣTU TUΣV T ,Where U TU = I
=VΣ2V T . (C.3)
Thus we can relate the eigenvalues of the variance-covariance matrix to the singular
values from SVD by
D =
Σ2
n−1 , (C.4)
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where principal components are given by XV =UΣV TV =UΣ as V TV = I .
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C.2 IMD basis projection forest plots
Forest plots showing the context of JIA subtype projections for all PCs. Coloured
points indicate the difference in trait scores with synthetic control, marked with
a red dotted line. Error bars indicate 95% confidence intervals. For clarity basis
trait PC scores (purple) have been merged with overlapping UKBB traits. Whilst
non-basis UKBB traits have been filtered to show only those that are significantly
different from control at FDR < 5%, other traits are included regardless, these are
shown with dashed error bars. UKBB SRD, UKBB SRM and UKB SRC labels
in the legend correspond to UK Biobank self-reported disease, medication and
cancer categories respectively.
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Folic Acid Product
Methotrexate
Multiple Sclerosis
PSC
Systemic Lupus Erythematosis Sle
Crohns Disease
Ulcerative Colitis
Type 1 Diabetes
Malabsorption Coeliac Disease
Asthma
PBC
Rheumatoid Arthritis
ERA
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Mesalazine
Ulcerative Colitis
Anaemia
Colitis Not Crohns Or Ulcerative Colitis
Multiple Sclerosis
Type 1 Diabetes
Malabsorption Coeliac Disease
Systemic Lupus Erythematosis Sle
Rheumatoid Arthritis
PBC
Asthma
Hypertension
Crohns Disease
PSC
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PO
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Hydroxychloroquine
Methotrexate
Vitamin B12 Preparation
Levothyroxine Sodium
Folic Acid Product
Thyroxine Product
Metformin
Ventolin 100micrograms Inhaler
Seretide 50 Evohaler
Multiple Sclerosis
Sarcoidosis
Crohns Disease
Hyperthyroidism Thyrotoxicosis
Rheumatoid Arthritis
PSC
Hypothyroidism Myxoedema
Systemic Lupus Erythematosis Sle
Type 1 Diabetes
Diabetes
Malabsorption Coeliac Disease
PBC
Ulcerative Colitis
Hayfever Allergic Rhinitis
Asthma
RFpos
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Vitamin B1 Preparation
Bumetanide
Levothyroxine Sodium
Thyroxine Product
Ferrous Sulphate
Insulin Product
Methotrexate
Fexofenadine
Prednisolone
Nasonex 0 05  Aqueous Nasal Spray
Montelukast Product
Cetirizine
Loratadine
Bricanyl 250mcg Inhaler
Salbutamol
Azathioprine
Salmeterol Fluticasone Propionate
Fluticasone
Salamol 100micrograms Inhaler
Rino Clenil 50micrograms Nasal Spray
Beconase 50micrograms Nasal Spray
Beclazone 50 Inhaler
Beclometasone
Flixonase 50micrograms Aqueous Nasal Spray
Budesonide
Salbutamol 100micrograms Spacehaler
Salmeterol
Qvar 50 Inhaler
Antihistamine 60mg Tablet
Symbicort 100 6 Turbohaler
Ventolin 100micrograms Inhaler
Becotide 50 Inhaler
Beclometasone Dipropionate Salbutamol
Seretide 50 Evohaler
Uniphyllin Continus 200mg M R Tablet
Beclomethasone
Flixotide 25micrograms Inhaler
Terbutaline
Pulmicort Ls 50micrograms Inhaler
Serevent 25mcg Inhaler
Salmeterol Product
Phyllocontin Continus 225mg M R Tablet
Fracture Metatarsal
Systemic Lupus Erythematosis Sle
Emphysema Chronic Bronchitis
Hypothyroidism Myxoedema
Rheumatoid Arthritis
Hyperthyroidism Thyrotoxicosis
Allergy Or Anaphylactic Reaction To Food
Eczema Dermatitis
Allergy Hypersensitivity Anaphylaxis
Bronchiectasis
Chronic Obstructive Airways Disease Copd
Malabsorption Coeliac Disease
Crohns Disease
Hayfever Allergic Rhinitis
Multiple Sclerosis
Ulcerative Colitis
Type 1 Diabetes
PSC
PBC
Asthma
Nasal Polyps
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